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ABSTRACT 
Accurate measurements of protein:DNA and RNA expression levels are critical to building 
meaningful models of gene regulatory networks. We develop here two new techniques 
doing such measurements using ultra-high-throughput DNA sequencing combined with 
extensive computational analyses, which we call respectively ChIP-seq and RNA-seq. To 
show the power and versatility of these techniques, we apply them to the study of two 
model problems that are representative of the research agenda of regulatory biology. We 
use ChIP-seq to study the conservation and evolution of the binding repertoire of the 
transcription factor NRSF/REST in boreoeutherian mammals, whereas we use ChIP-seq of 
RNA Polymerase II phosphoisoforms and RNA-seq to study a developmental time course 
of myogenesis in the C2C12 mouse cell line. Together, ChIP-seq and RNA-seq show the 
promise of ultra-high-throughout sequencing in mapping and studying gene regulatory 
networks which will likely supplant the previous generation of microarray-based 
technologies as the new generations of sequencers mature and become more generally 
available. 
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NOMENCLATURE 
Cohort. A set of sites or genes that are analyzed as a group 
ChIP. Chromatin Immunoprecipitation. A common technique for enrichment of DNA 
fragments bound by a protein using antibodies 
ChIP-seq. ChIP experiment assayed with ultra-high throughput-sequencing 
Cistematic. Software library written in Python for analyzing genes and motifs on a 
genome-scale 
CTD. C-Terminal Domain of RNA polymerase II that is highly conserved in Eukaryotes 
and consisting of the repeated heptad YSPTSPS. It can be phosphorylated on every Serine 
ERANGE. Enhanced Read Analysis of Gene Expression. A set of programs written on 
Python to analyze both ChIP-seq and RNA-seq data (dual-use) 
GO. Gene Ontology. A set of structured vocabulary terms describing the function of a gene 
Motif. A representation of a set of sequences with a common pattern 
Multiread. Read that maps equally well to more than one position onto the genome 
NRSE. Neuron Restrictive Silencer Element. The binding site of NRSF 
NRSF. Neuron Restrictive Silencer Factor 
Polymerase stalling. Distinctive accumulation of RNA polymerase II at the promoter of 
genes with little or no productive poly-A RNA output 
PSFM. Position Specific Frequency Matrix. A matrix representation of a motif that is 
closely related to Position Weight Matrices (PWM) 
Read. Short 25–35 bp long sequence of DNA  
RNA-seq. Ultra-high-throughput sequencing of RNA 
Ultra-high-throughput sequencing. Sequencing of millions of short reads of DNA in 
parallel 
Uniquely mappable read. Read that maps best to only a single position on the genome 
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C h a p t e r  1  
INTRODUCTION 
The regulation of gene expression is the central, foundational problem of regulatory 
biology. While post-transcriptional and post-translational processes play a critical role in 
modulating the expression level of any RNA and of its derived protein, their absence or 
presence in a cell is ultimately dictated by transcription factor proteins that interact with 
DNA to recruit or repel the eukaryotic transcriptional machinery. The last 40 years have 
revealed a stunningly elegant and combinatorial use of multiple transcription factors that 
respond to the current regulatory state as well as extra-cellular signaling cues to control 
transcription of any gene with the necessary precision in time and space according to both 
its lineage and its environment (Davidson, 2006). While much of our current model of 
transcriptional regulation is built on a multitude of studies of particular aspects of this 
process at a few genes at a time, the availability of sequenced genomes and of ultra-high-
throughput methods affords us also an approach to the problem from a genome-wide, top-
down perspective of: what constitutes the repertoire of all genes regulated by a single 
transcription factor, as well as how cells turn on gene expression in a coordinated fashion 
upon differentiation. But any successful top-down approach is dependent on both 
measurements that are more accurate than those used to date and new computational 
methods to analyze and integrate the data.  
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This thesis uses a new generation of ultra-high-throughput DNA sequencing technologies 
to analyze with unmatched accuracy both the binding repertoire of a multi-faceted, 
vertebrate transcription factor — the Neuron Restrictive Silencer Factor (NRSF) — and the 
transcriptome of the C2C12 mouse myogenic cell line through differentiation. These 
analyses shed light respectively on the evolution of the binding repertoire of a transcription 
factor over 100 million years of evolution, as well as some of the key general 
transcriptional changes that accompany the differentiation of muscle myoblasts into 
myotubes. 
NRSF as a tractable model of the evolution of gene regulatory networks 
The Neuron Restrictive Silencer Factor, also known as the RE-1 Silencing Transcription 
factor (NRSF/REST), was discovered simultaneously by the Anderson and Mandel labs 
(Schoenherr, 1995; Chong, 1995) and has accumulated an impressive and rapidly 
expanding literature that makes it one of the most studied vertebrate-specific transcriptional 
repressors. The ever-expanding roles of NRSF beyond neurogenesis as a tumor suppressor 
(Westbrook, 2008; Westbrook, 2005), guardian of genome stability (Guardavaccaro, 2008), 
and necessary factor in maintaining the pluripotency of embryonic stem cells (Singh, 2008) 
have significantly increased its profile across different subfields of biology.  
Several features of NRSF make it particularly interesting for us to study in the context of 
the evolution of gene regulatory networks. NRSF has a large binding site (NRSE), which 
makes it practical for us to identify its target binding site in all sequenced genomes. While 
the co-repressors of NRSF are present in invertebrates, there is no convincing evidence to 
date that NRSF is present in invertebrates (Dallman, 2004), and the canonical NRSE is 
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missing from their genomes (Mortazavi, 2006). However, all available vertebrate genomes 
have a copy of both NRSF and an enrichment of NRSEs in genes associated with a 
neurosecretory phenotype. There appears to be no functional paralogs of NRSF in any of 
the genomes and the DNA binding site has remained extremely conserved in all 
vertebrates. NRSF is thus a tractable example of a vertebrate-specific evolution in gene 
regulation which affords us the opportunity to quantify the change in its target repertoire 
using both computational and in vivo experiments. 
The discovery of the Neuron Restrictive Silencer Element (NRSE) and of its cognate 
binding factor NRSF 
Early independent studies of the transcriptional regulation of neuronal genes such as 
Superior Cervical Ganglion 10 (SCG10, now known as Stathmin2) and the sodium channel 
Nav1.2 (now Scn2a) revealed the presence of a repressive element proximal to their 
promoters which restricted the expression of these genes outside of neurons. Unlike most 
cis-regulatory elements that are 6–10 bp long, the repressive element, which was called the 
Neuron Restrictive Silencer Element (NRSE, also RE-1 for Repressive Element 1) was 
determined to be nearly 21–23 bp long (Mori, 1992; Kraner, 1992). This element was used 
to identify NRSF as a zinc finger transcription factor that bound the canonical NRSE/RE-1, 
that repressed constructs with the NRSE, and whose expression pattern was predominantly 
non-neuronal. The full-length NRSF is thought to bind its cognate site without the 
combinatorial assist of other transcription factors. While this makes it unusual in the 
context of the current transcriptional literature, NRSF and its fellow canonical zinc finger 
CTCF (Lobanenkov, 1990; Filipova, 2008) may be representative of the large family of 
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zinc finger repressors that have been expanding rapidly in the mammalian and primate 
lineages (Huntley, 2006). 
An early survey of available genomic sequences revealed that the NRSE was embedded in 
a host of frankly neuronal genes such as BDNF, but was also found in the proximity of 
other genes such as skeletal muscle actin and the hormone somatostatin (Schoenherr, 
1996). Nevertheless, NRSF was proposed as master regulator of neuronal fate through a 
control of neuronal gene batteries (Schoenherr, 1996). However, the early embryonic lethal 
knockout failed to reveal any ectopic neurogenesis or even mis-expression of the several 
known targets at the time (Chen, 1998), while the neurogenic ability of several bHLH 
factors with similar functional homologs in Drosophila, such as NeuroD, were 
demonstrated conclusively (Lee, 1995). As the primacy of the activators in neurogenesis 
took hold, NRSF was demoted to being an eccentric repressor of some neuronal genes. 
The interaction of NRSF with its co-repressors  
The next decade of NRSF research focused on the biochemistry of NRSF and of its 
repression, which is accomplished by the recruitment of 3 different complexes. The N-
terminus recruits the ubiquitous eukaryotic repressor mSin3a (Huang, 1999). The C-
terminus recruits another repressor named CoREST, which has attracted much attention 
because it also shares a similar expression pattern that is non-neuronal (Andres, 1999). 
CoREST works in conjunction with HDAC2 and, while recruited by NRSF, it is thought to 
stay behind after the NRSF protein is degraded (see below) and to continue repression of its 
targets until a further de-repression event that is CoREST specific (Ballas, 2005). Small 
CTD Phosphatases (SCP) are a third family of NRSF co-repressors that have recently been 
5 
 
identified that also play a role in the repression of NRSF targets (Yeo, 2005). SCP family 
members work by dephosphorylating the 5th serine of the heptad repeats of C-terminal 
domain of RNA polymerase II, which would either prevent initiation or promote the early 
termination of transcription. All 3 modes of repression (mSin3A, CoREST, and SCP 
mediated) are known to repress different genes (Ballas, 2005; Lunyak, 2001; Yeo, 2005). It 
is not known what determines the recruitment and/or the selectivity of the different co-
repressors to their appropriate targets. 
NRSF splice isoforms affect its DNA binding domain and likely function  
A parallel series of efforts determined that NRSF can be found in a variety of splice 
isoforms that includes three different 5’ UTRs, the N-terminal (sin3A-interacting) domain, 
and different fractions of the DNA-binding domain and C-terminal (CoREST interacting) 
domains. In particular, some neurons and cancers express a splice isoform, called REST4, 
that include zinc fingers 1 through 5 (Shimojo, 2001). Mutagenesis studies of the different 
fingers of NRSF showed that fingers 5, and 6 through 8, are most important for binding to 
the full NRSE, and that REST4 binds much more weakly to the right half of the canonical 
NRSE (Shimojo, 2001; Lee, 2000). NRSF was shown early on to be first degraded at the 
protein level before being transcriptionally shutdown. Recent work shows that NRSF is 
degraded by the ubiquitin conjugating enzyme "TRCP, which recognizes a degron present 
in the C-terminal domain of NRSF and which is absent in REST4 (Westbrook, 2008). 
While the role of REST4 as an activator has been debated over the years, given conflicting 
results (Magin, 2002), a recent report shows that whereas full-length NRSF is a repressor 
of glutamine synthetase, REST4 interacts with the glucocorticoid receptor (GR) to activate 
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the transcription of the same gene (Abramovitz, 2008). It is unknown to what extent 
REST4 would activate the remainder of the target repertoire of NRSF and whether REST4 
or full-length NRSF can act as activators in conjunction with other transcription factors 
besides GR. 
The NRSF gene target repertoire 
The availability of whole genome sequences rejuvenated the search for NRSF targets 
through computational means. Genomic scans with the NRSE consensus (Schoenherr, 
1996; Bruce, 2004) or more sensitive position-specific-frequency-matrix-like methods 
(Mortazavi 2006;  Zhang, 2006) revealed that NRSE was associated with a large, specific 
subset of genes highly enriched for neuronal expression, including several neuronal 
transcription factors and RNA splicing factors. Another insight from computational studies 
that was quickly confirmed in vivo related NRSF-mediated repression to the expression of 
neuron-specific microRNAs, such as miR-124 and mir-9 (Conaco, 2006; Johnson, 2008). 
Thus NRSF-derepression is necessary for the coordinate expression of neuronal-specific 
genes, microRNAs, and splicing factors, which together change dramatically the regulatory 
state of cells commited to neurogenesis (Lim, 2005). Whereas NRSF knockouts or 
dominant negatives (without the N- and C-terminal domains) cannot transform non-
neuronal cells into neurons, an NRSF-VP16 activator does transform C2C12 myoblasts 
into neuron-like cells (Watanabe, 2004). Hence NRSF de-repression is a necessary step in 
neurogenesis, although it is not sufficient without the concomitant action of neurogenic 
activators such as those of the NeuroD1 activator.  
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The availability of a large list of true positive and of several good chromatin 
immunoprecipitation (ChIP) “grade” antibodies made NRSF an ideal candidate for a 
genome-wide survey of its in vivo binding across the genome. Whereas we surveyed the 
NRSF binding repertoire using a novel, high-resolution technique called ChIPSeq (also 
ChIP-seq) as described in Chapter 3, the Mandel lab and their collaborators independently 
surveyed the same repertoire using a related method called SACO (Otto, 2007). Both 
surveys revealed that NRSF had a wider set of targets than expected based on the 
computational surveys alone, due to the fact that NRSF had an expanded family of split 
sites, where the two halves of the canonical NRSE are separated by a spacer that is 
preferentially between 5–8 bp and the repressive ability of these sites was soon verified 
(Otto, 2007; Patel, 2007). In addition to additional members of known gene family targets, 
these genome-wide surveys revealed novel NRSEs, such as the one in the exon NeuroD1, 
which provides a clear link between NRSF-mediated repression and the neurogenic 
phenotype of NRSF-VP16. The new targets also pointed to a potential role for NRSF in the 
specification of pancreatic islet cells. 
NRSF as a regulator of the neurosecretory phenotype 
While NRSF is found associated with a variety of neuronal gene ontology terms, much 
attention has been given to the particular enrichment in genes that are important in 
neurosecretion (Bruce, 2006). In particular, NRSF expression in rat PC12 cells blocks 
secretion (Pance, 2006; D’alessandro, 2008) and beta-cell specific expression of NRSF (see 
below) reduces insulin secretion (Martin, 2008). Combined with the lack of expression of 
full-length NRSF in some cancers with neurosecretory phenotypes such as small-cell lung 
cancer (Coulson, 2000), this suggests that NRSF may play a critical role in allowing the co-
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option of the neuroendocrine phenotype in novel, non-neuronal settings. Several studies 
have demonstrated a role for NRSF in the cardiac program as well as a potential role in the 
specification of pancreatic islet cells (Kuwahara, 2003; Atouf, 1997; Kemp, 2003), neither 
of which are part of the ectodermal lineage. However, several NRSF targets such as 
somatostatin are expressed in endocrine cells besides the nervous system and islet cells 
such as gastric and intestinal endocrine cells. We would thus expect that NRSF de-
repression to turn out as a prerequisite for the development of any endocrine cells, such as 
somtatin-producing cells, or indeed any cell found to express neurosecretory gene markers 
such as SNAP-25. NRSF would thus permit non-ectodermal lineages to acquire this 
neurosecretory gene battery, given the appropriate expression of activators that would only 
turn on parts of the neurogenesis program. Since NRSF must be absent in order to have a 
neuroendocrine phenotype, and therefore cannot play its other role as a tumor surpressor, 
these cells will likely turn out to be more susceptible to uncontrolled proliferation that 
ultimately could turn into neuroendocrine tumors. Thus future studies will likely return to 
the topic of re-expressing NRSF and maintaining the expression of full-length NRSF to 
control proliferation (Fuller, 2005).  
Theme of Thesis 
This thesis develops the techniques and principles to analyze gene regulatory networks in 
mammalian genomes. In Chapter 2, I show how to search for transcription factor binding 
sites with and without restrictions of conservation, and how to analyze the resulting set of 
genes using gene ontology analysis and microarray gene expression data. I also show that 
the canonical NRSEs are absent in invertebrates and that NRSF is predicted to regulate 
both neuronal microRNAs, as well as alternative splicing factors. Evonne Chen Leeper and 
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Sarah T. Garcia of the Rick Myers lab at Stanford did the ChIP validation of a subset of our 
predicted sites. Chapter 2 was published in Genome Research in 2006 (Mortazavi, 2006). 
Our collaboration with the Myers lab continued in Chapter 3 with the development of ultra-
high-throughput sequencing of ChIP (ChIP-seq) as a replacement for previous microarray 
methods (ChIP-chip) and in its application in identifying the binding repertoire of NRSF in 
the human jurkat cell line. While Dave Johnson of the Myers lab and his team of 
technicians developed and performed all of the original ChIP-seq protocols in human, I 
performed mouse and dog ChIP-seq experiments and did all of the data analysis in Chapter 
3 (which is an expanded version of our human-centric 2007 publication in Science 
(Johnson, 2007) that includes massive updates to account for the comparative analysis).  
Chapter 4 switches gear to the application of ultra-high-throughput sequencing to the 
analysis of the transcriptome of multiple tissues and of the C2C12 myogenic model, by 
sequencing of the polyA-selected RNA (RNA-seq) and ChIP-seq of the RNA polymerase 
II phosphoisoforms to correlate Pol II occupancy to the observed mRNA. Brian Williams 
did all of the wet-bench development of RNA-seq, Lorian Schaeffer built and sequenced 
the bulk of the libraries, and Ken McCue developed the RNA-seq read uniformity metrics. 
I developed the entire RNA-seq analysis pipeline, designed and did the actual polymerase 
ChIP-seqs, and did the integrated RNA-seq and polymerase analysis. Chapter 4 will be 
published as two separate publications, one focusing on RNA-seq in a methods-oriented 
paper (Mortazavi, 2008), and another focused on the C2C12 differentiation story and the 
polymerase stalling changes. Chapter 5 concludes with a brief discussion of the future of 
studies of gene-regulation using the methods described herein. 
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C h a p t e r  2  
COMPARATIVE GENOMICS MODELING OF THE NRSF/REST REPRESSOR 
NETWORK: FROM SINGLE CONSERVED SITES TO GENOME-WIDE 
REPERTOIRE 
Abstract 
We constructed and applied an open source informatic framework called Cistematic in an 
effort to predict the target gene repertoire for transcription factors with large binding sites.  
Cistematic uses two different evolutionary conservation-filtering algorithms in conjunction 
with several analysis modules.  Beginning with a single conserved and biologically tested 
site for the neuronal repressor NRSF/REST, Cistematic generated a refined PSFM (position 
specific frequency matrix) based on conserved site occurrences in mouse, human, and dog 
genomes.  Predictions from this model were validated by chromatin immunoprecipitation 
(ChIP) followed by quantitative PCR.  The combination of transfection assays and ChIP 
enrichment data provided an objective basis for setting a threshold for membership and 
rank-ordering a final gene cohort model consisting of 842 high-confidence sites in the 
human genome associated with 733 genes. Statistically significant enrichment of NRSE-
associated genes was found for neuron-specific Gene Ontology (GO) terms and neuronal 
mRNA expression profiles.  A more extensive evolutionary survey showed that NRSE sites 
matching the PSFM model exist in roughly similar numbers in all fully sequenced 
vertebrate genomes but are notably absent from invertebrate and protochordate genomes, as 
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is NRSF itself.  Some NRSF/REST sites reside in repeats, which suggests a mechanism for 
both ancient and modern dispersal of NRSEs through vertebrate genomes.  Multiple 
predicted sites are located near neuronal microRNA and splicing factor genes, and these 
tested positive for NRSF/REST occupancy in vivo. The resulting network model integrates 
post-transcriptional and translational controllers, including candidate feedback loops on 
NRSF and its co-repressor, CoREST. 
The Cistematic source code and associated databases are available at 
http://cistematic.caltech.edu. All data in this paper, as well as the scripts used to generate 
them, can be found at http://cistematic.caltech.edu/~alim/cispaper. 
Introduction 
Specific repressors, such as canonical zinc finger transcription factors, stand out in 
vertebrate genomes because of their large number, significant expansion in mammals, and 
the diversity of cellular and organismic functions they affect (Hamilton, 2003).  The Krab 
family of zinc finger sequence specific DNA-binding repressors, for example, numbers 
over 400 in rodent and human genomes (Dehal, 2001; Shannon, 2003).  For the vast 
majority of these, nothing is known about their target gene repertoire or binding motif.  A 
few, studied in more detail, play important roles in diverse cellular and organismic 
functions ranging from regulation of rodent male specific genes by the Rsl (regulator of sex 
limitation) Krab repressors (Krebs, 2005), to lipid metabolism and possible predisposition 
to hypoalphalipoproteinemia by znf202 (Wagner, 2000).  Much more is known about 
NRSF/REST, a zinc finger repressor famous for negative regulation of neuronal genes in 
non-neuronal cell types, and in neuronal stem cells and progenitors prior to differentiation 
(Schoenherr, 1995; Chong, 1995; Chen, 1998).  The main isoform of NRSF represses 
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transcription by recruiting cofactors such as CoREST (Andres, 1999), CTD phosphatases 
(Yeo, 2005), mSin3A, and histone deacetylases (Huang, 1999). Another isoform, REST4, 
is thought to act in a dominant negative fashion (Hersh, 2003). In addition to neuronal 
development, NRSF/REST may have other roles in cardiac development (Kuwahara, 
2003), pancreatic islet development (Atouf, 1997; Abderrahmani, 2001), and perhaps B- or 
T-cell lineages (Scholl, 1996).  Little is known about which genes affecting these non-
neuronal lineages are direct NRSF/REST targets, or how many overlap with the neuronal 
set.  
A first step toward understanding how a regulator fits into the design logic and function of 
a gene network is to define its genome-wide target gene set.  In multicellular animals and 
plants, this is not easily done by direct experimental measurements, because the matrix of 
all possible target DNA sites, across many tissues and developmental states, is so vast.  An 
alternate starting point is to use comparative genomics, constrained by some smaller sets of 
functional data, to generate a computational genome-wide model that can then be tested 
directly and interrogated to develop new focused hypotheses.   
Two considerations make the NRSF/REST repressor a superior candidate for this analysis.  
First, factors with tandem arrays of zinc fingers can recognize relatively long and specific 
target motifs, and this makes computational approaches for finding target genes more 
feasible.  Specifically, NRSF has a 21 bp binding site (NRSE or RE-1), and  much is 
known about where and how NRSEs function.  They can direct repression from positions 
within 5’-UTRs, in introns and at intron/exon junctions, as well as upstream of the 
transcription start and downstream of the coding stop (Schoenherr, 1996; Thiel et al., 
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1998).  One study also reported that repression can extend to neighboring genes at one 
locus, although it is not clear whether this is general or not  (Lunyak, 2002).  NRSF 
transcriptional repression also appears to be tuned in vivo for strength and timing at 
different target genes during the progression from pluripotent stem cell to differentiated 
neuron or glial cell (Kuwabara, 2004; Ballas, 2005).  It is not known whether these 
distinctions, so far studied for only a few genes, reflect differences in the sequence, 
number, or organization of NRSE sites.  
The second virtue of NRSF/REST for genome-wide target prediction is that a collection of 
NRSF sites has been quantitatively assayed for activity in vivo (Schoenherr, 1996; Bruce, 
2004).  These assays, which include sequences that resemble the consensus binding site but 
lack function, are invaluable for calibrating and interpreting any model of NRSF binding 
derived by other criteria, including evolutionary conservation of NRSE occurrences. 
In addition to direct transcriptional regulation, post-transcriptional and translational 
mechanisms mediated by microRNAs are implicated in neurogenesis.  Cells undergoing 
terminal differentiation express tissue-specific microRNAs that are currently thought to 
modulate translation and/or degradation of large networks of target mRNAs (reviewed in 
Kosik, 2005).  miR-124a, for example, is neuron-specific and can target hundreds of genes 
when expressed in HeLa cells (Lim, 2005).  A broad survey of microRNA expression in 
brain and neuronal cell culture (Sempere, 2004) suggests there are at least a dozen different 
microRNAs that are predominantly expressed in the brain. While prediction of likely target 
sites in 3’ UTRs of known mRNAs has been very active (John, 2004; Krek, 2005; Lewis, 
2005), little is known about how microRNAs are themselves transcriptionally regulated, 
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except that microRNAs located within introns of protein coding genes tend to be expressed 
along with their “host” gene (reviewed in Ying, 2004).  This emerging picture raises the 
question of how transcriptional regulators are connected to and coordinated with the post-
transcriptional ones. 
 In the first part of this work, we use NRSF/REST as an amenable test case to build a 
comprehensive genome-wide model for the corresponding gene cohort.  To do this, we 
develop a set of generally applicable algorithms and open source software tools 
(Cistematic) to make and refine site predictions and enumerate the target gene cohort.  We 
show it is possible to begin with a single biologically defined, evolutionarily conserved 
NRSF/REST site, then use conservation among mouse, human and dog genomes to 
develop a refined model for NRSF sites.  The resulting model is compared and contrasted 
with prior ones (Schoenherr, 1996; Bruce et al., 2004), and we show that the major known 
functions of NRSF can be deduced computationally by using RNA expression and GO 
analysis modules in Cistematic.  We test our model by experimentally measuring in vivo 
binding at 113 loci by chromatin immunoprecipitation followed by Q-PCR.  In the second 
part of the study, we use the PSFM model to investigate evolution of the NRSF network 
over much greater evolutionary distances, and to develop and test specific hypotheses about 
links between NRSF/REST and post-transcriptional regulatory pathways.  High confidence 
candidate sites near neuronal microRNAs and splicing factors are identified, and in vivo 
interaction of NRSF at these loci is experimentally verified.  
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Experimental outline 
The availability of multiple whole-genome DNA sequences raises the possibility of 
building strong predictive models for the entire binding site repertoire of a sequence-
specific DNA binding factor by leveraging preferential conservation of functionally 
important sites.   We used a two-part strategy that begins by deriving and refining a PSFM 
model for the binding site.  The starting point is one or more functionally tested and 
conserved instances to seed a multi-genome search for additional conserved instances.  The 
cisMatcher algorithm used to do this is designed to focus on site instances that are 
embedded in somewhat larger conserved domains.  The reasoning is that functional sites 
are often located within larger conserved cis-regulatory modules.  At later times in the 
process,  one can exercise an option to recover other instances of the site that do not require 
conservation beyond the boundaries of the site model.  The second process develops a 
model for the genome-wide cohort of genes associated with sites defined by the fact that 
they match the PSFM at or above a specified score.  At this stage, various conservation and 
gene geography criteria are selected and applied.  They can require, for example, that 
PSFM match sites occur near orthologs in multiple genomes and that candidate cohort 
genes be located within a specified distance of a PSFM match site.  Thus the refined PSFM 
from the first part of the process is used to interrogate the genome(s) to find which genes 
are located near site instances.  The PSFM match score, coupled with archival and new 
experimental data, is then used to help establish an appropriate threshold for inclusion in 
target gene cohort.  
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Deriving and refining a conservation-based PSFM site model.  
The Cistematic pipeline is outlined in Figure 2.1 and summarized here, with details in 
Methods.  In one experiment, the derivation pipeline was initiated with orthologs from a 
single gene, SCG10 (STMN2) in human, mouse, and dog genomes (Mori, 1992; 
Schoenherr, 1995).   This seed PSFM was used to run a genome-wide search that used the 
cisMatcher algorithm. It collected additional similar instances that occur in domains of 
conservation (here set for 87.5% PSFM match and 85% similarity in a 25–65bp window) 
shared by at least two of the three participating genomes (Fig 2.2 and below).  These  
 
conserved occurrences (81) of the motif were then used to derive a refined SCG10 PSFM, 
which we call NRSE2.  In a second experiment, by contrast, we began with a collection of 
Figure 2.1. Experimental approach — A. 
Matches from genome-wide matches to the 
initial NRSE PSFM (SCG10) were analyzed 
with cisMatcher and used to create a refined 
NRSE PSFM (NRSE2). B. A refinement 
starting with a PSFM of 33 known sites 
(Table S2) produces a result very similar to 
NRSE2. C. NRSE1 (consensus: 
NTYAGMRCCNNRGMSAGNNNN; Bruce, 
2004) and NRSE2 were searched for, 
genome-wide, with either its consensus or 
with its position-specific frequency matrix 
(PSFM). Their respective gene cohorts were 
then analyzed for Gene Ontology (GO) 
enrichment and expression analysis (I). The 
NRSE2 PSFM was further processed and 
analyzed for GO enrichment and expression 
analysis of two subsets: (II) human genes 
with matches that co-occur in mouse and/or 
dog, and (III) human genes that are nearest to 
the “most conserved” matches, as identified 
by cisMatcher. 
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33 different known NRSEs, used them to develop the seed PSFM (nrsePWM33). In a third 
experiment, we ran the PSFM pipeline on several other individual NRSE instances.   
 
The resulting site models were remarkably similar to each other (Fig 2.3).  We conclude 
that cisMatcher, operating over this set of genomes, derives a set of convergent PSFM 
models for NRSE sites.  This means that our refinement process, which draws into the 
model many additional conserved instances, is robust to the identity of the specific 
initiating NRSE.  
Figure 2.2. cisMatcher algorithm. After 
mapping motif instances across multiple 
genomes, each of these sequences are 
compared to one another in order to match 
conserved motifs across genomes regardless 
of their proximity to gene annotations. 
Example genome inputs and outputs are 
given on the right-hand side for a human 
versus mouse and dog comparison. 
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Estimating a membership threshold   
How similar to the site model does a sequence need to be to function in vivo?  We used 
multiple kinds of experimental data to iterate toward an informed and increasingly 
objective membership threshold.  Setting a threshold is, at this stage, a useful and necessary 
simplification, but there is no biochemical or biological reason to expect a crisp boundary 
between sites that do and do not bind the factor.  Fig 2.4A displays archival data for known 
NRSE sites, plus a few previously tested negative sites that resemble the NRSE, plotted as 
a function of PSFM match score.  These data suggested starting with an estimated 84% 
match score threshold.  We also asked if the PSFM match score correlated with the 
bioactivity of individual instances in a reporter transfection assay, drawing on data from 
Schoenherr (1996).  Remarkably, there was a significant correlation of PSFM match score 
with repression strength (R2 = 0.82, Fig 2.4B).   The repression activity data are in general 
Figure 2.3 Different seed motifs converge following motif refinement. A. 10 initial 
seed motifs from known or predicted sites are compared using the motif similarity score (see 
methods) to our starting motif (SCG10), as well as a PSFM of 33 known instances 
(NRSEpsfm33) and the refined version (NRSEpsfm33+R). The correlation median is 0.80. B. 
Motif refinement of SCG10 (called NRSE2) and of the 10 initial motifs (denoted with a +R) are 
markedly more similar, with a motif correlation median of 0.91, and several inter-motif 
correlations rising above 0.95. 
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agreement with panel 2.4A, and support a threshold value in the low 80s.  The relationship 
of PSFM match score with repression efficiency in the transfection assay may also indicate 
that both reflect binding affinity. 
 
 
 
 
 
Assembling and testing target gene cohort models.   
The three mammalian genomes were then searched for every match to NRSE2 above a 
predetermined threshold, and genes within a 10 kb radius were grouped into cis-regulatory 
cohorts of genes.  This cohort of human NRSE2-associated genes was filtered for 
evolutionary conservation by requiring that matches also exist within 10 kb of an ortholog 
in mouse and/or dog genomes using Cistematic’s cisAssociator algorithm.  Because some 
Fig. 2.4. Selection of a threshold for NRSE2 and correlation of score with 
repression activity. A. 33 known instances (filled triangles) and 4 false positives (filled 
ovals) listed in Table S1 were scored with the NRSE2 PSFM using a consensus score, as 
described in the text and methods. A threshold of 84% of the best possible score (match #5) 
was selected conservatively to exclude the known false positives. The PSFMs exclude about 
6% of known instances at this relatively high threshold. B. The NRSE2 PSFM score of 10 
known instances and 3 false positives were plotted against their relative repression in a 
transient transfection of a reporter from Schoenherr et al. (1996), where 100% and above 
reporter activity represents no repression. The regression shows a marked correlation between 
PSFM match score and repression (R2= 0.82). 
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known NRSF sites can apparently act in isolation without surrounding conserved elements, 
cisAssociator deliberately does not require alignment or additional conservation outside the 
site.  Note that when a match is within 10 kb of more than one gene, cisAssociator includes 
all genes into the cohort.  This choice is based on the report that single NRSE instances can 
apparently silence multiple nearby genes (Lunyak, 2002).  However, it also means that, 
even if the definition of the NRSE2 PSFM is optimal, some genes included in the cohort 
model will be false positives.  We also wanted to collect additional sites that might function 
from distances greater than 10 kb, but without greatly increasing false-positives.  The 
cohort was therefore expanded by using the Cistematic cisMatcher algorithm to identify 
genes with conserved NRSE2 matches that are distal.   
We then used the cohort model to revisit the threshold issue, evaluating it experimatally by 
sampling 113 candidate NRSE sites that spanned a range of high scoring and low scoring 
PSFM scores. Chromatin immunoprecipitation (ChIP) was performed and and assayed by 
quantitative PCR (QPCR)  (Fig 2.5).  These in vivo protein:DNA interaction data generally 
validate the PSFM model (see below) and the Probit model in Fig 2.5B suggests that a 
threshold around 84 is reasonable, but also indicates that there is no sharp PSFM boundary.  
This means that users of this and related models will select membership thresholds, or 
ranges for thresholds, to best serve different specific uses of the model for which pressure 
on sensitivity versus selectivity are different. 
How do previously identified NRSE cohorts, based on conventional consensus sites, 
compare with the new PSFM?  We compared the NRSE2 PSFM matches with instances 
found using the original (NRSE0) consensus of Schoenherr et al. (1996) and the recent 
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(NRSE1) consensus used in the genome survey of Bruce et al. (2004).  Cistematic  
recovered the respective gene cohorts corresponding to NRSE0 and NRSE1 instances. 
 
Fig 2.6 shows that NRSE1 contains a significant fraction of matches that score poorly with 
the PSFM model (< 80%), with many low-scoring NRSE1 matches occurring in complex 
repeats.  Matches within repeats were excluded from subsequent analyses for both NRSE1 
and NRSE2, although we note that individual instances embedded within repeats might be 
functional. 
Figure 2.5. Quantitative Analysis of 
Chromatin Immunoprecipitation of 
NRSF. A. 113 potential NRSE2 
matches, 42 of whom fell below our 
threshold of 84% (green vertical line), 
were assayed using chromatin IP followed 
by quantitative PCR. Fold enrichments 
were calculated by dividing the absolute 
number of genomic equivalents of each 
NRSE by the mean of the recovered 
amounts of 5 random non-genic, non-
conserved regions.  Fold enrichments that 
were above 3 standard deviations from the 
mean of the 5 random non-genic amounts 
(red line, 2.44x enrichment), were 
considered to be occupied sites. An 
exponential regression (black line in this 
semilog plot), which would correspond to 
the regression in Fig 2b, accounts for 
about half of the data’s variation (R2 = 
0.56). 13 of the 83 occupied sites (16%) 
fell below our 84% threshold. B. 
Cumulative normal distribution function 
of probit coefficient versus score with 
95% confidence levels shown by dashes. 
The estimated chance of a success match 
goes up by nearly half between 80 and 
84%. 
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We then asked how cisMatcher positive sites are distributed relative to gene anatomy.  
Many known instances of the NRSE that have been studied in detail are either intragenic or 
are located near the promoter, but it is not known how great a role ascertainment bias based 
on proximity has played in selecting them for study.  We mapped the genome-wide 
cisMatcher set, which is not biased by the method of selection for its position relative to 
adjacent genes.   There is an obvious enrichment of NRSF motifs within 5 kb of gene 
model start sites (40%), although a full quarter of the conserved matches are more than 10 
kb from either the 5’ or 3’ boundary of the nearest gene model, and 3’UTRs have 
substantial numbers.   
 
 
Figure 2.6. NRSE matches in repeats. Genome-wide human matches for the NRSE1 
(Bruce) consensus (top), the NRSE0 (Schoenherr) consensus, and the NRSE2 PSFM (threshold 
of 84%) are scored using the NRSE2 PSFM. Whereas all three NRSE motifs show matches 
within repeats (black), the NRSE1 motif disproportionally matches within repeats at scores 
between 70 and 76%. 
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Chromatin Immunoprecipitation (ChIP) analysis of predicted NRSEs 
We tested the NRSE2 cohort experimentally at 113 sites (Fig 2.5), 42 of which fell below 
our 84% threshold, by using chromatin IP coupled-with Q-PCR in Jurkat cells (see 
Methods).  Of 71 candidate sites ranking above the 84% threshold, 70 were ChIP positive. 
In contrast, at slightly lower PSFM match scores, 29 of 42 sites were negative for NRSF 
ChIP.  Thus, predicted sites could be quite effectively partitioned by PSFM score into those 
that will certainly be ChIP positive and those that are likely to be negative (p-value = 
8.6*10-16, Fisher’s exact test).  The associated Probit analysis allows one to select other 
thresholds and to consider the confidence limits at any selected threshold.  
Figure 2.7. Spatial distribution of cisMatcher-identified NRSEs. cisMatcher matches 
were binned based on their distance from the start of the gene model (either transcription or 
translation, depending on the model), which show that while there is a clear enrichment of NRSE 
around the start of the model, more than half of the matches are further than 5 kb away. 
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The 84% value is a conservative membership threshold designed to minimize false-
positives as much as possible, at the cost of accepting some false negative predictions 
(13/83, or 16%).  Cistematic provides the option of sliding the threshold to provide cohort 
models that correspond to differing stringencies for false positive or false negative 
members. 
Gene Ontology (GO) analysis of the NRSE2 cis-regulatory cohort.   
We next asked if functions of the NRSF-regulated cohort could be inferred based on 
enrichment of Gene Ontology (GO) terms.  Statistically significant enrichment, subject to 
Bonferroni correction for multiple hypothesis testing, was observed for each cohort model 
but not for a large set of randomly scrambled version of the PSFM (Methods).  The NRSE2 
PSFM identified a larger cohort (660 human genes within 10 kb of an NRSE2) than the 
original NRSE0 consensus (362 human genes) or the seed SCG10-based PSFM (192 
human genes), with significant enrichments in functional GO categories such as “synaptic 
transmission”, “neurogenesis”, and “transporter activity”. These functions nicely 
recapitulate much of the NRSF literature.  In contrast, several GO categories significantly 
enriched in the larger NRSE1 cohort (1270 genes), such as “synaptogenesis” or “calcium-
dependent cell-cell adhesion”, are conspicuously absent from the other NRSE cohorts.  On 
detailed inspection, the latter results are mainly due to NRSE1 matches within the 
paralogous protocadherin " cluster.  This calls attention to a specific interpretation issue in 
GO enrichment analysis, which is the power of very similar paralogs in gene families to 
drive an entire term to significance.  Similar paralogy issues do not appear to dominate 
most significant other terms for any of the NRSE models. 
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Cistematic’s orthology matching function was next used to develop a conserved cohort.   
NRSE2 instances in human, mouse, and dog were collected and subjected to both 
cisMatcher and cisAssociator conservation criteria.  505 human genes met at least one of 
these criteria.  GO analysis of the resulting conserved cohort (Fig 2.8) shows further 
enrichment of several GO terms such as “transporter activity”, “synapse”, and “synaptic 
vesicle” when compared to the larger NRSE2 cohort, but these effects were not substantial. 
 
 
 
 
Figure 2.8. Gene ontology enrichment comparison of different NRSE cis-regulatory 
cohorts. Cohorts of human genes within 10 kb of a candidate NRSE0 (Schoenherr, 1996), NRSE1 
(Bruce, 2004), SCG10 (the original seed motif), NRSE2, All NRSE2 matches, and conserved 
NRSE2 matches were filtered of repeat matches and were analyzed for GO term over-
representation. Significantly enriched GO terms in at least one of the cohorts (out of 4576 possible 
GO terms) are shown. Numbers in cells represent the genes with the term in the cohort while 
numbers in parentheses represent the cohort size. Cells shown in color pass the threshold of 
significance, as determined by a Bonferroni correction. GO terms are sorted in decreasing order by 
p-values of the leftmost column. Note that GO enrichments are in term of decrease in p-values, 
which are directly correlated to the size of the cohorts, the number of genes in the shared 
association cohort with a particular GO term may go down or stay the same, while its significance 
increases. The NRSE1 motif behaves differently from the other definitions, as seen in the 
enrichment of synaptogenesis, which is the result of weak matches within the paralogous 
protocadherin " family. 
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To test the robustness of the GO analysis, the columns of the NRSE2 PSFM were 
scrambled repeatedly and the entire analysis pipeline was repeated 100 times (data not 
shown).  Only two scrambled motifs recovered any significantly enriched GO term, and 
they found just one each. No scrambled motif recovered significant GO terms when either 
of our conservation criteria was applied.  These results argue that enrichment of specific 
GO terms for NRSE2 is statistically sound.  
Comparative Expression Analysis of NRSE2 
We asked if the NRSE2 cohort is enriched in genes with a specific RNA expression 
pattern.  One prediction from prior studies of NRSF is that genes expressed predominantly 
in neurons will be enriched among true biological targets of NRSF (Ballas, 2005; Chen, 
1998).  The GNF gene atlas (http://symatlas.gnf.org, Su, 2004) of mRNA expression across 
79 human tissues was used to investigate the expression profile of our gene cohorts. 
CompClust (Hart, 2005) was used to cluster the NRSE2 cohort with k-means, k-medians, 
and DiagEM for k=5, 10, and 15. While all three algorithms returned similar pan-neuronal 
clusters, k-medians with a Pearson correlation metric and k=5 performed best qualitatively 
and was used for all subsequent analyses. The NRSE1 cohort was also clustered for 
comparison and produced similar clusters (Fig 2.9). The NRSE2 clustering is shown in Fig 
2.10A. In every clustering, one or more clusters had a distinctly brain-specific expression 
pattern, whose medoid weights are shown in Figure 2.10B. The percentage of each cohort 
falling within these brain-specific clusters ranged from 21% for NRSE1 to 40% for 
NRSE2. These reactions are significantly higher than the percentage of genes in GNF that 
have a Pearson correlation coefficient > 0.4 with our pan-neuronal medoid vector (1,482 
out of 16,054 genes with current NCBI Gene IDs, or about 9%), which gives a p-value of 
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8.0 * 10-71 (#2 = 316.58, #2 test for equality of distributions) for the neuronal enrichment of 
the NRSE2 cohort.  Nevertheless, the majority of neuronal genes are not associated with a 
recognizable NRSE. As would be predicted if many NRSE2 genes are regulated by NRSF 
in a neuronal context, there is a large (> 4-fold) enrichment for brain expression to 40% of 
all NRSE2-associated genes (Fig 2.10C, 2.9). 
Fig 2.10D gives match score distributions for the subset of genes that display a 
predominantly brain-specific RNA expression pattern. Genes within the brain-specific 
expression clusters share a similar scoring distribution pattern to the entire population of 
matches for both NRSE0 and NRSE2, whereas NRSE1 pan-neuronal matches show a 
bimodal distribution with a local minimum at 77%, which is below our predicted cut-off for 
repression activity (Fig 2.4B). Based on the PSFM score and its relation to functional 
assays, these NRSE1 instances are unlikely to be biologically active on their own. 
Confusion matrices (Hart, 2005) were used as a generalized Venn diagram to compare the 
overlap of the genes and expression pattern of the different cohorts. Fig 2.9 shows the 
confusion matrix for NRSE1 versus NRSE2; while both motifs agree on about 323 genes, 
both cohorts have large sets of non-overlapping genes (also known as outersects or relative 
complements; see Methods).  The outersect of NRSE1 is comprised of 615 additional genes 
not present in the NRSE2 cohort, whereas the corresponding NRSE2 outersect includes 
172 genes.  Neuronal genes comprise 34% of the NRSE2 outersect, but only 14% of the 
NRSE1 outersect (p-value = 5*10-9, #2 = 34.07, #2 test for equality of distributions) 
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Figure 2.9. Confusion matrix comparison of tissue expression pattern of NRSE1 
and NRSE2 matching genes. Human genes with an NRSE1 (top row) or NRSE2 (right-most 
column) with an expression pattern in the GNF survey of 79 human tissues, were clustered using 
the k-medians algorithm as described in the methods, with the cluster number in the upper-right-
hand corner, and the cluster size in the upper left hand. Genes that were unique to each dataset 
are shown in the bottom row / rightmost column, whereas genes that are in common between the 
two datasets are shown at the intersections of their respective clusters.  In both datasets, clusters 
with a blue border represent those genes with a high expression pattern in neuronal tissues and 
low expression pattern elsewhere.  These highly brain-enriched expressed genes make up a 
greater percentage of the NRSE2 cohort (40%) and of its outersect (34 %) than of the NRSE1 
cohort (21 %) or of its outersect (14%), the latter containing low-scoring matches by our PSFM.   
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Figure 2.10. Tissue expression pattern of NRSE associated-genes shows brain-specific 
expression enrichment. A. Human genes with an NRSE2 with an expression pattern in the GNF 
survey of 79 human tissues, were clustered using the k-medians algorithm as described in the 
methods. The second and fifth clusters, which encompass 40% of the NRSE2-associated genes 
shows a clear, brain-specific expression pattern. B. Weights of the k-medoid for cluster 2, with 
brain tissues highlighted in black. Note that cardiac myocytes and pancreatic islet cells also have 
positive weights. C. NRSE2 shows a 3.5 fold enrichment of “brain specific” genes (as defined by 
the medoid in B) compared to the GNF datasets and show greater enrichment than NRSE1. D. 
NRSE0 (top), NRSE1, and NRSE2 matches associated with genes than have a greater than 0.4 
correlation with the medoid vector in B. NRSE1 shows a double-humped distribution of matches, 
with matches weaker than 77% accounting for half of its matches; these low scoring matches are 
likely false-positives. 
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suggesting that consensus-based approaches like NRSE1 likely miss neuronal, NRSE-
associated genes (Figure 2.11) as also suggested by Zhang et al (2006).  
 
 
 
NRSEs are only found in vertebrate genomes 
NRSE2 matches were sought in genomes representing four invertebrate phyla (arthropod, 
nematode, echinoderm, and urochordate), together with seven additional vertebrate species.  
The remarkable result is that there are essentially no matches in invertebrate genomes, 
while all vertebrate genomes have the same order of magnitude of matches, regardless of 
genome size, with the pufferfish genome being especially informative (Fig 2.12).   
Figure 2.11. Venn diagram of NRSE1 and NRSE2 matching genes. A. Human genes 
with an NRSE1 or NRSE2 with an expression pattern in the GNF survey of 79 human tissues. B. 
Highly brain-enriched expressed genes make up a greater percentage of the NRSE2 cohort (40%) 
and of its outersect (34 %) than of the NRSE1 cohort (21 %) or of its outersect (14%), the latter 
containing low-scoring matches by the NRSE2 PSFM.   
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Tetraodon has a highly compressed genome that retains functional sequences such as ORFs 
at 3–5-fold elevated density.  A similar enrichment is seen for NRSE2 occurrences, which 
suggests that many of them are functional. The notable paucity of NRSE2 sites from the 
sea urchin, Drosophila, and Ciona (a urochordate) genomes argues that this repression 
network is absent up into protochordata, and it calls into question a previous tentative 
assignment of NRSF orthology to CoREST-interacting zinc fingers in C. elegans 
Figure 2.12. NRSE distribution in vertebrate and invertebrate genomes. A. The 
number of NRSE2 matches in mammalian genomes is relatively constant and include a 
significant number of matches within repeats when compared to other vertebrates, 
compared to the virtual absence of NRSE2 matches in invertebrates. B. The higher density 
of all NRSE matches / Mb of genomic sequences in pufferfish and zebrafish when 
compared to chicken suggest that fish and mammalian NRSE matches may have been 
expanding independently.  
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(Lakowski, 2003).  We also found that there is only one NRSE2 instance in the entire C. 
elegans genome, and it is not conserved in related worm genomes (C. briggsae and C. 
remanei).  
NRSE2 PSFM matches in the Tetraodon genome were related to matches in the human 
genome using cisAssociator to identify genes that remain associated with a high scoring 
NRSE in both fish and mammals.  There were only 33 matches that pass our criteria for 
best reciprocal match of the corresponding gene models. Occurrences of NRSE1 and 
NRSE2 in human repeats were analyzed using the UCSC repeatMasker annotations 
(http://genome.ucsc.edu, Kent, 2002; Karolchik, 2005) to address whether NRSE instances 
were found preferentially within the same repeat families.  While most NRSE2 matches 
(285 instances that meet or exceed the 84% match score threshold of Figure 2.4) reside 
mainly in the old vertebrate LINE2 family (226 matches, 79%), the overwhelming majority 
of NRSE1 consensus matches are in the ERV1 SINE family (1,858 of 2,339 matches, 
79%), which score between 70 and 74%.  This dichotomy is particularly striking because 
there are no NRSE2 matches in the ERV1 family.  With two or three strategic chance 
mutations, many of these repeats could achieve a low functional match score upon which 
selection could operate to favor further optimization. 
NRSE2 PSFM matches associated with microRNAs   
We proceeded to identify microRNAs in the human genome located within a 25 kb radius 
of a non-repeatmasked NRSEs.  The search radius was increased from the cisAssociator 10 
kb used for the NRSE2 cohort to respond to the observation that some microRNAs are 
embedded in, and expressed as part of, primary transcripts from protein coding genes 
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(Ying, 2004).   The sites were mapped against the UCSC entries of the microRNA registry 
(Griffiths-Jones, 2004; Weber, 2005).  Twenty-one microRNAs were identified (out of 326 
in the annotations) that represent sixteen distinct families.  All but one of these microRNAs 
had been previously characterized in the context of mammalian neuronal differentiation 
(Sempere, 2004).  MiR-375 was shown separately to be pancreatic "-cell line specific (Poy, 
2004).  It has been shown to target at least one gene (myotrophin) in the murine pancreatic 
cell line MIN6 in coordination with miR-124a (Krek, 2005).  Six NRSE-associated miR 
families also assayed in Sempere belong to 14 families (out of 100 surveyed) categorized in 
Sempere et al (2004) as “brain specific” or “brain enriched”. This pattern of coherent tissue 
specificity in expression is significant by the criterion of p-value of 0.02 (Fisher’s exact 
test). Seven of these microRNAs are located in introns of genes in the NRSE2 cohort, i.e., 
miR-153 in PTPRN, miR-139 in PDE2A; miR-9-1 in CROC4; miR-7-3 in C19orf30); and 
miR-24-1, miR-27b, as well as miR-23b in C9orf3.  In the case of miR-153, miR-139, and 
miR-9-1, the RNA expression pattern of the “host” gene falls in the brain-specific cluster 
(Fig 2.10A).  We assayed NRSEs from 11 of these by ChIP, and 10 scored positive for 
NRSF/REST occupancy. Our results for miR-124a and miR-9 agree with those reported in 
by Conoco et al. (2006). 
By inspecting lists of predicted target RNAs for NRSE-associated MicroRNAs (Lewis, 
2005) we found that CoREST (GenBank D31888) is a candidate target for three of our 
sixteen microRNA families (miR-29b, miR-124a, miR-153), and that NRSF itself 
(GenBank U22680) is a prospective target of miR-153, which has recently been shown to 
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be brain-specific in the zebrafish embryo (Kloosterman, 2006).   These postulated 
interactions create a potential feedforward loop that might have the effect of more quickly  
Name NRSE2 
PSFM 
(%) 
Distance 
(bp) 
Human 
Brain 
Mouse 
Brain 
P19  
+ RA 
NT2  
+ RA 
ChIP Fold 
Enrichment 
miR-153-1 97 14,208 Low Low Low  87.9 
miR-135b 93 10,826 Low Low Medium Low 79.6 
miR-124a-2 (*) 92 934 Medium Medium Low Low  
miR-9-1 (*) 91 5,681 High Medium High Low 7.97 
miR-29a (clust 1) 91 11,106 Medium Medium  Low 48.03 
miR-29b-1(clust 1) 91 11,818 Medium Medium  Low 48.03 
miR-212 (clust 2) 88 111    Low  
miR-132 (clust 2) 88 252 Medium High    
miR-133a-2 88 23,034 Low Low  Low 10.32 
miR-124a-3 (*) 87 487 Medium Medium Low Low 1.00 
miR-375 87 9,768 - - - - 8.56 
miR-7-3 86 1,097 Medium Medium Low Low  
miR-139 86 2,255 Medium Medium   29.37 
miR-9-3 (*) 86 3,050 High Medium High Low 11.12 
miR-124a-1 (*) 86 21,763 Medium Medium  Low 10.09 
miR-124a-3 (*) 86 2,394 Medium Medium Low Low  
mirR-24 (clust 3) 85 1,743      
miR-27b (clust 3) 85 2,319 Medium Low Low Low  
miR-23b (clust 3) 85 2,556 High Low Medium Medium  
miR-203 85 15,684 Low Low    
 
 
 
 
 
Table 2.1. microRNAs with associated NRSE2 matches in the human genome have a 
neuronal expression pattern. MicroRNAs with an NRSE2 match with PSFM score greater 
than 84% within 25 kb are shown along with their expression pattern from Sempere et al. 
(2004) in human and mouse brain as well as in mouse P19 and human NT2 cell lines 
undergoing retinoic-acid induced neuronal differentiation and where several miRs (bold) were 
categorized as “brain specific” or “brain enriched”.  Multiple microRNAs that are near the 
same NRSE are  labeled with the same “clust” ID. Entries with asterisks mark members of 
the same microRNA family that only have one entry in Sempere et al. (2004), and are hence 
shown with the same expression pattern. miR-375 was found separately to be expressed 
specifically in pancreatic " cells by Poy et al. (2005). Chromatin Immunoprecipitation fold 
enrichments for those microRNA-associated NRSE2 matches that were part of our 113 sites 
tested that are higher than 2.44 are considered positives. 
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or definitively down-regulating NRSF mRNA, as NRSF activity begins to fall (Figure 
2.14). This is given additional impetus by the observations that miR-153 is the microRNA 
with the best-scoring NRSE site (Table 2.1), and that its NRSE is embedded in PTPRN, a 
gene  expressed  strongly and widely in the nervous system. 
Discussion  
Our effort to model the conserved NRSF binding site and its target gene cohort differs 
substantially in design, tools, and outcome from prior attempts (Lunyak et al., 2002, Bruce 
et al., 2004).   We show that a successful PSFM site model can be derived from a single 
starting conserved NRSE by using iterations of motif refinement that incorporate additional 
site instances based on their conservation in multiple mammalian genomes.  Prior designs 
started from collections of multiple genes and produced conventional consensus sites. The 
NRSF PSFM model, unlike standard consensus motif, captures more information about site 
structure and affords a way to rank score matches, according to how well they match the 
model site.  We then tested the model experimentally across a range of PSFM match 
scores, including below-threshold borderline values, by ChIP/QPCR experiments.  This 
allowed us to assess the predictive qualities of the model relative to PSFM score.  These 
results encourage us to think that other relatively large and well-specified motifs could be 
usefully modeled in the same manner.   However it is important to recognize that shorter or 
less well-specified motifs — those with lower information content — will be difficult or 
even impossible to treat in this manner without additional algorithms to help discriminate 
functional occurrences from chance occurrences.  
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The PSFM site model captures more information about site preferences at each position 
than does a basic consensus.   We showed that the PSFM score correlated well with 
repression activity in transient transfection assays, arguing that it is a good first-order 
predictor of function.  Our ChIP independently showed that a high PSFM match score is 
predictive of in vivo NRSF occupancy at a given locus.   In most prior attempts to develop 
genome-wide target site models, including NRSF/REST studies, thresholds for 
membership were set arbitrarily. Based on NRSF/REST results, we think that integration of 
functional data in this manner is a natural way to bound computational models, establish 
confidence limits,  and then further refine them.  However, the apparent intensity of the 
ChIP interaction differed greatly from one positive locus to another, and we do not yet 
know what modulates levels of ChIP signal.  Obvious biological possibilities include 
chromatin structure, the presence or absence of various collaborating factors, and 
contributions from weaker NRSE sites near strong ones. 
Cistematic permitted us to efficiently generate and compare families of related models by 
varying parameters for conservation, position of sites relative gene anatomy, PSFM match 
stringency, and initiating seed sites.  The ability to do this in an automated manner is useful 
for finding out if a model is vulnerable to changes in input parameters.  In one pertinent 
example, we ran the pipeline beginning with different individual starting site instances, as 
well as a starting site pool, and found the results are robust to these variations in the initial 
seed site. 
The NRSE2 matches were analyzed for statistically significant functional covariates, from 
GO and from RNA expression data, using Cistematic modules designed for these purposes. 
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The software architecture (Fig 2.2, 2.13) and Open Source license are meant to encourage 
users to add other analytical modules at will.  A key conclusion from these experiments is 
that the principle function of NRSF could have been inferred solely from analysis of the 
final NRSE2 cohort model.   The enrichment relationships for neuronally expressed RNAs 
and neuronal GO functions within the NRSE2 cohort model were statistically far above 
background, despite incompleteness of GO annotations and imperfections in large-scale 
expression databases. RNA analysis of the NRSE cohort model benefited from strong 
sampling of brain tissues in the GNF data, and application of this approach to other motifs 
will be effective as global RNA datasets and GO annotations become more extensive.   Had 
we not already known that NRSF acts as a repressor, this also could have been inferred de 
novo from the NRSE2 cohort, together with expression data for NRSF/REST itself.  In 
mouse and human, the RNA profile for NRSF/REST is in frank opposition to the 
expression of its direct target repertoire.  These inferences show that PSFMs based on 
evolutionary conservation, and the target gene cohort models derived from them, can 
successfully predict organismic and molecular functions. The model generates hypotheses 
at the level of the entire network and also at the level of individual genes (Fig 2.14 and 
below).  
We think the approach taken here will be applicable to many transcriptional regulators in 
vertebrates that meet several criteria.  In practical terms, the cardinal requirement is a long 
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Figure 2.13. Cistematic architecture 
— Cistematic’s three-tiered architecture 
consists of the top-level Experiment classes, 
which provide a framework for accessing 
the data and results produced by the middle-
tier classes that form the Cistematic core. 
The Cistematic core itself relies on the 
Genome class and external programs to 
retrieve sequence data, annotations, and 
candidate motifs. 
 
and specific binding motif.   The length of the NRSE2 PSFM was critical for evading the 
most dire consequences of Wasserman and Sandelin’s “futility theorem”, namely that the 
vast majority of binding site instances predicted based on motif knowledge will have no 
functional significance (Wasserman, 2004).  Large families of factors whose members are 
likely to be eligible for Cistematic PSFM models include multifinger zinc finger class 
regulators that have been expanding rapidly in mammals (Shannon, 2003).  The second 
criterion is evolutionary conservation.  If a site/factor pair is very new, it will not be 
possible to leverage conservation, although the addition of increasing numbers of genomes 
will provide more branch length and resolution within clades such as the mammals 
(Boffelli, 2004).  Finally, whether the data are obtained before the initial PSFM model 
building or after, quantitative functional analysis of a sample of true positive and true 
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negative sites makes a powerful contribution that can be used to bound model membership 
and, in the best cases, to predict which instances are likely to be most active in vivo.  
The NRSF/REST network is a chordate invention.   
All currently available data argue that the neuronal NRSF repression network is a chordate 
invention.  Extending the analysis of NRSE2 matches to an additional eleven available 
genomes (Fig 2.13) revealed that while NRSE2 is not only absent in Drosophila as 
previously noted (Bruce 2004, Dahlman, 2005; Yeo, 2005), but also is essentially absent 
from all invertebrate genomes.  In sharp contrast, all vertebrate genomes we surveyed have 
between 302–1047 non-repeat matches, with an average of 750.  Within mammals the 
average number is modestly higher (842). Furthermore, preliminary surveys of amphioxus 
(a cephalochordate) and lamprey (a basal vertebrate) whole genome shotgun traces found 
that NRSE2 matches are present in both at high densities, while the motif is entirely absent 
from the urochordate, Ciona intestinalis.  This, along with the absence of any gene models 
that are convincingly similar to NRSF in Ciona or invertebrate genomes, suggests that 
NRSF emerged after the time of the last common ancestor shared by vertebrate and 
urochordates.  Paralleling this, NRSF/REST itself is present and highly conserved in all 
vertebrate genomes but absent from Ciona and multiple invertebrate genomes.  We did not 
detect NRSF in searches of sea urchin or C. elegans, and others have reported it absent 
from Drosophila, even though its principal co-repressors are present there (Dallman, 2004; 
Yeo, 2005). We did not detect NRSF in amphioxus trace coverage either, which could be a 
simple technical issue, but also raises the possibility that the target motif might have 
emerged ahead of the factor itself.  
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These data, combined with the existence of high-scoring sites within old LINE2 elements 
in the human genome, suggest that NRSEs may have first been distributed across vertebrate 
genomes via repeats at roughly the same time the NRSF DNA binding factor first 
appeared.  In such a scenario, NRSEs that land near or in genes and also confer some 
advantage when repressed by NRSF, are starting points to expand an NRSF network.  The 
much larger reservoir of weak, probably inert, NRSE1 (Bruce consensus) sites present in 
other repeat families might provide new NRSF/target gene pairs, given one or two key 
mutations. 
A subset of neuronal genes belong to the NRSE cohort   
RNA expression and GO term analyses showed that, under the NRSE2 model, NRSF does 
not directly act on a majority of genes with broad brain expression or with distinctly 
neuronal GO classifications.  There are roughly 1,400 genes preferentially and broadly 
expressed in adult brain, but only 11% of these have a high confidence NRSE2 motif.  
Some of the non-NRSE brain genes are probably glial, while another subset might be 
explained by weaker NRSEs, functioning individually or multiply. NeuroD1/Beta2, for 
example, is an attractive candidate target based on its expression pattern and function in 
neurogenesis and pancreatic islet cell genesis (Lee 1995, Huang 2000).   It has one NRSE  
~ 4.5 kb upstream that scores above our threshold in mouse and dog, but slips below 
threshold in human.  However, closer inspection shows that NeuroD1, like the related 
factors, NeuroG1 and NeuroG2, has additional low scoring NRSE matches embedded in its 
open reading frame.   Learning the rules governing use of weaker sites awaits a fully 
comprehensive experimental mapping of NRSF/REST in vivo interactions, but many 
neuronal genes probably depend on other factors for their neuronal expression.  A corollary 
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is that substantial numbers of additional pan-brain genes present in relaxed-stringency 
models, including the NRSE1 cohort, are likely neuronal due to other regulatory factors, 
rather than by the action of a functional NRSE.   
The converse is also true. Significant  (~ 4-fold) enrichment of the NRSE2 cohort for a 
brain expression profile leaves 60% unaccounted for.  Some reasons for this include 
incomplete gene annotations, genes restricted to specific kinds of neurons,  mRNAs present 
at levels below microarray threshold, and inclusion of some extra NRSE2 neighborhood 
genes into the model by the cisAssociator algorithm.  For example, several of the NRSE2 
associated transcription factors are well known for important functions in specific neuronal 
populations (Neurogenin-3, POU4F1, POU4F3, LHX3, and LHX5), but none are in the 
pan-brain cluster, nor is their expression utterly specific to brain.  It is also unclear how 
many genes in this model cohort might be targets of NRSF regulation relevant to its 
cardiac, pancreatic, or other functions. 
NRSF/REST interactions at neuronal transcription factor, microRNA and RNA  splicing factor loci   
The NRSE2 model target gene cohort included other transcription factors, microRNAs and 
splicing regulatory factors, all of which could extend the regulatory effects of NRSF/REST.  
Multiple NRSE instances are associated with transcription factors.  In addition to an 
expected complement of channels and synaptic proteins, highly conserved NRSE instances 
shared between human and fish are associated with transcription factors of interest.  LHX5 
and LHX3 are LIM homeobox factors important for specification and function of distinct 
neuronal populations.  LHX5 also controls regulation of neuronal precursor exit from the 
cell cycle in the hippocampus (Zhao, 1999).  Among NRSE2 instances conserved among 
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mammals, there are at least 25 other transcription factors, including NeuroD2 (McCormick, 
1996), a known mediator of neuronal differentiation; its conserved NRSE is located ~ 13 
kb downstream in mammalian genomes and was validated by the ChIP experiments.  
Another pro-neural transcription factor with an NRSE is Neurogenin-3, which marks both a 
subset of neuronal precursors and the early precursors of pancreatic islet cells (Sommer, 
1996; Gradwohl, 2000). In addition, several genes encoding RNA-binding proteins 
involved in RNA splicing and editing have NRSEs. Among these, NOVA2 is especially 
interesting because it regulates brain specific RNA splicing for a substantial group of 
synaptic proteins (Ule, 2005).  Both of NOVA2’s NRSEs (one in the third intron, the other 
one downstream in a LINE2 repeat) were occupied by NRSF/REST according to the ChIP 
data.  
NRSE2 matches are also associated with multiple neuronal microRNAs, several of which 
(miR-9-1, miR-9-3, miR-29a/miR-29b, miR-124a-1, miR-133, miR-135b, miR-139, miR-
153, miR-375), were validated by ChIP.  This suggests the circuit model in Fig 2.14: In 
stem cells and progenitors of Fig 2.14A, NRSF acts by repressing hundreds of protein 
coding genes and a handful of microRNA genes.  Upon developmental progression to the 
differentiated state (Fig 2.14B), NRSF is downregulated, first at the protein level and then 
transcriptionally (Ballas, 2005). Thus, its targets are freed — perhaps sequentially 
according to NRSE strength and number — for induction by various transcription 
activators.  In this model, feedforward connections of microRNAs onto CoREST and  
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Fig. 2.14. NRSF gene regulatory network model. A. NRSF in conjuction with CoREST 
and other co-repressors prevents the transcription of several hundred targets, including neuronal 
splicing factors, transcription factors, and microRNAs, as well as many terminal differentiation 
genes in a stem cell. B. Upon receiving neurogenic signals to terminally differentiate, the NRSF 
protein is degraded, which leads to derepression of its targets, which are now available to 
activators. In particular the NRSE-associated miR-153, which is embedded in the pan-neuronal 
gene PTPRN that has a NRSE in one of its introns, is predicted to down-regulate both NRSF and 
CoREST mRNAs (which is also the predicted target of the NRSE-associated miR-29b and miR-
124a), thus maintaining the derepression. 
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NRSF may modulate or accelerate the change from precursor cell to neuron.    MicroRNAs 
and splicing factors can go on to down-regulate other target genes not wanted in 
differentiating neurons.  This extended reach of NRSF from direct negative regulation to 
indirect positive regulation may also explain why only a fraction of neuronal genes are 
direct NRSF targets.  Embryonic lethality of NRSF null mice at day E10.5, before the onset 
of neurogenesis (Chen, 1998), might therefore result from mis-expression of neuronal 
microRNAs or splicing factors. 
METHODS 
Cistematic 
Cistematic is a Python package for automated motif identification in eukaryotic genomes. 
Cistematic has a 3-tiered architecture of objects written in the Python scripting language, 
which encapsulate the concepts of motifs, genome sequences and annotations, as well as 
motif-finding programs (Fig 2.13). The sequences and annotations that Cistematic uses for 
vertebrate genomes are derived from the UCSC Genome database. The primary objectives 
of Cistematic are to identify, refine, and/or map candidate motifs by determining their 
genome-wide distribution, their association with potentially co-expressed or co-regulated 
genes, and their GO enrichment. 
A typical Cistematic script consists of Python commands that perform a set of operations 
on certain Cistematic objects. A set of Experiment objects provides ready-made logic to do 
much of the work for the user. Most of these Experiment objects are designed to handle 
various aspects of phylogenetic footprinting across multiple metazoan and fungal genomes. 
Cistematic stores all of its information and results in SQL-queryable databases, using the 
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Sqlite 3.0 database library and the pysqlite 2.0 Python library. Cistematic can also generate 
tab-delimited files that can be imported into Excel for browsing. Cistematic currently runs 
on Mac OS X, Linux, and Solaris with Python 2.4 and sqlite installed and is available at 
http://cistematic.caltech.edu, along with the scripts used to generate the data in this paper, 
which are available at http://cistematic.caltech.edu/~alim/cispaper . 
Motif Similarity Score 
We define the motif similarity score of two PSFMs A and B as: 
MSS(A, B) = Max($ PearsonCorr(Ai,Bi),$ PearsonCorr(Ai,revBi))/length(A) 
where the index i represents the corresponding columns in the PSFMs, revB is the reverse 
complement PSFM of B and PearsonCorr is the Pearson Correlation. The MSS of two 
motifs ranges between 0 and 1.0. 
Genome-wide Cis-Regulatory Cohort Identification  
We used the Cistematic Locate experiment object class to map every instance of our motifs 
in human, mouse, and dog with either the consensus or the PSFM. The consensus score for 
a candidate window m of length L was calculated as: 
 
 where fi is the frequency of the nucleotide at position mi in the  i
th column of the PSFM. 
The best possible score for each PSFM was calculated and all matches that scored higher 
than the best score times a predetermined threshold (see Results and Fig 2.4) were accepted 
$ fi(mi) i 
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as matches. We have found that this particular scoring function performs as well as the 
traditional log-likelihood scoring (data not shown), allows us to use PSFMs without 
resorting to pseudo-counts or Dirchlet distributions to account for unseen valid nucleotides, 
and that the threshold can be intuitively related to the number of mismatches of the site to 
the consensus of the PSFM (about 5% per major mismatch in the case of NRSE2). 
One or more genes were identified for every match as members of the cis-regulatory cohort 
using the criteria that the match instance is (a) within the gene model or (b) within a 10 kb 
radius of either the 3’ or 5’ gene model boundaries. The relative location of the motif to 
each neighboring gene was noted as upstream, 5’-UTR, coding sequence, intron, 3’-UTR, 
or downstream. Results from each genome were saved to a separate file to serve as inputs 
for the ensuing steps of the analysis. 
We used the following annotations from NCBI or UCSC along with the corresponding 
genomic sequences from UCSC: human (NCBI Build 35), mouse (NCBI Build 35), dog 
(NCBI Build 2), and Tetraodon (geneid, UCSC tetNig1).  
Orthology Matching 
Genes from each genome that were flagged as neighbors in our genome-wide search were 
cross-matched using the Cistematic orthology database, which is built from a combination 
of NCBI’s Homologene (version 41.2) supplemented with pre-computed best reciprocal 
Blast searches for additional genomes that are not yet included into Homologene. 
Cistematic considers a motif occurrence in genes in a genome (human) conserved if the 
orthologous gene was present in the genome-wide search results for one or more of the 
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other genomes (here mouse and dog) or if it was present in another paralog in the original 
genome.  
cisMatcher and Motif Refinement 
Cistematic can identify motif conservation arbitrarily far from a gene using the cisMatcher 
algorithm, as outlined in Fig 2.2 and described below. The objective is to be able to specify 
gene proximity with flexibility that will bring in all flanking sequence to the next gene, for 
example, whether that distance is several hundred kilobases in a gene desert or only one kb 
in a gene-dense neighborhood. Cistematic genome-wide results were purged of matches 
that were marked as occurring within repeats; operationally, these are any of the partially or 
completely lower-case matches in the genomic sequences from UCSC, which are soft-
repeatmasked. Remaining matches were used to retrieve 65 bp sequences with 22 bp 
upstream from the motif, the motif itself, and the remainder downstream of the motif, 
which were saved in one file in fasta format per genome. The resulting sequence files from 
mouse and dog were used to build a Blast database, which was then searched using the 
human sequences. For each human match, the best match with an e-value less than 0.01 
with length longer than 25 bp and similarity greater than 85% in each of mouse and dog 
were imported into a custom sqlite database. A query was used to retrieve the best mouse 
or dog match for each human sequence that was available. For each human match with a 
conserved match in another genome, the nearest human gene within 200-kb was mapped 
using a radius that was expanded in 1-kb increments; in cases where more than one gene 
are within the same radius, the one with the lower starting numerical coordinate on the 
pseudomolecule was picked. Matches were annotated as occurring upstream, in the 5’-UTR 
or 3’-UTR, in the coding sequence, introns, or downstream relative to their nearest gene. 
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Matches within coding sequences were optionally filtered where indicated. Matching 
sequences, and their corresponding gene and relative locations are sorted in decreasing 
order of similarity and length. 
Human matches that were picked up by cisMatcher as well as their corresponding mouse 
and/or dog matches are then used to calculate the refined PSFM, which can then be used 
again by Cistematic to repeat the analysis. 
Gene Ontology Analysis 
Cistematic can flag particular Gene Ontology terms as enriched or depleted, at a 
statistically significant level, for any set of genes.  Cistematic tabulates gene ontology (GO) 
terms associated with a gene cohort using its own GO annotations, provided for 
mammalian genomes from NCBI’s loc2go dataset.  P-values are calculated for every GO 
term using the hypergeometric.  We apply a stringent protocol for significance in which the 
Bonferroni correction is applied to account for multiple hypotheses testing, where each GO 
term in the genome represents a hypothesis.  We report as significantly enriched or 
depleted GO terms that (a) are still significant following the Bonferroni correction, and that 
(b) contain more than 15 genes in the genome. Note that we only show the GO terms 
(rows) in our GO summary figures that have at least one statistically significant enrichment 
or depletion in one cohort (column) included in each figure.  
To test for the robustness of our analysis, we also generated 100 motifs where we 
scrambled the order of the columns in NRSF and repeated the entire analysis pipeline in 
Fig 2.1 and asked whether we recovered any enriched GO terms. 
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Expression Analysis 
The GNF expression dataset was pre-processed by discarding all entries with NCBI gene 
ID’s that are missing or that are not found in the latest NCBI human annotations.  If more 
than one expression pattern for the same gene ID was available, only the first one was kept. 
For the remaining genes, tissue replicates were averaged and each gene was median-
centered.  
Confusion matrices were done as by Hart el al (2005), with the following modifications to 
accommodate genes present in only one cohort. Outersects were defined as the relative 
complement of each cluster i of set A with respect to set B, i.e.,  
Ai \ B = {x | x % Ai, x & B} 
Cell Culture Conditions 
Culture conditions were as follows: Jurkat cells (Schneider et al., 1977) were grown in 
Advanced RPMI 1640 (GIBCO Invitrogen Cell Culture, Carlsbad, CA) supplemented with 
15% fetal bovine serum, 100 U/ml of penicillin-streptomycin, and 1x Glutamax (GIBCO 
Invitrogen Cell Culture, Carlsbad, CA) at 37°C with 5% CO2. 
Chromatin Immunoprecipitation 
This protocol was adapted from the laboratory of Peggy Farnham  
(http://mcardle.oncology.wisc.edu/farnham/protocols).  We cross-linked the Jurkat cells by 
adding formaldehyde to a final concentration of 1% for 10 minutes.  Cross-linking was 
stopped by adding glycine to a final concentration of 0.125 M.  Then, we collected 2 x 107 
cells per IP and washed once with 1x phosphate-buffered saline (PBS). We resuspended the 
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cells in lysis buffer (5 mM 1,4-piperazine-bis-(ethanesulphonic acid), pH 8.0, 85 mM KCl, 
0.5% NP-40, Protease Inhibitor Cocktail [Roche, Indianapolis, IN]) and centrifuged to 
collect the crude nuclear preparation. We resuspended the crude nuclear preparation in 
RIPA buffer (1x PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate [SDS], Protease Inhibitor Cocktail) and sonicated at power output 5–6 with the 
Sonics Vibra-Cell VC130 (Sonics, Newtown, CT) 4 times for 30 seconds each on ice to 
produce an average DNA fragment size of 500 base pairs. We centrifuged the chromatin 
solution at 4°C for 15 minutes at 20,000 rcf. Sonicated chromatin was incubated with 
NRSF mouse monoclonal antibody (12C11; Chen et al., 1998) coupled to sheep anti-mouse 
IgG magnetic beads (Dynabeads M-280, Invitrogen, Carlsbad, CA). After bead pelleting, 
the supernatent was retained as mock IP DNA for use in quantitative PCR. The magnetic 
beads were washed five times with wash buffer (100 mM Tris, 500 mM LiCl, 1% NP-40, 
1% Deoxycholate), and washed once with TE (10 mM Tris at pH 8.0, 1 mM EDTA). After 
washing, the bound DNA was eluted by heating the beads to 65°C in elution buffer (0.1 M 
NaHCO3 and 1% SDS). The eluted DNA and mockIP DNA were incubated at 65°C for 12 
h more to reverse the cross-links. Then, we extracted with phenol-chloroform and back 
extracted the organic phase once. We concentrated the DNA in the aqueous phase using the 
QIAquick PCR Purification Kit (QIAGEN Inc., Valencia, CA ), substituting 3 volumes of 
Qiagen Buffer PM for 5 volumes of Qiagen Buffer PB. 
Quantitative PCR 
We used Primer3 software to design primers by inputting 500 bp of upstream genomic 
sequence and 500 bp downstream of each predicted NRSE. Each primer pair was required 
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to flank the NRSE. We performed real-time PCR to quantitate the absolute amount of 
enriched DNA for each NRSE (amplicon size range between 60–217 bp, average size of 79 
bp). Each reaction contained 3.5 mM MgCl2, 0.125 mM dNTPs, 0.5 uM forward primer, 
0.5 uM reverse primer, 0.1X Sybr Green (Molecular Probes Invitrogen Detection 
Technologies, Carlsbad, CA), 1U Stoffel fragment (Applied Biosystems, Foster City, CA), 
and template DNA in a final volume of 20 uL. For each amplicon, we measured a standard 
curve of 50 ng, 5 ng, 500 pg, and 50 pg mock IP DNA in addition to our replicate ChIP 
DNA samples. We measured product accumulation for 40 cycles on the Bio-Rad Icycler 
and calculated the threshold cycle for each dilution of the standard curve. We then 
performed a linear regression to fit the threshold cycle from our ChIP DNA sample to this 
standard curve and divided that result by the amplicon size to measure the absolute number 
of genomic equivalents of that NRSE in the pool of ChIP DNA. We measured the levels of 
five random non-genic, non-conserved regions in each ChIP DNA preparation to normalize 
for any variation in absolute quantities of DNA in each prep. 
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C h a p t e r  3  
A COMPARATIVE ANALYSIS OF NRSF BINDING SITES IN 
BOREOEUTHERIAN MAMMALS USING CHIP-SEQ 
Abstract 
In vivo transcription factor-DNA interactions connect each transcription factor with its 
direct targets to form a gene network scaffold.  To map these interactions comprehensively 
across multiple mammalian genomes, we developed a large-scale chromatin 
immunoprecipitation assay (ChIP-seq) based on direct ultra-high-throughput DNA 
sequencing.  This sequence census method was then used to map in vivo binding of the 
neuronal restrictive silencing factor NRSF/REST, to 2155 regions in the human, 2520 
regions in the mouse, and 2104 regions in the dog genomes.  The data display sharp 
resolution of binding position (+/-20 bp), which facilitated motif finding and allowed us to 
identify noncanonical NRSF binding motifs.  These ChIP-seq data also have high 
sensitivity and specificity (ROC area > 0.96), properties that were important for inferring 
new candidate interactions that include key transcription factors in the gene network that 
regulates pancreatic islet cell development. Analysis of the evolution and turn-over of 
NRSF binding sites in the three boreoeutherian genomes shows that while there is a core 
subset of conserved sites and of conserved target-genes, two-third of the sites and target 
genes are specific to each species, and also show a preferential evolution of non-canonical 
sites into canonical sites over time. 
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Introduction  
Although much is known about transcription factor binding and action and the conservation 
of their binding sites at specific genes, far less is known about the composition, function, 
and conservation of entire factor:DNA interactomes, especially for organisms with 
genomes larger than yeast (Harbison, 2004), beyond several computational analyses of 
conservation of non-coding elements in fly (Stark, 2007), and mammals (Xie, 2005).  Now 
that the human, mouse, and dog genomes have been sequenced, it is possible in principle to 
measure how any transcription factor is deployed across each genome for a given cell type 
and physiological condition and to assess the evolution of the target repertoire.  Such 
measurements are important for systems level studies because they provide a global map of 
candidate gene network input connections and provide us with a test case for the value of 
transcription factor binding site conservation in identifying functional sites.  These direct 
physical interactions between transcription factors or cofactors and the chromosome can be 
detected by chromatin immunoprecipitation (ChIP; Kim, 2006).  In ChIP experiments, an 
immune reagent specific for a DNA binding factor (an antibody) is used to enrich target 
DNA fragments to which the factor was bound in the living cell.  The enriched DNA 
fragments are then identified and quantified. 
For the gigabase-size genomes of vertebrates, it has been difficult to make ChIP 
measurements that combine high accuracy, whole-genome completeness, and high binding 
site resolution (less than 200 bp).  These data quality and depth issues dictate whether 
primary gene network structure can be inferred with reasonable certainty and 
comprehensivity, and how effectively the data can be used to discover binding site motifs 
by computational methods.  For these purposes, statistical robustness, sampling depth 
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across the genome, absolute signal, and signal-to-noise ratio must be good enough to detect 
nearly all in vivo binding locations for a transcription factor with minimal inclusion of false 
positives.  A further challenge in genomes large or small is to map factor binding sites with 
high positional resolution. To address this issues, we turned to ultra-high-throughput DNA 
sequencing to gain sampling power and applied size selection on immuno-enriched DNA to 
enhance positional resolution.  
The ChIPSeq assay shown here differs from other large-scale ChIP methods such as ChIP-
chip (Kim, 2006), ChIP-SAGE (SACO; Impey, 2004) or ChIP-Pet (Wei, 2006) in design, 
data produced, and cost.  The design is simple and robust as, unlike SACO or ChIP-Pet, it 
involves no plasmid library construction.  Unlike microarray assays, 75% of the genome 
sequence that is single-copy are accessible for ChIP-seq assay (Fig 4.1D), rather than the   
~ 50% that are selectable to be array features in custom or tiling arrays. In addition, the 
sequence counting nature of ChIP-seq avoids constraints imposed by array hybridization 
chemistry, such as Tm-related base composition constraints, cross-hybridization, and 
secondary structure interference.  Finally, ChIP-seq is feasible for any sequenced genome, 
rather than being restricted to species for which whole-genome tiling arrays have been 
produced and hence makes genomes such as dog as practical to work with as human and 
mouse. 
ChIP-seq illustrates the power of new sequencing platforms, such as those from 
Solexa/Illumina and ABI/SoLID, Helicos (Harris, 2008), and Polonies (Kim, 2007) to 
perform sequence census counting assays.  The generic task in these applications is to 
identify and quantify the molecular contents of a nucleic acid sample whose genome of 
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origin has been sequenced.  The very large numbers of short of individual sequence reads 
produced by these instruments (currently reaching up to ~ 80 million reads of 25 nt, per 
instrument run, depending on the platform used) are extremely well suited for making 
direct digital measurements of the sequence content of a nucleic acid sample.  By 
determining a short sequence read from each of many randomly selected molecules from 
the sample that was incorporated into the library, then informatically mapping each 
sequence read onto the reference genome, the identity of each starting molecule is learned 
and its frequency in the sample calculated.  Desired levels of sensitivity and statistical 
certainty needed to detect rare molecular species can be achieved, in principle, by 
sequencing the library deeper.  Sequence census assays do not require knowing in advance 
that a sequence is of interest as a promoter, enhancer or RNA-coding domain as most 
current microarray designs do.  The Solexa/Illumina platform used in this chapter provides 
the best combination of price effectiveness and robustness at this time. 
We used ChIP-seq to build a high-resolution interactome map for human mouse and dog 
Neuron Restrictive Silencer Factor (also known as RE-1 Silencing Transcription Factor).  
This vertebrate-specific zinc finger repressor negatively regulates many neuronal genes in 
stem and progenitor cells and in non-neuronal cell types, such as the Jurkat T-cell line 
studied here using a variety of cofactors such as Sin3a, CoREST, and Small CTD-
phosphatases (Ballas, 2005). A primary reason for selecting NRSF as a test case is that 
prior studies provide a rich set of known “gold standard” target genes, including more than 
80 in vivo binding sites defined by ChIP-QPCR (Mortazavi, 2006).  A subset of these have 
also been tested for regulatory function by transfection assays (Schoenherr, 1996).  In 
56 
 
addition, the DNA motif bound by NRSF, called NRSE (also called Repressor Element-1), 
is long (21 bp) and well specified (Mori, 1992), and was in fact used to identify NRSF. 
This has led to a rich group of computational models for the site and for all its occurrences 
in several mammalian genomes (Mortazavi, 2006; Schoenherr, 1996; Bruce, 2004; Zhang, 
2006; Wu, 2006).  These sites provide a framework of explicit predictions that can now be 
tested by measuring repressor binding globally.  Finally, there is a high quality monoclonal 
antibody (Chen, 1998) that recognizes the N-terminus of NRSF efficiently in ChIP 
experiments in human (Mortazavi, 2006), mouse, and dog as well as a polyclonal antibody  
to the C-terminus that is also used in ChIP-studies (Ballas, 2005). 
An earlier version of this work focusing on identifying NRSEs in human Jurkats using only 
the monoclonal antibody was published in Science (Johnson, 2007) using an early version 
of the peak-finder. The results and figures below were rederived using the current enhanced 
version of the peak finder and also include unpublished comparisons to the polyclonal 
antibody as well as additional sites that are only found once, including low-prevalence 
multireads (reads that map to more than one, but less than ten locations in the genome). 
The mouse and dog ChIP-seqs are also novel and, when combined with the original data, 
allow for new insights that we could only speculate on at the time of the original paper. 
ChIP-seq with N-terminus monoclonal antibody in human Jurkat cells 
We first prepared two DNA samples for each ChIP-seq experiment: an NRSF/REST-
enriched ChIP sample and a companion control sample of the same fixed chromatin, but 
without immuno-enrichment.  In an effort to increase positional precision and to provide 
optimal substrate for the Solexa/Illumina sequencing platform, we introduced a size 
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selection step after crosslink reversal (Materials and Methods), which likely greatly 
contributes to our increased positional resolution.  DNA sequencing of each sample was 
performed by the standard Solexa protocol.  2 to 5 million 25 nt sequence reads were 
produced per sample, of which approximately half mapped to single sites in their respective 
genome (Table 3.1).  Sequence reads that map to more than 1 but less than 10 location in 
the genome were analyzed separately to gage their effect on the enrichment predictions, 
while reads mapping to more than 10 sites were removed from subsequent analyses.  This 
eliminates sequences in simple repeats and in some recent complex repeats.  The location 
of each remaining unique sequence read in the genome was recorded.  To accommodate 
polymorphisms relative to the reference genome, up to 2 mismatches were allowed.  The 
resulting sequence read distribution was processed with a ChIP-seq peak locator algorithm 
developed for this purpose (now part of dual use ERANGE package).  The algorithm finds 
a local concentration of sequence hits (a location cluster), and within that location calls a 
peak.  We then required of these a minimum 5-fold enrichment of sequence reads in the 
ChIP sample relative to the corresponding location in the control.  Five-fold enrichment is a 
conservative choice among enrichment thresholds commonly used in contemporary large-
scale ChIP studies.  A location that passed these criteria and also had 8 or more sequence 
reads per million reads (8 RPM, a threshold value selected based on the sensitivity and 
specificity analysis described below) was called as an NRSF-positive binding event. 
An example of primary ChIP-seq data from two independent experiments is shown in Fig 
3.1 for the NeuroD1 locus, a transcription factor involved in neurogenesis (Lee, 1995).  
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This positive signal, which has intermediate signal intensity identifies a novel NRSF 
binding target that is recognizably, but weakly related to the NRSF consensus.  The   
 
NRSF/REST sequence tag distribution centers directly over the only canonical NRSE motif 
in a 4 kb region, which is located in the open reading frame of the NeuroD1 gene.  The 
Figure 3.1. ChIP-seq reveals a canonical 
NRSE within the coding sequence of 
NeuroD1. 25 bp reads from multiple ChIP-
seq experiments in the Jukat cell line were 
mapped onto the human genome (UCSC 
hg18) in a 3 kb region of the neurogenic 
NeuroD1 locus. Individual reads for the 
control and ChIP and control for experiment 2 
using the monoclonal anti-NRSF N-terminus 
are shown in blue or purple, depending on 
whether they map to the forward or reverse 
strand, respectively. A 500 bp region was 
called by the ERANGE peak finder as 
enriched (black), within which 2 candidate 
sites were found. The canonical NRSE (CAN) 
is within 3 bp of the peak of the signal. The 
normalized UCSC genome browser 
wigglegram representations of experiment 2, 
experiment 1, and an experiment using the 
upstate polyclonal antibody against the C-
terminus are also shown. Note the that while 
all three signal peaks agree, experiment 2 
show a substantial signal enrichment versus 
both experiment 1 and the upstate experiment, 
even though the upstate experiment was done 
following the exact same protocol as 
experiment 2. The upstate (anti-C-terminus) 
experiment shows an equally strong peak at 
the non-canonical site (NC10), whereas the 
signal from the canonical site predominates in 
the anti-N-terminus experiments. 
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reads further show the typical ChIP-seq directionality transition at the binding site. This site 
was called as a ChIP-seq peak by the locator algorithm (now part of ERANGE). A previous 
study had implicated NRSF in repression of NeuroD1, but had failed to find a local site 
computationally and hence theorized long-distance repression to explain the effect 
(Lunyak, 2002), but our ChIP-seq results suggest a simpler explanation of a degenerate site 
within the NeuroD1 coding sequence.  Over the entire primary dataset, the distribution of 
sequence-tag number per location ranged from the threshold value of 8 RPM (Reads Per 
Million, threshold determined from the ROC curve analysis discussed below) to a 
maximum of 3174 RPM at the highest signal. The two ChIP-seq experiments produced 
similar results (Fig 3.2), with our experiment 2 mapping 2155 enriched regions, most of   
 
 
 
 
Figure 3.2. Comparison of ChIP-seq normalized counts between different experiments 
in enriched regions. We compared the results obtained from our different experiments done 
in Jurkats in the regions identified by our algorithm as enriched in experiment 2 above 
background. We first compare experiment 1 (60 IPs pooled, unamplified) versus experiment 
2 (4 IPs pooled, LM-PCR amplified before gel selection) and find a reasonable correlation 
(R2 = 0.64). The correlation of signals between experiment 2 and the anti-C-terminus 
(upstate) experiment is quite good (R2 = 0.85), suggesting that both antibodies see the same 
set of sites. 
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which occur in or near 1272 genes. We can recover 90% of these regions in Experiment 1, 
even though our enrichment is substantially lower. Since all subsequent experiments are 
done following the protocol for experiment 2, we will only use the results for experiment 2 
in all further comparisons. 
Assessing ChIP-seq efficiency with the C-terminus NRSF antibody in Jurkats 
ChIP-seq is only as good as the immunoprecipitation that is performed before the library 
building. Major sources of ChIP variability include experimental design (how many cells, 
how much cross-linking), epitope availability, as well as biological variability (expression 
level of a factor). In addition, the epitope might be species-specific, such as in the case of 
NRSF, where the N-terminus antibody was raised to specifically not recognize the chicken 
ortholog (Chen, 1998) A less-efficient ChIP would result in wanted bound-DNA fragments 
representing a smaller fraction of the total pool of recovered DNA; the resulting higher 
background would hence give a lower signal-to-noise ratio. Hence we will use the fraction 
of reads that fall within enriched regions as a measure of IP efficiency (called fIP) that 
allows us to compare the performance of the same antibody across different conditions or 
of different antibodies. The fIP for the two human monoclonal experiments are 0.12 and 
0.2 and are listed for all experiments in this chapter in Table 3.1. 
The availability of a second ChIP-grade commercial polyclonal antibody to the C-terminus 
of NRSF from Upstate allows us to compare our enriched regions independently in the 
same Jurkat cell line and assess the strength of the two antibodies relative to one another. 
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Sample IP reads Mock reads #regions (8RPM+) IP efficiency (fIP) 
Jurkat 1 3.7M 3.8M 1991 0.12 
Jurkat 2 1.7M 2.3M 2155 0.2 
Jurkat Upstate 3.1M 2.3M 1033 0.03 
EL4 6.5M 7.2M 1320 0.1 
C2C12 3.4M 7.5M 2520 0.1 
MDCK 5.9M 4.3M 2104 0.1 
Table 3.1. Summary statistics of our ChIP-seq experiments 
Our C-terminal NRSF ChIP-seq analyzed with the same parameters as experiment 2 only 
returned 1033 regions with a fIP of 0.03, which matches our expectation for lower 
enrichment with the polyclonal antibody based on ChIP-QPCR (data not shown). A scatter 
plot of the upstate polyclonal ChIP-seq regions to the monoclonal antibody shows that the 
signal from the two antibodies are highly correlated (Fig 3.2), but that the C-terminus 
ChIP-seq simply does not capture the weaker regions seen by the monoclonal antibody 
above threshold. While there exist neuronal settings where we expect the two antibodies to 
give us biologically significant differences in signal from recognizing different NRSF 
splice isoforms (see REST4 below), we do not believe this to be the case in Jurkats.  
NRSF ChIP-seq in mouse and dog 
In order to study the extent of conservation of NRSE in mammals, we performed NRSF 
ChIP-seq using the monoclonal N-terminus antibody in the mouse lymphoblastoid EL-4 
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cell line, the undifferentiated mouse myoblast C2C12 line, and the dog MDCK cell lines. 
While the EL-4 cell line can be thought of as roughly equivalent to Jurkats, C2C12 and 
MDCK cells are adherent cell lines. Using the same threshold as used previously, we found 
1320 enriched regions associated with 945 genes in EL-4s, 2520 enriched regions 
associated with 1927 genes in C2C12s, and 2104 enriched regions associated with 1300 
genes in MDCK. All three ChIP-seq experiments have an fIP of 0.1. However only 994 
regions and 716 genes were in common to both EL4 and C2C12, suggesting that the NRSF 
binding repertoire is not static, but might change to a certain extent depending on the cell 
state including variables such as chromatin accessibility. 
Assessing ChIP-seq resolution by comparison to known sites 
Human NRSF binding sites previously identified by QPCR or transfection assays 
(Mortazavi, 2006) plus a set of known negatives derived from custom Agilent tiling array 
experiments (data not shown) were used to measure sensitivity (successful detection of true 
positives) and specificity (successful rejection of true negatives) of the ChIP-seq assay in 
human.  A ROC (receiver operator characteristic) analysis provides a way of measuring 
and graphically portraying sensitivity (fraction true positive on the Y axis) versus 
specificity (1- the fraction false positives, displayed on the X axis) (Fig 3.3). The observed 
ROC areas for experiment 2 is high at 0.96.  The selected threshold of 8 sequence reads per 
region per million reads required for inclusion in the ChIP-seq interactome corresponds to a 
sensitivity of 87% and a specificity of 98%. We conclude that the ChIP-seq NRSF 
measurements are accurate and, as suggested by P-values (not shown), statistically robust. 
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We next assessed the precision of ChIPSeq site location  relative to 771 computationally 
high-scoring NRSE motifs in the genome that also have positive ChIPSeq signals by 
measuring the distance from the experimental ChIPSeq peak to the center of the 
computational NRSE sequence motif.  754 sites in this group were ChIP-Seq positive in the 
two human monoclonal experiments, and the center of a 21 bp NRSE motif was within +/- 
 
 
 
 
Figure 3.3. ROC curve for experiment 2 
(area under curve > 0.96) showing the 
performance of ChIP-seq in detecting 
previously validated true positives (y-axis, 
83) and true negatives (x-axis, 130). Our 
sensitivity at the thresholds used for our 
analyses are 87% and our specificity is 98%. 
All of the ChIP-seq false negatives are at 
marginal sites that barely pass the threshold 
in the validation assay. 
Figure 3.4 Distribution of the distance of the center of 771 canonical human NRSEs 
(84%+ of optimal score) in ChIPSeq enriched regions to the called ChIPSeq peaks in 
experiment 1. 46% of these peaks fall within the boundaries of the NRSE (here, +/- 10 
bp), and 94% of the canonical NRSEs fall within 50 bp of the peak. Increasing the number 
of reads, as in the case of the NRSF EL4 experiment, improves our resolution to within 20 
bp of 751 canonical sites. 
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50 bp of the called ChIP-Seq peak for 94% of these (Fig 3.4). Increasing read numbers as 
in the case of our mouse and dog NRSF ChIP-seqs improves our resolution to +/- 20 bp 
(Fig 3.4), while a new generation of ChIP-seq peak finders may achieve base-pair  
resolution level for solo sites. The resolution, which depends in part on size selection of 
sheared chromatin after immunoenrichment, is much higher than is typical for ChIP-chip or 
ChIP-SAGE (+/- 500 to 1,000 bp; Impey, 2004; Cawley, 2004).  
How comprehensive are the NRSF ChIP-Seq measurements?  Several lines of evidence 
address this question.  First, as shown in Fig 3.5, virtually all strong canonical NRSF motifs 
instances across the human genome were detectably occupied.  We defined strong sites as 
those having > 90% match to a previously developed motif model (a position specified 
frequency matrix), which is based on evolutionarily conserved site instances across 
multiple mammalian genomes (Mortazavi, 2006).  This high representation of detectable 
binding suggests that no strong sites were missed by undersampling.  It also implies that all 
sites are accessible for NRSF/REST binding in Jurkat cells, at least part time in some 
individual cells, although the degree of accessibility might vary and may account for wide 
differences in the number of tags per site (Fig 3.2).  Second, we observed ChIP-seq positive 
signals for sites previously studied in detail by transfection analysis (Schoenherr, 1996), 
and they correspond to a wide range of ChIP-seq signals, with all but one scoring positive 
in both ChIP-seq experiments.  Taken together with the sensitivity results (Fig 3.3), these 
observations suggest that the NRSF/REST interactome measurements are genome-
comprehensive and have been sampled deeply enough to include most sites known by any 
other criteria to be biologically active, even if relatively weakly.  This level of genome 
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completeness is attributable to the depth of Solexa/Illumina sequence sampling, and is 
substantially greater than in prior studies of the CREB interactome measured by SACO 
(Impey, 2004) and the p53 interactome measured by ChIP-pet (Wei, 2006). 
 
The impact of multireads on region and site prediction 
Two of the previously validated NRSEs in Jurkats (Mortazavi, 2006) that failed to pass the 
threshold using unique reads are associated with HBA1 and HBA2, which are the result of 
a relatively recent gene duplication in the human lineage. We therefore evaluated the effect 
of including multireads (reads that can map up to 10 places in the genome) on our 
predictions.  We reran dual-use ERANGE on the human Jurkat experiment 2 dataset 
supplemented with 0.2M ChIP Multireads mapping to 0.8M locations and 0.3M Control 
Multireads mapping to 1.4M locations. This resulted in 2276 enriched regions associated 
with 1,358 genes with an fIP of 0.19 with a 29 k additional enriched reads coming from the 
multireads (8%), which is in proportion with multiread prevalence in the genome. Many of 
these reads come from sites that we already called as enriched based on unique reads alone, 
Figure 3.5. Fractional site occupancy of 
NRSEs (y-axis) in Jurkat cells as a 
function of PSFM score (x-axis) for 
experiment 1 (unamped) and experiment 
2 (amped). Nearly all high-scoring sites 
scoring 90% or better are detected. 
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but we indeed recover 117 new genes that are part of gene families that are part of 
segmental duplications, including both HBA genes (Fig 3.6); while it is formally possible 
that only one of the gene family members would be associated with NRSF, it is difficult to 
justify that given the similarity of the binding region. However the increase in total number 
of reads means that some regions that barely passed our threshold with unique reads alone 
would fail to pass the same threshold once we included additional reads unless these 
regions also accumulated additional multireads; 31 genes that made the threshold 
 
 
Figure 3.6. Multireads can also be used to define NRSEs. The HBA1 and HBA2 NRSEs, 
which had been validated in Jurkats (Mortazavi, 2006), did not make our threshold with 
unique reads. The inclusion of multireads that map between 2 to 10 locations in the genome 
does indeed reveal both sites. 
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with unique reads alone fail to make our threshold once including multireads. While the 
rest of the analysis below is done without further inclusion of multireads, their inclusion 
may be ultimately necessary in order to correctly track the amount of site turnover in the 
evolutionary analysis. 
 
Identification of a novel family of non-canonical NRSE 
The positional resolution and low number of false positives in these experiments can 
greatly facilitate motif finding algorithms by significantly restricting the search space to a 
smaller region around the peak, which both improves signal-to-noise and also greatly 
reduces the run times for many algorithms.  The canonical NRSF binding site (NRSE) has 
Figure 3.7. Canonical NRSE weblogo 
(top) showing the two half-sites (“L” 
and “R”) and the canonical 11bp 
distance between the center two half 
sites of 11bp compared to weblogo of 
noncanonical NRSE (bottom) with 
half-site distance of 17, showing the 
lack of conservation in the spacer 
nucleotides. 
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been studied extensively (Mortazavi, 2006; Bruce, 2004), and this allowed us to ask 
whether we recover it using the motif finding algorithm MEME (Bailey, 1995) when a 
sample of the experimental interactome peak domains are used.  When given all sites in the 
top 10% of signal intensity (100 bp segments from 198 regions having 500 reads or more), 
MEME returned the full previously known known motif as its top motif.  Single or multiple 
matches to this canonical motif, using a 70% match threshold, account for 75% of all ChIP-
seq regions mapped in this study. 
 
We next focused attention on those remaining ChIP-seq positive regions that have 175+ 
RPM, yet have no canonical motif match.  There are 22 such locations, and when they were 
run in MEME, only two candidate motifs stood out. By inspection, the large canonical 
NRSF binding motif of 21 bp is naturally subdivided into two prominent, non-identical, 
non-pallindromic half-sites (Fig 3.7).  The two motifs from the MEME search correspond 
directly to the separate left and right sides of the canonical motif.  We next asked if these 
motifs occur at other ChIP-seq binding locations, and if they are organized in any 
Figure 3.8. Histogram of half-site 
distances in base pairs in the 
ChIP-seq-enriched regions, 
showing the observed (grey) and 
expected (black, based on 
frequency in genome) counts. In 
addition to the expected canonical 
peak at distance 11, there is also a 
enrichment of half-sites occurring 
within non-canonical distances of 
16–19 bp. 
1366 
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discernable pattern.  A distinctive pattern was discovered within 50 bp of many ChIP-seq 
peaks, in which left and right half site motifs are separated by additional “spacer” sequence 
that increases the center-to-center distance from the canonical 11 bp to 16–19 bp, or 
decreases it by one base pair to 10 bp (Fig 3.8).  Thus, the canonical site has two central 
positions that have no sequence specificity, and the noncanonical group is similarly 
oriented but has increased the separation distance by an additional 5–9 bp (Fig 3.7).  These 
linked half sites, oriented with respect to each other in the same way as in the canonical 
site, occur in NRSF ChIPSeq binding domains in a statistically significant manner relative 
to random sequence windows in the genome (#2= 1,309 for half-site distance of 17, P-value 
of 0) and account for 197 regions lacking a canonical motif (Fig 3B and S4). We also found 
that some binding locations have multiple clustered occurrences of noncanonical motif(s) 
along with a canonical one. 
There are no structural data available for NRSF, so we cannot relate this new family of 
binding site motifs to a known DNA binding structure.  However, the protein has eight zinc 
fingers in its DNA binding domain, and other C2H2 zinc finger proteins such as 
Zif268/Egr-1 bind DNA with three fingers per 10 bp turn, but they show considerable 
strain when binding with six fingers (Peisach, 2003).  This makes simultaneous binding of 
one molecule of NRSF to these non-canonical half-site configurations plausible, but it is 
also possible that the protein is bound to only one half-site at a time by using a subset of its 
fingers in these cases. Mutagenesis studies show that Fingers 3–8 are necessary for binding 
the full NRSE (Shimojo, 2001.) However, the REST4 isoform of NRSF, which only has 
the first 5 of the zinc finger and is missing the C-terminal, CoREST-interacting domain, 
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can act as an activator when binding cooperatively with the glucocorticoid repressor to turn 
on glutamine synthetase (Abramovitz, 2008), which is normally repressed by full-length 
REST. The REST4 binding site does indeed resemble the right half-site (Lee, 2000). 
Interestingly, REST4 would be recognized by our monoclonal N-terminus antibody, but 
not by the Upstate C-terminus antibody, which would allow us to verify its binding in vivo 
in the right setting. It will be interesting to learn if there are other functional and molecular 
characteristics that set the different classes of sites apart.  For example, do the different 
NRSF co-repressors differ in their interactions at non-canonical sites compared with 
canonical ones?  (Ballas, 2005; Yeo, 2005).  
We also asked whether half-sites are significantly enriched in our ChIP-seq neighborhoods, 
without regard to orientation or spacing, relative to expectations based on their occurrence 
in the genomes, and found that these regions are greatly enriched for left half-sites (#2= 
3,070) and right half-sites (#2= 11,674).  This range of configurations, from concentrated 
half-sites to the noncanonical 16–19 bp spaced left and right sites, to the canonical 11 bp 
spaced full site, is quite striking.  Significant NRSF binding occurs in vivo, according to 
our data, at all three kinds of loci. An analysis of the genes with NRSEs (Fig 3.9) reveals 
that while most of the genes with canonical (75–77%) and non-canonical sites (57–71%) 
are detected in both C2C12 and EL4, few of the genes with half-sites (6–21%) are in 
common. In particular, we found far more enriched half-sites in both C2C12 and MDCK 
when compared to EL4 and Jurkats, which could be a reflection of the more active 
metabolic state and hence open chromatin state of the two adherent cell lines. We discuss 
site conservation in the “transcription factor binding site evolution” section. 
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The conserved core network 
101 of the genes in the NRSF gene cohort in Jurkats are involved in transcriptional 
regulation (GO:0006355), and we found NRSEs associated with 22 microRNAs, and five 
splicing regulators.  NRSEs occur prominently in introns, including a non-canonical site 
located about 500 bp downstream of the transcription start site of the NRSF gene itself, 
which suggests the possibility of negative autoregulatory feedback.  We also found, as 
expected, that NRSF-bound loci are highly enriched in GO terms related to neurons and 
their development (Fig 3.10).  The enrichment for the experimentally determined sites 
exceeded that achieved for any computationally predicted target gene cohort (Fig 2.9).  
Synaptic transmission and nervous system development rank in the top three GO terms 
among 6,000, with P-values for over-representation of the NRSF target genes of 10-24 and 
10-17 (Fig 3.10).  
 
Figure 3.9. Comparison of the 
genes in common between the 
ChIP-seq experiments between 
C2C12 and EL4. While genes 
with canonical NRSEs were most 
likely to be in common between 
the two datasets, genes with half-
sites showed little overlap and may 
represent binding that is 
dependent on chromatin state. 
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How much of the NRSF gene cohort is shared across all three genomes? We find that 538 
genes have an NRSE in human and/or dog (Fig 3.11). While this number is quite close to 
what we predicted computationally, the number of genes falling into particular GO groups 
are quite different, in particular for genes related to ion transport. Furthermore, the genes 
analyzed in this section are being identified as conserved without multireads, whereas our 
Figure 3.10. Gene Ontology analysis of Jurkat NRSE gene cohort. The bulk of 
enrichment is coming from the canonical gene cohort (CAN). While the non-canonical 
gene cohort (NC) also shows some characteristic neuronal enrichment, the half sites 
(half) are only enriched in non-specific terms. 
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computational predictions do include genes that are impacted by multireads. All observed 
enriched GO categories come from conservation of the canonical gene cohort, as few genes 
with non-canonical or half sites show up as conserved (Fig 3.11). Interestingly, not all GO  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Gene Ontology analysis of Conserved NRSE gene cohorts. All of the 
GO enrichment is coming from the conserved canonical gene cohort. Neither the non-
canonical gene cohort nor the half sites show any enrichment. 
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terms are equally conserved. While two thirds of the genes annotated as involved in 
synaptic transmission show conservation, all of the genes annotated as neurotransmitter 
secretion are conserved, as well as most genes that have voltage-gated potassium channel 
activity or sodium transport annotations. 
The Pancreatic islet cell network 
Amongst the transcription factors identified is a set that have not previously been suggested 
as NRSF targets, but that are known to be critical in the gene network that drives islet cell 
development in the pancreas (Fig 3.12).  The transcription factors NeuroD1/Beta2, HNF4a, 
HNF6/Onecut1, and Hes1 were all detected here for the first time as in vivo binding targets 
of NRSF, and — together with Neurogenin3, which is a previously identified target 
(Mortazavi, 2006) — they are positioned critically in the regulatory network that controls 
pancreatic "-cell development (Davidson, 2006). We further find that Pax4, which has 
previously been described as a target of NRSF (Kemp, 2003) is only bound in mouse; this 
also extends to Ptf1a. Although in vivo binding does not ensure NRSF repression activity, 
these regulators are known to function as positive drivers of pancreatic neuroendocrine 
development.  If NRSF repression is active at all these sites, as might be the case in 
progenitor cells, the circuit repression would be very effectively blocked.  In this 
hypothesis, NRSF acts as a permissivity factor, gating entry into and progress through the 
developmental pathway. These pancreatic network sites are among the more modest ChIP-
seq signals, ranging from 33 RPM for HNF6 to 119 RPM for NeuroD1 in Jurkats, values 
that are comfortably above the significance threshold of 8 RPM, yet they fall in the bottom 
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quartile.  Thus these ChIP-seq data were statistically robust enough to map parts of this 
gene network that might otherwise have gone undetected or been highly uncertain.  
There are precedents in other systems that show that relatively weak sites are biologically 
important, specifically because they are, in the biochemical binding sense, suboptimal.  For 
example, in C. elegans, the Pha4/FoxA factor is the key activator of a large interactome, 
 
 
 
 
Figure 3.12. A role for NRSF in pancreatic islet specification. Current ChIP-seq-based 
implied scaffolding of NRSF regulatory interactions on top of gene regulatory network of 
pancreatic islet "-cell specification (adapted from Davidson, 2006) shows that NRSF represses 
several key transcription factors that sit on top of the GRN hierarchy, including the key 
gatekeepers ngn3 and NeuroD1, in addition to its already known terminal differentiation gene 
battery targets such as SNAP25. These targets represent some of the main drivers of "-cells’ 
neuroendocrine-like behavior. However, only part of the NRSF sub-network is conserved in all 
three genomes, which is most likely the set of genes most directly related to turning on the 
neurosecretory network. Note that NRSF is also found bound to one of its own promoters, 
presumably in order to autoregulate itself. 
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and a subset of target genes have suboptimal sequences and numbers of sites (Gaudet, 
2002).  In that system binding suboptimality is believed to help program the temporal order 
of action during development, with poor binders turning on at later times in the 
developmental progression, when Pha4 levels are highest.  By analogy, the regulators that 
govern the pancreatic network may be released from NRSF repression relatively early in 
downregulation of the repressor to create a permissive state that must be established before 
launching the neuroendocrine development program.  Also following this logic, the critical 
neurosecrotory gene SNAP25 is a classic NRSF target that is expressed later in 
development in differentiated islet cells, and it displayed relatively higher ChIP-seq tag 
scores than most of the transcription factors that are positioned higher and earlier in the 
network, thanks to its double-site.  Independent evidence suggests that SNAP25 expression 
depends on relief from NRSF-mediated repression in islet cells (Martin, 2008). Targets of 
the regulatory class highlighted here (Fig 3.12) can also participate in positive 
autoregulatory and cross-regulatory interactions that we expect would stabilize and push 
forward the circuit once it begins (Davidson, 2006).  This makes a “protective” repressor, 
active in nonpancreatic cell types or progenitor cells, an attractive piece of regulatory logic. 
Transcription factor binding site evolution 
Our gene level analysis showed that only about half of the NRSF gene cohorts in any one 
genome were present in the conserved core of the network, suggesting either a large 
turnover of sites or sites that are only bound in some conditions. We further wanted to find 
out whether there was any conversion between different types of NRSEs. Because the half-
sites are much shorter than the full 21 bp NRSE motif, they also occur widely over the 
genome, presumably mainly by chance.  This would mean that there is a rich pool of 
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possible binding sites from which higher affinity canonical sites could be gradually made 
and tested in evolution, as suggested previously (Zhang, 2006).  However, these sites were 
considered unlikely to interact with NRSF specifically (Zhang, 2006), whereas the non-
canonical motif family we define here show binding on their own, especially when 
clustered. We mapped human jurkats onto mouse EL4 binding sites and asked what 
fraction of these sites mapped onto sites in these two lymphoblastoid cell lines.  
We found that only 677 of the 1774 sites (38%) that were mappable between the two 
genomes actually overlapped between the two genomes (Fig 3.13). These numbers are 
similar when comparing jurkats to C2C12 and MDCK (data not shown), which suggest that 
this is not related to cell-type specificity. We then asked whether we could determine the 
state of the ancestral NRSE and see whether there is a preferred directionality of changes 
between the different classes by asking for sites that change classes in human when 
compared to mouse/dog and in mouse when compared to human/dog. We find a small, but 
definite preference for converting a non-canonical site into a canonical site rather than the 
other way around (Fig 3.14); this is in fact more pronounced, given that there is a larger 
starting pool of canonicals than non-canonical ones in our set of sites. We see almost no 
conversion of half sites into any of the other classes, but do see a couple of canonical sites 
decay into half sites. 
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Figure 3.13. Confusion matrix for human Jurkat NRSEs (rows) mapped onto mouse 
EL4 NRSEs (columns) using UCSC’s liftOver annotation between genome builds, 
which are based on global alignments. Of the three quarters of the sites that could be 
mapped onto the mouse genome, 38% were also enriched in our ChIP-seq experiment 
in mouse. 82% of these sites were of the same class as in human (red). 
Figure 3.14. Motif evolution for NRSF. Comparing sites that change class in one 
genome (mouse or human) but stay the same in dog and the other genome were pooled 
and show that there is a preference for going from a non-canonical site to a canonial one 
(red), rather than the other way around (blue). 
Mouse EL4 sites 
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Discussion 
From a technical perspective, the unparalled resolution of ChIP-seq in identifying the 
global map of NRSF binding sites in mammalian cell lines compared to previous 
technologies such as tiling arrays highlights the benefits of global assays. While non-
canonical sites were also enriched in our Agilent and Affymetrix tiling arrays (data not 
shown), we could not  locate or derive a motif to account for their reproducible binding 
without the 21 bp NRSE. The combination of ChIP-seq with motif finding delivered the 
unexpected surprise of the non-canonical NRSEs, which have been independently 
confirmed and also tested for function (Otto, 2007; Patel, 2007). As a well-documented test 
case of a repressor that was already known to be bound to many of its functional sites in 
multiple cell types, it was relatively straightforward for us to develop a strategy to identify 
the likely bound sites. However, our own data in this chapter, as well as ChIP-seq 
experiments for other factors that have been done since our original science paper, show 
that there can be a wide variability in IP efficiency and that using the same threshold can 
cause us to miss valid sites if using a single threshold. Although lowering our threshold 
requirements will recover additional regions, it would be difficult to know off-hand what 
the adequate threshold should be without the evidence from the monoclonal data. We could 
also justify a lower threshold by simply sequencing the upstate and control libraries deeper 
such that even the lower threshold and fold enrichment become unlikely to be seen by 
chance alone. For factors and antibodies where we don’t have existing calibration data, 
current rule of thumb for ChIP-seq sequencing used by the ENCODE community is to 
sequence a library to 10 million mappable reads, assuming that library complexity (the 
number of unique molecules actually captured in the library) is not a limiting factor. 
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What is the significance of the non-canonical NRSEs and of the half-sites? Our original 
Jurkat, as well as our mouse and dog data, make it clear that the canonical sites form the 
bulk of the sites associated with the neuronal targets that are typical of NRSF and are also 
the ones most likely to be conserved. While the gene ontology profile of the non-canonical 
genes is similar to that of the canonical set, our motif evolution analysis implies that they 
are more likely to become canonical than the other way around. Meanwhile, the half-sites 
remain something of a mystery, as they not only do not fit the gene ontology profile, but 
seem to change dramatically even between cell types. These half sites might only be bound 
opportunistically (or maybe more appropriately, incidentally) when the chromatin state is 
permissive, as opposed to the full sites (canonical or non-canonical) which more likely 
control/dictate chromatin state by recruiting its co-repressors. 
NRSF has long been thought to control the neurosecretory phenotype (D’Allessandro, 
2008; Pance, 2006; Bruce, 2006) and our results tie beautifully with the neurosecretory 
phenotype of the islet cells.  However, the most enlightening pancreatic islet gene is not 
even in Fig 3.12 and has been known since the very first survey done over a decade ago by 
Schoenherr et al. (1996). Somatostatin has two closely spaced NRSE in its intron. While 
somatosatin-producing '-cells are a minor component of pancreatic islets, somatostatin is 
highly expressed in the brain and several other endocrine cell types through the rest of the 
body such as the gastric D-cells. It is probable that any cell expressing somatostatin has 
shut off NRSF. It also suggests that the '-cells may have been the ancestral cell types from 
which the other islet cells were derived.  
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The direct cis-regulatory connection of NeuroD1 and NRSF provides an exciting 
connection between the most famous repressor of neurogenesis and the best known 
neurogenic factor. It is worth noting that other members of the NeuroD family are also 
NRSE associated, although not in their coding sequence. This brings the question of 
whether the NeuroD family became neurogenic because of NRSF or whether the fact that 
these factors were neurogenic permitted the rise of NRSEs. Together with NRSF’s 
regulation of neuronal microRNAs such as miR-124 and of neuronal splicing factors, this 
connection with NeuroD brings NRSF back into the role of an organizing regulation of 
neurogenesis. The fact that NRSF simply doesn’t seem to exist in non-vertebrates makes 
this fundamental role in neurogenesis even more remarkable. It will be fascinating to 
understand how NRSF arose and acquired such a critical role. 
Methods 
Cell culture and chromatin immunoprecipitation 
The Jurkat human T lymphoblast cell line was cultured according to standard protocols.  
NRSF/REST chromatin immunoprecipitation was performed as previously (Mortazavi, 
2006) with a custom monoclonal antibody (Chen, 1998).  For experiment 1, 70 separate 
chromatin immunoprecipitations, corresponding to a single batch of chromatin, were 
pooled for a single Solexa library preparation.  For experiment 2, four chromatin 
immunoprecipitations, corresponding to one batch of chromatin, were pooled for a single 
Solexa library preparation.  For both experiments, the controls used chromatin that was 
reverse crosslinked, phenol extracted, and purified on a QIAQuick PCR cleanup column 
(Qiagen).  The control chromatin matched the chromatin preps of the ChIPs used for each 
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experiment. EL4, C2C12, and MDCK experiments followed the experiment 2 protocol, 
except that a single IP was used for C2C12 and MDCK each. 
Library preparation for Solexa 
The Solexa library was prepared as per Ilumna's instructions.  The size selection of this 
library was performed by gel electrophoresis and subsequent excision and purification of 
DNA (QIAex II, Qiagen) in the ~ 200–700 bp range. The control library for experiment 1 
was constructed in an identical manner, using ~ 2 !g input DNA.  For experiment 2, we 
modified the Solexa library construction protocol to include a PCR preamplification (30 
sec at 98oC; [10 sec at 98oC, 30 sec at 65oC, 30 sec at 72oC] x 25 cycles; 5 min at 72oC) 
following linker ligation and preceding gel electrophoresis.  Size selection was performed 
by gel electrophoresis and subsequent excision and purification of DNA in the ~ 150–300 
bp range.  The control library for Experiment 2 was prepared in an identical manner, using 
~ 50 ng input control DNA.  We used QPCR (Mortazavi, 2006) to estimate the enrichment 
of five loci in these two libraries.  QPCR loci are (in genome build hg17, NCBI v35):  
chr1:151353339-15153415 (QPCR1), chr1:158498975-158499043 (QPCR2), 
chr16:88520383-88520482 (QPCR3), chr17:3247959-3248037 (QPCR4), and 
chr2:165920458-165920534 (QPCR5).  To calculate fold enrichment, each primer pair was 
normalized against two putative "negative" primer pairs, chr7:115817618-115817717 
(NEG1), and chr7:115712789-115712882 (NEG2). 
Enriched Region Identification 
Solexa ChIP and control reads were analyzed jointly for each experiment, to identify 
regions that have an over-representation of reads in the ChIP sample versus the control 
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sample, using a set of python scripts (available at http://woldlab.caltech.edu/ChIPSeq), 
which are now part of dual use ERANGE (Chapter 4).  Candidate enriched regions were 
identified as aggregations of 8+ RPM not separated by more than 75 bp and were assigned 
the normalized number of reads as a score. The threshold of 8 RPM was selected on the 
basis of the ROC analysis described in the text and in Fig 3.3; this threshold will need to be 
selected in future studies based on the structure of each data set, and with consideration of 
the false discovery rate that will be tolerated in a given study. Regions (a) with at least 20% 
or more control reads within the same boundaries (these regions corresponded typically 
either to satellite repeats or to the mitochondrial genome), (b) with peaks having less than 
five partly overlapping reads, or (c) with more than 90% of the reads in a single direction 
were filtered out and did not participate in subsequent analyses.   
Site Analysis 
We performed all motif-oriented analyses by using Cistematic (Mortazavi, 2006).  The 
NRSE2 PSFM (position specific frequency matrix) derived in that work was used to 
identify and local canonical NRSE sites (match score thresholds specified in the text and 
figure legends), across human genome hg18 (NCBI v36).  These site locations were then 
used to compare and call the distances from peaks of ChIPSeq read-tag distributions at 
each location.  The analysis of NRSE2 locations relative to called peak site locations was 
done on the shared set of NRSF ChIPSeq positive regions. Analyses in mouse and dog 
were done against mouse mm9 and dog cf2 genomic builds, respectively. 
We merged enriched shared regions within 500 bp of one another and combined reads 
within these regions.  We then applied a triangular 5-point smooth to reads within these 
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consolidated regions to identify the coordinate(s) with the greatest number of overlapping 
reads as the peak(s).  If there was more than one coordinate with the maximum score in the 
region, we selected the first one as the peak. 
Motif Searches by Meme and NRSE half-sites 
Enriched shared regions with > 500 reads (a subset that was selected to keep compute 
resources modest but to focus on quantitatively robust signals) were analyzed with MEME 
(Bailey, 1995) from within Cistematic using the zoops model for 10 motifs of 8–28 bp in 
length. We repeated the same analysis with enriched shared regions with 300 or more reads 
but no 70% NRSE2 match within them to identify non-canonical motifs. 
Following the results of the MEME analysis of the strongly enriched non-canonical 
regions, we divided NRSE2 into two half sites, i.e., NRSE2-left (position 1 through 10) and 
NRSE2-right (position 12–21).  Position 11 serves as motif-center, allowing us to compare 
distances between motifs in an orientation-independent manner.  We also defined the 
distance between positions 5 of NRSE2-left and NRSE2-right (corresponding to position 
16 of NRSE2).  This gives a canonical distance of 11 bp between the two half sites within 
NRSE2 and allowed us to consider shorter as well as longer distances.  We tabulated the 
occurrences in experiment 1 enriched regions of half-sites with distances of 1 up to 25 bp in 
various orientations, in addition to the canonical orientation (NRSE2-left followed by 
NRSE2-right) and compare their observed occurrences to their expected occurrences based 
on their genome-wide occurrences adjusted for the fractional size of the enriched regions 
(0.06% of the genome, for experiment 1).  We also analyzed other motif arrangements, 
such as right-left (opposite of canonical), left-left, and right-right. 
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P-value estimation for NRSEs 
P-values for sites were estimated by counting the number of 25 nt sequence reads in a 400 
bp window centered on the motif and comparing them to the observed frequency of that 
window count in the control. The P-values presented are from an extremely conservative 
calculation, in which the entire control dataset was used, unfiltered for sequence read 
pileups in repeat DNA sequences.   We know the latter to be artifactual because they also 
occur at the same location in the ChIP experiments.  Using instead a control from which 
these reads have been filtered eliminates any and all 400 bp windows with more than 11 
reads.  This results in effective P-values of 0 for all ChIP-seq positive sites. 
Final Site Analysis 
Based on the enrichment of particular distances in the canonical arrangement, we used the 
following procedure to identify NRSEs in each region of the common enriched region set: 
1. Analyze each region with NRSE2left and NRSE2right PSFMs using a threshold of 
70%. 
2. Accept any canonical half-sites with distances of 10, 11, 16, 17, 18, 19. 
3. Accept any 70% or higher canonical NRSE2 site that has not already been picked 
up by 2. 
4. If there is still no site assigned, pick the nearest half site to the peak of the region. 
5. Filter sites to only retain those with P-values lower than 10-4. 
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Associated Gene and Gene Ontology Analysis 
We used Cistematic to identify the nearest NCBI gene model in the human, mouse, and 
dog genomes within 20 kb of each enriched regions in the shared set of ChIP-seq positive 
regions.  We then analyzed this gene cohort for Gene Ontology enrichment using 
Cistematic, as previously described (Mortazavi, 2006).  Briefly, we tabulated the count of 
each GO term in our gene cohort, calculated a P-value for that occurrence by chance in a 
gene cohort of that size, and applied a Bonferroni correction for multiple hypotheses 
testing.  
Cistematic was also used for the orthology matching between the genes in the multiple 
genomes. 
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C h a p t e r  4  
QUANTITATION OF MOUSE RNA BY RNA-SEQ AND RNA POLYMERASE  II 
CTD PHOSPHOISOFORMS BY CHIP-SEQ REVEAL A NOVEL FORM OF 
PROMOTER STALLING  
Abstract 
We map and quantify mammalian transcriptomes by sequencing them deeply and recording 
how frequently each gene is represented in the sequence sample (RNA-seq).  This 
application of ultra-high-throughput DNA sequencing provides a digital measure of the 
presence and prevalence of transcripts from both known and novel genes.  Reference 
measurements consisting of 20 to 40 million mapped 25 bp reads are reported for polyA 
selected RNA from three adult mouse tissues and the C2C12 muscle cell line.  Exogenous 
RNA standards established linear quantification spanning five orders of magnitude in 
prevalence that allow for the calculation of transcripts/cell for all genes.  RNA splice events 
were detected for thousands of genes in each transcriptome by direct mapping of splice-
crossing sequence reads.  An independent and complementary genome-wide transcriptome 
map was made by measuring RNA polymerase II occupancy across the genome C2C12s, 
using phosphoisoform specific antibodies that mark different Pol II activity states.  We 
identify two distinct stalled pol II signatures  at a subset promoters with no detectable 
RNA-seq expression based on the level of Ser 2 phosphorylation. We finally show the 
change in these polymerase stalling states at genes upon myogenic differentiation of 
C2C12 cells correlates with specific biological processes. 
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Introduction 
Transcriptome analysis has become an important general phenotyping method, with 
microarrays of several kinds now in routine use.   However some significant limitations 
remain for expression array methods, including hybridization and cross-hybridization 
artifacts, dye-based detection issues, and design constraints that preclude or limit detection 
of RNA splice patterns and previously unmapped genes.   A different approach to large 
scale RNA analysis has been SAGE (serial amplification of gene expression) and related 
methods that use DNA sequencing of previously cloned 17–25 bp long tags from the 
transcripts’ 3’ (or 5’) ends (Harbers, 2005).  These sequence tags are then identified by 
informatic mapping to mRNA reference databases or, for longer tag lengths, to the source 
genome.  A strength of SAGE methods is that they produce digital counts of transcript 
abundance in contrast to the analog style signals from fluorescent dye-based microarrays.  
However, SAGE family methods rarely provide information about splice isoforms, 
promoter choice, or new gene discovery.   Past SAGE studies required bacterial cloning 
intermediates and have generally been limited to < 200,000 tags, so that fully 
comprehensive measurements across all abundance classes have been beyond reach. 
Recently, very dense whole-genome tiling microarrays have been developed and applied to 
transcriptome mapping (Kapranov et al., 2007).  In contrast to SAGE or conventional 
expression arrays, they have the capacity to discover new exons for known genes or 
entirely novel genes, and many new RNAs of different kinds have been reported.   But the 
amount of input RNA needed for these multi-slide tiling formats is high, and the other 
limitations of microarray sensitivity and specificity remain. 
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RNA-seq 
A simpler and potentially more comprehensive way to measure transcriptome output is to 
deeply sequence cDNA made from source RNA by ultra-high-throughput sequencing 
(Wold, 2008).  Resulting DNA sequence reads are then informatically mapped back to the 
source genome and counted so that the number and density of reads corresponding to any 
gene, exon, splice event, or previously unknown candidate gene can be calculated and 
compared with any other sequenced sample (Fig 4.1A).  If enough reads (> 20-40 M) are 
collected from a sample, it should be possible to unambiguously detect and quantify RNAs 
from all biologically relevant abundance classes, to map RNA splice choices in transcripts 
of moderate and high abundance classes, to discover previously unknown RNAs or exons, 
and to detect at least some characteristic transcripts from minority cell populations in 
mixed tissues such as brain.  
We tested these expectations by performing RNA-seq on polyA selected RNA from mouse 
liver, muscle, and brain tissues, and from the myogenic C2C12 cell line, using the Solexa 
1G sequencing system.   Among ultra-high-throughput sequencing platforms in wide use in 
2008, it maximizes total read number produced per machine run and per dollar.  High read 
number is critical for this assay because it optimizes the number of independent pieces of 
evidence (sequence reads) for the presence and abundance of transcripts from all genes.  In 
preliminary experiments we found that controlled hydrolysis of RNA samples prior to 
cDNA synthesis steps significantly improved uniformity of sequence coverage across 
transcripts (data not shown), which translates into greater sensitivity of detection, accuracy 
of quantification, and the completeness of splice and exon maps. Randomly primed cDNA 
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Figure 4.1. RNA-Seq outline. A Following 2 rounds of polyA selection, RNA is fragmented to 
an average length of 200 bp, which is then converted into cDNA via random priming. The 
resulting cDNA is then converted into a library for Solexa 1G sequencing. The resulting 25 bp 
reads are then mapped onto the genome. Normalized transcript prevalence (in RPKM — Reads 
Per Kb per Million reads) is then calculated with an ERANGE package algorithm.  B. Primary 
data from C2C12 myocyte RNA that map uniquely to a 1 kb region of the MyoD locus, 
including reads that span to introns.  The RNASeq graph above the gene model summarizes the 
quantity of reads, where each point represents the number of reads covering each nucleotide per 
million reads (normalized scale of 0 to 4.5). C. Detecting and quantifying differential 
expression. Mouse polyA-selected RNAs from brain, liver, skeletal muscle, and C2C12 
myocytes and myoblasts are shown for a 35 kb region of chr7 containing Myod, which is 
muscle specific, and its neighboring gene Kcnc1, which is adult muscle and brain-specific.  D. 
Multireads form a significantly larger fraction of the sequenced transcriptome than their 
fraction of the genome. E. A 10 kb region of the ubiquitin Ubb locus is shown. An ERANGE 
algorithm allocates multireads (2–10 occurances in the genome) using a weighting function 
based on the density of uniquely-mapping reads at each paralog (shown in red). 
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was made from 100 ng of 200–300 nt  hydrolyzed polyA RNA per sample, and a Solexa 
molecular library was then constructed according to the manfacturer’s standard protocol 
(Fig 4.1A).  10–30 million mappable reads were obtained from each library, with two or 
more independent libraries made for each tissue.  
Enhanced Read Analysis of Gene Expression (ERANGE) 
To analyze these data, we developed ERANGE package (Enhanced Read Analysis of Gene 
Expression, Fig 4.2) in order to 1) assign reads that map uniquely in the genome to their 
site of origin (Fig 4.1B, 4.1D), or, for reads that match equally well to several sites in the 
genome (“multireads”), allocate them to their most likely site(s) of origin (Fig 4.1D, 4.1E); 
2) detect splice-crossing reads and assign them to their gene of origin (Fig 4.1B); 3) 
organize reads that cluster together, but do not map to an already known exon, into 
candidate exons or parts of exons; and 4) calculate the prevalence of transcripts from each 
known or newly proposed RNA, based on sums of weighted unique reads, spliced reads, 
and multireads that mapped onto exons (Fig 4.2; Materials and Methods).  The new 
candidate RNA exons can be thought of as ESTs and, like ESTs, some are provisionally 
appended to existing gene models, if they meet several additional criteria (Materials and 
Methods).  Remaining unassigned candidate transcribed regions (labeled RNAFAR) can 
then be used, in conjunction with polymerase location data presented below, to support new 
or revised gene annotations.  
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Primary data from a 21 million-read transcriptome measurement of C2 myogenic cells (Fig 
4.1B,C) show key characteristics.  Prior studies (reviewed in Berkes, 2005) have 
established that the MyoD gene is expressed at a modest level in myoblast, at a lower level 
in adult muscle tissue, and is silent in liver and brain.  RNA-seq data matched these 
Figure 4.2. Enhanced Read Analysis of Gene Expression (ERANGE). The main steps of the 
computational pipeline are outlined to the left, with different aspects of read assignment and 
weighing diagrammed to the right, with the corresponding number of gene model reads in 
muscle shown in parenthesis. Reads under consideration are shown as black rectangle with their 
assignment to gene models shown in color, while reads falling outside of known or predicted 
(RNAFAR) exons are shown in grey. RNAFAR regions are shown as dotted lines and can either 
be assigned to neighboring gene models if close enough (purple) or assigned their own predicted 
model otherwise (green). Multireads (shown as trapezoids) are assigned fractionally to their 
different possible locations based on the expression levels of their respective gene models. 
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expectations, with 5,002 25 bp reads mapping uniquely to MyoD exons out of 21 M reads 
from a C2 myocyte RNA-seq library, but only 1 and 2 reads from individual liver and  
Sample 
 
Uniques 
 
Splices 
 
Multi (2-10) 
 
Multi (11+) 
 
Spikes 
 
No Match 
 
Used 
 
Total 
 
Brain 1 
 
50.3% 
 
3.1% 
 
9.7% 
 
1.7% 
 
0 
 
34.7% 
 
63.5% 
 
28.8M 
 
Brain 2 
 
54.3% 
 
3.3% 
 
10.6% 
 
1.6% 
 
0.1% 
 
25% 
 
73.4% 
 
48.8M 
 
Liver 1 
 
44.3% 
 
3.4% 
 
12.8% 
 
2.3% 
 
0 
 
37.2% 
 
60.5% 
 
29.6M 
 
Liver 2 
 
42.7% 
 
3.4% 
 
13% 
 
2.4% 
 
1% 
 
37.6% 
 
60% 
 
41.5M 
 
Muscle 1 
 
46.2% 
 
4% 
 
14% 
 
1.6% 
 
0 
 
34.2% 
 
64.1% 
 
30.1M 
 
Muscle 2 
 
44.6% 
 
3.5% 
 
15.3% 
 
1.6% 
 
1.6% 
 
33.3% 
 
65.1% 
 
37.2M 
 
C2C12 Undiff 1 
 
51.5% 
 
3.8% 
 
18.7% 
 
6.1% 
 
0 
 
19.9% 
 
74.0% 
 
22.8M 
 
C2C12 Undiff 2 
 
49.6% 
 
3.6% 
 
18.5% 
 
7.8% 
 
2.2% 
 
18.3% 
 
73.9% 
 
16.4M 
 
C2C12 24h R 
 
36.1% 
 
2.6% 
 
16.8% 
 
2.8% 
 
0 
 
41.8% 
 
55.4% 
 
35.2M 
 
C2C12 24h T 1 
 
34% 
 
2% 
 
16.2% 
 
2.8% 
 
0 
 
44.9% 
 
52.3% 
 
39.4M 
 
C2C12 24h T 2 
 
44.8% 
 
3% 
 
20.5% 
 
9.3% 
 
1% 
 
21.4% 
 
69.3% 
 
10.9M 
 
Table 4.1. RNA-seq summary read statistics 
brain RNA-seq libraries, respectively.   Reads mapping to exons are prominent, while reads 
in MyoD introns are at much lower density.  Another 255 reads that did not map to the 
mouse genome mapped uniquely across MyoD’s splice junctions, while 62 reads that can 
map from 2 to 10 places in the genome (“multireads”) fell on MyoD exons. However 
multireads are present at much higher percentages in our sequenced transcriptome than in 
the genome as a whole (Fig 4.1D) and can dominate over uniquely mappable reads for 
paralogous genes or genes with highly conserved domains, such as Ubiquitin B (Fig 4.1E), 
which has 1,946 unique reads, but also 65,466 multireads. Across the transcriptome, the 
read density in introns for all expressed genes was < 1% of levels in exons, as expected for 
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partially processed precursors present in whole-cell polyA RNA.  Data for technical and 
biological replicate determinations showed high reproducibility, with R2 of 0.96 (Fig 4.3A) 
and 0.95 respectively. Primary sequence read data for the mouse brain, muscle and liver 
replicates are available at http://woldlab.caltech.edu/RNA-Seq, and submitted to the Short 
Read Archive (SRA10030). The summary data about the datasets are in Table 4.1.  
 
 
 
Figure 4.3. Reproducibility, linearity, sensitivity, and splice detectability. A. Comparison of 
two brain technical replicate RNASeq determinations for all mouse gene models (UCSC), 
measured in RPKM (reads per kilobase of exon per million mapped sequence reads) which is a 
normalized measure of exonic read density (R2 = 0.96). B. 6 reference transcripts of lengths 0.3 
to 10 kb were added to the liver RNA sample  (1.2x104 to 1.2x109 transcripts per sample)  (R2 > 
0.99). C. The number of expected spliced reads for each gene model was predicted based on the 
number of introns and the exonic read density is compared with the observed number of splices 
(R2 = 0.90). D. Genes with two splice isoforms in the same tissue. 
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Mapping spliced reads and alternative splicing 
Splice-crossing reads, as shown for MyoD (Fig 4.1B), were identified by mapping 
otherwise unassigned sequence reads across all known splice events in all UCSC mm9 
 
 
 
 
 
Figure 4.4. Alternative splicing in Mef2D. A. 40 kb region encompassing mef2D, which is 
expressed in the myoblast and adult muscle (28 RPKM in muscle and 45 RPKM in brain) and 
its neighboring gene, which is expressed at a much lower level in brain. Whereas RefSeq has 
only a single annotation for Mef2d, UCSC has five (labeled  (-)).Whereas ( corresponds to the 
RefSeq model, * is a muscle-specific isoform (Martin, 1994). Our RNAFAR algorithm 
identified 7 regions enriched with reads that fell outside of the NCBI gene annotations (red) that 
were assigned by the algorithm to the Mef2d locus. B. 1.5 kb close-up of muscle specific 
alternative splicing at RNAFAR region “B”. The prevalence of splicing switches from the 
canonical exon to the RNAFAR exon upon muscle differentiation, as seen both in the ratio of 
spliced reads and in the number of reads falling on the two diagnostic exons. C. 5 kb closeup of 
3’ end of Mef2d. RNAFAR region C1 has a greater density of reads in the brain than in adult 
muscle. Both the brain and muscle datasets show reads across region C2, which is consistent 
with ) being the 3’UTR for mef2d in muscle. Spliced reads also show that the partially 
overlapping transcript AK007191/AK00852 is present in brain.  
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gene model splices.  Over our entire dataset, splice-spanning reads comprised ~ 3% of all 
mapped reads (Table 4.1), which is consistent with expected splice frequency from gene 
models across the genome (see Methods).  To assess the efficiency of splice detection, we 
computationally predicted all reads expected to cross known splices in a transcriptome, by 
considering all gene models and their respective levels of expression based on exon reads. 
Observed splice-crossing reads were in good agreement with predictions (Fig 4.3C).  We 
conclude that splice events can be readily detected and quantified for abundant and 
moderately abundant transcripts.  Alternative splice isoforms were detectable in proportion 
to their relative prevalence within and across tissues. For example, Mef2D (Fig 4.4) has a 
muscle-specific exon that is only prominent in adult muscle (Fig 4.4B), whereas Mef2D in 
the brain has a bleeding exon that does not go through a canonical splice (Fig 4.4C). In 
both cases, these features were not part of the NCBI or RefSeq annotations for that gene 
model and were thus picked up by our RNAFAR algorithm. However, our calculations of 
RNA prevalence were at the locus level and we explicitly did not attempt to quantitate 
transcript isoform prevalence, which would be greatly helped by the use of paired reads 
given that we typically detect more than 1 splice isoform for an alternatively spliced gene 
within the same tissue (Fig 4.3D) Detection of splice events is primarily a function of 
transcript prevalence (Fig 4.3C).  
Transcript quantitation 
To assess the dynamic range, linearity, sensitivity, and sequence coverage, we introduced 
into each experimental RNA sample a set of known RNA standards that were transcribed in 
vitro from Arabidopsis and phage lambda templates (Fig 4.3B). The RNA standards were 
designed to test for possible effects of sequence length and sequence composition on the 
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observed transcript abundance, and were added to the sample RNA at concentrations 
spanning the full range of abundances observed in natural transcriptomes.    RNA-seq data 
for the standards were linear across a dynamic range of five orders of magnitude in RNA 
concentration (R2 = .99) (Fig 4.3B).    
The RNA standards showed that the sensitivity of RNA-seq is, as expected, a function of 
molar concentration and transcript length.  We therefore quantified transcript levels in 
RPKM units (Reads Per Kilobase of exon model per Million mapped reads, Fig 4.1A), 
where reads counted include weighted unique, splice, and assigned multireads (Fig 4.2).  
This measure of read density transparently reflects the molar concentration of a transcript 
in the starting sample. The RPKM unit also normalizes for the total read number per 
measurement, which allows direct comparison of expression levels across multiple 
transcriptomes.  Finally, if used in conjunction with the RNA standard data, it allows 
calculation of absolute transcript amounts (supplementary materials and methods). In the 
case of our C2C12 cell lines, we recovered 100 ng of polyA RNA per 2.8 * 106 myoblast 
cells, whereas we needed only 9*105 nuclei (to account for any early fusion of myocytes 
into myotubes) of the 24 hour differentiated myocytes to recover the same amount of 
polyA RNA. While the RPKM of MyoD goes down from 270.6 RPKM in the myoblast 
down to 188 RPKM in the myocyte, its abudance actually increases during that period from 
35.4 transcripts per cell to 156.1 transcripts per nuclei, assuming uniform recovery of RNA.  
At current practical sequencing capacity and cost (~ 20–40M mapped reads from 4–8 lanes 
of one Solexa 1G flowcell), transcript detection was robust down to 1.1 RPKM, which 
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showed that sequence coverage throughout a long transcript is highly reproducible and 
quite uniform.  Whereas uniquely placed 25-mers provide surprisingly good coverage of 
single copy and many distant paralogs, such as the four transcription factors of the MyoD 
family, few of these reads fall on genes such as ubiquitin (Fig 4.1E) or Gapdh that have 
either very recent duplications or pseudogenes in the genome. We found that 76% of the 
genome is uniquely mappable with 25-mers, a further 6% are accessible when considering 
reads that could map from 2 to 10 positions on the genome (Fig 4.1D). Given that these 
mappable multireads contribute between 14 to 30 percent of the reads from RNA-seq 
depending on the tissue suggests that these multireads are most likely contributed by highly 
expressed genes. In order to avoid underestimating the expression of genes that would be 
sensitive to multireads, we calculate the probability that a multiread comes from a 
particular gene based on the expanded exon read density (unique plus splice-spanning 
reads) already calculated for that gene, versus the expanded exon read density for the other 
possible source locations (see materials and methods).  Genes so similar that they lack 
uniquely assigned reads will receive a symmetric distribution of multireads.  But for older 
and more diversified gene families, ERANGE distributes multireads asymmetrically in 
proportion to the unique and splice reads recorded.   The impact on the analysis pipeline 
from identifying and allocating multireads in this manner was to change RNA quantitation 
for ~ 32% of genes above 1 transcript / cell in the myocyte transcriptome by more than 
30%. 
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RNA polymerase II CTD phosphoisoform ChIP-seq  
RNA polymerase II catalyzes transcription of protein-coding genes and many small RNA 
precursors. Pol II is recruited to promoter regions by sequence specific transcription factors 
where, according to current models, the enzyme might pause, then initiate transcription and 
finally traverse the body of the gene (Core, 2008). Elongation can occur with or without 
pausing and, and in most genes continues on considerably beyond the 3’polyA processing 
site before finally disengaging somewhere downstream at a location that is well mapped for 
only a few metazoan genes (Gromak, 2006, Tantravahi, 1993), although increasing 
evidence links factors involved in polyadenylation to termination (Buratowski, 2005). 
Measuring Pol II occupancy across the genome is an independent way to map a 
transcriptome.   This can be done by chromatin immunoprecipitation experiments (ChIP) in 
which an immune reagent against Pol II is used to retrieve small DNA segments occupied 
by Pol II in the cell, followed by deep sequencing (Barski, 2007; Schones, 2008) or dense 
tiling microarray assays (Zeitlinger, 2007; Guenther, 2007), which have shown that a large 
fraction of genes, including genes with little or no expression, have a distinct polymerase 
signal at the promoter 
Pol II initiation and elongation activities are associated with phosphorylation of specific 
serine residues in its C-terminal domain (CTD) domain. The CTD contains 52 repeats of a 
heptad consensus YSPTSPS motif which is highly conserved in eukaryotes and can be 
phosphorylated at every serine, though not necessarily uniformly on each of the 52 repeats 
(Chapman et al., 2007; Egloff et al., 2007).  The CTD apparently serves as an organizing 
scaffold for RNA processing enzymes involved in 5’ capping, splicing, and 
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polyadenylation, among others (Phatnani and Greenleaf, 2006). These enzymes have 
 
 
 
 
 
 
 
Figure 4.5 CTD. polymerase ChIP-seq defines several classes of polymerase signatures. 
A. ChIPSeq profile of 3 different antibodies to RNA polymerase II that recognize the 
unphosphorylated (8WG16) and Pol II C-terminal domain S5 and S2 phosphorylation states 
for the 500 top genes expressed in c2c12 myocytes 24 hours after differentiation on a 
normalized gene model of 3 kb upstream in green, a normalized gene locus in red and 10 kb 
downstream in blue. While 8WG16 and CTD S5 show very similar enrichment patterns at the 
TSS and throughout the gene locus, The CTD S2 pol II mark rises throughout the gene model 
and peaks past the polyadenylation site that defines the final, mature mRNA. B. The direction 
and extent of a gene model can be mapped using the difference in the 8WG16 and CTD S2 
signals. Genes, and scales are the same as in A. C. Pol II phosphorylation marks define 5 
classes of genes: highly expressed genes with significant S2 in the vicinity of the TSS (actb in 
Myoblast), highly expressed genes with little CTD S2 signal in the vicinity of the TSS (Actb 
and Myog in Myocytes), genes with almost no polymerase signal above background (Myog in 
myoblasts), unexpressed genes with high 8WG16 and S5 but no S2 signal at the TSS (Fos), 
and genes with no expression but high S2 signal at the TSS (Ube2w in myoblast), which are 
lowly expressed when the S2 signal goes down at the TSS but come up at the 3’ end of the 
gene (Ube2w in myocyte). Ube2w is “stalled” in myoblasts in spite of having the S2 
phosphorylation, suggesting an additional process regulating productive elongation in at least 
some stalled genes. Estimated transcripts/cell in upper right corner of every panel. 
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domains that recognize and dock to CTD repeats with specific phosphorylation patterns 
(Meinhart et al., 2005), suggesting that there is a CTD phosphorylation code to coordinate 
Pol II activity with RNA processing machinery as the enzyme traverses the length of the 
gene (Corden, 2007).  Two key indicators of Pol II status are phosphorylation of  CTD-
Ser5 by TFIIH, which marks initiation, and phosphorylation of  Ser2 by PTEFb (also 
known as CTDK-I), which marks elongation  (Phatnani and Greenleaf, 2006).   
For ChIP analysis, we used immune reagents that specifically recognize Pol II with 
accessible Ser2P only or with Ser5P only CTD residues,   as well as an immune reagent 
(8WG16) which recognizes unphosphorylated repeats.   Each polymerase molecule can 
contain unmodified, singly modified (S2P or S5P), or doubly modified repeat motifs within 
its 52-motif CTD, which means that reactivity with the three immune reagents is expected 
to reflect a multiple modification code. We performed ChIPSeq on undifferentiated, 
actively proliferating C2 myoblasts and on actively differentiating C2s in the process of 
becoming myocytes.    Pol II occupancy maps were generated for the three phophoisoforms 
of the CTD repeat motif.    We first asked whether polymerase signal density was 
predictive of expression, and found it to be so only weakly (R2 = 0.37).  We next asked if 
the polymerase isoforms give distinct ChIP-seq profiles.  Fig 4.5A shows that ChIP-seq 
results for Ser5 and nonphosphorylated (8WG16) forms are indistinguishable from each 
other, but the occupancy map for Ser2 is distinct in an informative way.  The relative 
amount of Ser2 ChIP-seq signal increases markedly, compared to the other two isoforms, 
after the polyA addition site.   It is common to see Ser2 signals dominate the profile for 
kilobases downstream, if there is no other active gene in the region (Fig 4.5B).   When this 
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Pol II isoform difference pattern is observed, it can be used to postulate the orientation of 
transcription observed from the locus, such as at the locus of myocyte specific mir-206 and 
mir-133b (Fig 4.6).  These microRNAs occur in an otherwise unannotated region of mouse 
and human genomes. When the Pol II isoform data are integrated with RNA data, the 
picture is consistent with a novel ~15kb transcription locus, with a defined TSS, 
 
candidate conserved proximal promoter, polyA addition site and downstream transcription 
termination domain ~ 2 kb from the polyA addition site.  This primary transcript would 
produce the two microRNAs by processing, plus an RNA with two proposed larger exons, 
Figure 4.6. miR-206 and 
miR-133b transcript defined 
using RNA-seq and 
polymerase ChIP-seq. 30 kb 
region of chromosome 1 
centered on mir-206 and mir-
133b, which are expressed upon 
the myoblast to myocyte 
transition that are embedded in 
a novel transcript that is not in 
the NCBI or UCSC gene 
models and is also expressed 
upon differentiation. Our 
algorithm flagged the enriched 
regions as candidate exons, 
whereas the Pol II ChIP-seq 
marks show that the transcript 
is on the same strand (+) as the 
microRNAs. 
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one from each end of the proposed domain. 43 RNAFAR candidates were specific to 
muscle and myocytes.  
RNA polymerase II stalling and its change upon differentiaton 
We quantified polymerase stalling using a modified version of the polymerase stalling 
index that has previously been used for ChIP-chip (Zeitlinger, 2007) and ChIP-seq 
(Shones, 2008) with a higher threshold of 15 times more signal density around the TSS 
than along the rest of the gene for each phosphoisoform. While the 8WG16 and CTD S5 
signals correlate very well, we found that stalled promoters showed two distinct patterns of 
CTDS2 signal. Whereas 58% of the stalled promoters with expression of less than 1 
transcript / cell in the Myoblast, such as Fos and the heat shock factors, showed 8WG16 
stalling but no CTD S2 signal, the remainder showed stalling with both the 8WG16 and the 
CTDS2 signal — such as in the case of the ubiquitinating enzyme Ube2w (Fig 4.5C). In 
particular, we noticed that the CTDS2, but not 8WG16 stalling signal disappears from the 
promoter of Ube2w upon differentiation. We therefore decided to classify genes at both 
endpoints by their expression, 8WG16 stalling status, and CTD S2 stalling status to 
quantitate the size and magnitude of these transitions (Fig 4.7A). We found that 1034 genes 
followed the pattern of no-expression with high 8WG16, high CTD S2 stalling signal in 
myoblasts transitioning to expression with high 8WG16, low CTD S2 signal in the 
myocytes and that these genes tend to be enriched for gene ontology terms such as 
ubiquitin cycle, protein kinase activity, and mitochondrion (Fig 4.7B). These genes are 
presumably primed to go on upon differentiation, which presumably releases them from 
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one or more common repressor of elongation, whereas muscle specific genes show no 
preferential polymerase pre-loading at the myoblast or myocyte stage (data not shown). We 
finally note that RNA-seq is far more sensitive than ChIP-seq, as we are able to detect 
transcripts that are only present in a fraction of the cells in our sample, such as in the case 
of Myogenin which, while present at over 1461 RPKM in our myocyte sample (~ 1214.3 
Figure 4.7. Analysis of  Polymerase Stalling Transitions. Genes with genomic loci longer than 
1.2 kb were categorized in terms of their expression level, 8WG16 stalling index, and S2 stalling 
index in the myoblast and myocyte samples, where RNA Polymerase was considered stalled at 
the promoter if its stalling index is greater than 15. A. The top five transitions between 
expression and polymerase classes are shown. In addition to genes turning on upon 
differentiation (blue, purple, and red arrows), we have also unexpressed genes that change 
polymerase status (black arrow), and genes that are already expressed that lose their 8WG16 
stalling signature (green arrow). B. representative enriched Gene Ontology terms for each of the 
5 transitions. Many of the GO terms enriched for the genes with stalling in the myoblast that are 
expressed in the Myocyte are related to the upregulation of metabolic activity in the 
differentiated cell. Note that for some classes of genes with general GO terms such as 
Transcription (GO:0006350), a variety of strategies are used to regulate promoter loading. 
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transcript/nuclei), is detected at 17 RPKM (~ 2.3 transcripts/cell) in our mybolasts. Given 
that less than 1% of our myoblasts cells stain as Myogenin-positive and assuming that the 
expression of the few exponential cells that are myogenin positive is closer to 1214 
transcript/cell, then we calculate that as few as 1,600 cells in the myoblast sample (out of 
2.8 million, or 0.06%) are myogenin positive. Hence, we observe nearly no signal in our 
polymerase ChIP-seq from 2*107 cells at the Myogenin locus, while we can measure the 
mRNA.   
Discussion 
RNA sequencing revealed  ~ 18 k previously unannotated regions of transcription which 
might identify new exons of existing genes or new genes in 3 tissues and one cell line. 
RNA splicing has been problematic for microarray methods and inaccessible for SAGE.   
Here, the shear number of reads produced by the Solexa platform  RNA made it possible to 
identify splice events very effectively for high and moderate abundance RNAs, and to 
sporadically detect splice events for rarer transcripts.  To map splice isoforms 
comprehensively for RNAs of all prevalence classes and for rarer alternative splice 
isoforms, requires a different approach, such as building prevalence-normalized input 
cDNA samples to distribute the sequence sampling power evenly across all transcript 
species.  This would require no novel technology.   The long-range contiguity of splice 
choices cannot be extracted from our data, but the application of rapidly improving  
“paired-end” variations of ultra-high throughput sequencing can address this issue  
(“paired” sequences are determined for both ends of single segment of DNA, and starting 
DNA is of a known length class).   Coupled with additional bioinformatics tools, this could 
allow mapping of long-range splice contiguity by RNA-seq.   Combining prevalence 
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normalization of input RNA with paired-end sequencing would presumably give the most 
complete splicing pattern map, and this analysis might benefit from longer reads, such as 
those from the 454 platform, to gain more contiguity. 
Our data were very reproducible.  There was strong evidence for the presence and 
quantitfication of mRNA down to 1 transcript / cell.   These measurements reach the lowest 
mRNA levels that are likely to be biologically relevant in animal cells, although we caution 
that the lower limit of biological significance may well be function dependent, i.e. half a 
transcript / cell might still be significant for a transcription factor, whereas 10 transcript / 
cell might not be significant for genes that would need to be expressed at a high level such 
as actins or tubulins.    For mixed cell tissues like our differentiating C2C12 cells, RNA-seq 
at the sampling levels used was also able to detect transcripts that were prevalent in a 
minority cell population. However, current technology and costs mean that low prevalence 
RNAs from minority cells will not be accessible.  Instead, it should be possible to map the 
transcriptomes of rare cell types and states by greatly reducing the amount of input mRNA 
— aiming for the single-cell level.  Anticipated improvements in sequencing platforms also 
suggest that RNA-seq will increase in accuracy because of longer reads and increase in 
sensitivity because of larger read numbers. 
Although RNA-seq has no background from cross-hybridization as microarrays do, it is not 
free of ambiguities.   14 to 30% of 25 bp reads from each mouse (or human) RNA-seq 
sample matched equally well at 2–10 different locations on the mouse genome, rather than 
mapping best to a single site (Table 4.1).  Such “multireads” are expected, given the 
prominent role of gene and segmental duplications in genome evolution; they accounted for 
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83–90% of all multireads in our data.   Discarding all multireads (as default settings in 
current Solexa software does), will report that duplicated genes are expressed at very low 
levels or not expressed at all, as illustrated for the Ubb Ubiquitin gene family member (Fig 
4.1E). In less closely related gene families, multireads will have variable impact on RNA 
quantification, depending on the extent of sequence similarity within each gene and across 
the extended gene family.   The strength of evidence for detection of any given rare 
transcript by RNA-seq, especially if it has garnered multiple unique sequence reads, may 
be stronger than for microarrays, because array fluorescence signals from a low abundance 
true positive can be very difficult to distinguish, numerically and statistically, from 
fluctuations in background hybridization and dye-labeling.   However, short sequence reads 
that contain one or more errors (wrong base calls) might coincidentally match — in 
mutated form — to an existing sequence in the genome.  This creates a different kind of 
background in RNA-seq.  Different sequences will be more vulnerable to this than others, 
and future improvements in machine platforms, lengths of high quality sequence reads, 
better algorithms for base calling and for — especially — development of more 
sophisticated probabilistic error models for each transcriptome, should all contribute to 
improving certainty for the rarest RNAs.   Like RNA-seq, high density tiling arrays can 
discover previously unknown RNAs (Krapanov, 2007).   However, the data are not directly 
comparable, because our input RNA was doubly polyA selected, and because they used 
mixed sources of RNA.  This focuses the attention on protein coding mRNAs, and to a 
much lesser extent, on their partly processed precursors.  Future applications of RNA-seq 
to those other RNA preparations and also to very newly synthesized RNAs will allow more 
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direct comparisons to non-polyA selected data as well as to RNA polymerase II occupancy 
maps.   
The sensitivity of RNA-seq combined with the ChIP-seq of the different RNA polymerase  
II CTD phosphoisoforms revealed an unexpected dichotomy at stalled promoters 
depending on the presence or absence of a CTD S2 Pol II signal. We note that our CTD S2 
signal seems to be specific to heptads phosphorylated at S2 only, as opposed to repeats 
phosphorylated at both S2 and S5, which suggests that the S2 signal at these promoters is 
due to either S2 overphosphorylation or CTD S5 dephosphorylation of CTD S2–S5 repeats. 
In either case, this suggests that there is an additional process beyond the classically 
described control of elongation by phosphorylation of S2 by PTEFb. This could be a 
signature of known repressors of elongation such as NELF (Lee, 2008) or represent the 
presence of recruited CTD S5 phosphatases such as the SCP family that are recruited by 
repressors such as NRSF/REST (Yeo, 2005). Histone modification data under the same 
differentiation conditions should highlight whether these different stalled promoters have 
distinct histone modification profiles. 
Methods 
Cell culture and immunocytochemistry  
The mouse C2C12 skeletal muscle cell line was grown in 15 cm dishes in a 37˚C incubator 
at 5% CO2 in DMEM (Gibco) with 20% fetal bovine serum (Hyclone), penicillin at 50 
units/mL, and streptomycin at 50 ug/ml (Gibco).  At confluence, the cells were rinsed twice 
with phosphate-buffered saline (PBS), and the medium was changed to low serum medium 
(DMEM with 2% horse serum, 1 µM insulin, and penicillin/streptomycin).  Differentiated 
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cultures were fed every 24 hours until harvest.  At harvest, parallel plates were set aside for 
fixation in 4% paraformaldehyde or 70% ethanol for immunocytochemistry.  Primary 
antibodies were from Novocastra (NCL anti-myoD1), Cortex Biochem (CR2031R rabbit 
anti-myosin heavy chain), or from a laboratory supply of ascites fluid (myogenin — F5D).  
Cells were initially permeabilized in 0.15% Triton X-100 in PBS for 15 minutes, then 
rinsed twice in PBS and blocked for 1 hour in 10% normal goat serum.  The blocking 
serum was removed and an aliquot of primary antibody (1:500 anti-myogenin, 1:100 anti-
myoD, 1:300 anti-MHC) diluted in 1.5% goat or donkey serum in PBS was added and 
incubated at room temperature for 1 hour.  The primary was then removed, the dish was 
rinsed in 0.1% Triton in PBS 3 times for 5 minutes each at room temperature, and 
fluorescent secondary antibody was applied (goat anti-mouse Alexa 488, donkey anti-rabbit 
Alexa 564, Molecular Probes) for 1 hour at room temperature.  The dishes were rinsed 
again 3 times for 5 minutes in 0.1% Triton in PBS, rinsed once for two minutes in PBS, and 
then equilibrated in equilibration buffer (Anti-fade kit, Molecular Probes) before mounting 
in glycerol with DAPI.  Cells were visualized on a Zeiss Axiophot and > 1000 nuclei were 
counted in both channels for percentage of myogenin, myoD, and MHC-positive nuclei.  
Images were collected using OpenLab software.   
Estimate of nuclear counts  
Parallel cell preparations fixed in 1% paraformaldehyde were used for nuclear count 
estimates.  The cell pellets were lysed in 5mM PIPES, pH 8.0, 85 mM KCl, 0.5% NP-40, 
and the remaining nuclear fraction was subjected to overnight incubation at 65˚C in Tissue 
and Cell lysis buffer with Proteinase K (EpiCentre MasterPure DNA extraction kit).  
Genomic DNA was then extracted using the EpiCentre protocol, and quantified on the 
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NanoDrop spectrophotometer.  Genomic DNA yields were then converted to nuclei counts 
using the value of 6.4 pgs of DNA per nucleus.   
RNA preparation 
Cells were removed from the incubator, rinsed twice quickly with room temperature PBS, 
and then lysed with 2.25 ml Trizol per 15 cm plate (InVitrogen).  The lysate was sheared 
10 times through a 21 gauge needle and then frozen on pulverized dry ice until extraction.  
Lysates were thawed at room temperature, spun at 12,000 X g for 10 minutes at 4˚C, and 
the supernatant transferred to a new tube.  200 µLs of chloroform:isoamyl alcohol (24:1) 
were added, the tube was agitated vigorously by hand for 15 seconds, and then spun for 10 
minutes at 12,000 X g at 4˚C.  The supernatant was transferred to a new tube, and re-
extracted with an equal volume of phenol:chloroform:isoamyl alcohol equilibrated to pH 
4.5.  After spinning at 12,000 X g for 15 minutes at 4˚C, the aqueous phase was mixed with 
an equal volume of isopropanol, and placed on ice for 10 minutes to precipitate RNA.  The 
sample was spun for 10 minutes at 12,000 X g at 4˚C, the pellet was rinsed once with 75% 
ethanol, and then dried on the benchtop for 10 minutes, and resuspended in 20 !Ls of 
ddH2O for 10 minutes at 37˚C.  The sample was then treated with 10 !Ls Baseline Zero 
DNAse (EpiCentre Biotechnology) for 20 minutes, and respiked with an additional 5 !Ls 
of DNAse for another 20 minutes.  After the addition of stop buffer, the sample was 
phenol:chloroform extracted and precipitated overnight in 0.3M sodium acetate in 70% 
ethanol.  The sample was spun at 14,000 X g at 4˚C for 25 minutes, the pellet was rinsed 
once with 70% ethanol, spun for 5 minutes at 8,000 X g at 4˚C, and the supernatant 
removed.  The pellet was dried at room temperature, and then resuspended in 20 !Ls of 
ddH2O.  Concentration was determined on a Nanodrop spectrophotometer, and small 
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aliquots reserved for evaluation of RNA integrity on the Agilent 6000 BioAnalyzer.  Oligo 
dT selection was performed twice on 75 ugs of input total RNA using Dynal magnetic 
beads (InVitrogen) according to the manufacturer’s protocol.  After selection, a single 100 
ng aliquot of mRNA was reserved for evaluation on the BioAnalyzer.   
cDNA preparation 
100 ngs of double-selected mRNA was used as template for cDNA synthesis.  The mRNA 
was fragmented by addition of 5X fragmentation buffer (200 mM Tris Acetate, pH 8.2, 500 
mM KOAc, and 150 mM MgOAc) and heating at 94˚C for 2 minutes 30 seconds in a 
thermocycler.  The sample was immediately transferred to ice, and then run over a G50 
sephadex column (USA Scientific) to remove the fragmentation ions.  The sample was 
reduced to 10.5 µls in a speedvac, 3 µgs of random hexamers were added and the sample 
was reheated to 65˚C for 5 minutes in a thermocycler.  The sample was then placed on ice, 
and reagents for first-strand reverse transcription were added according to the 
manufacturer’s protocol (InVitrogen cDNA synthesis kit, catalog # 48190-011).  After the 
first strand was synthesized, a custom second strand synthesis buffer was added (Illumina), 
and dNTPs, RNAseH, and E. coli polymerase I were added to nick translate the second 
strand synthesis for 2.5 hours at 16˚C.  The reaction was then cleaned up on a QiaQuick 
PCR column (Qiagen) and eluted in 30 uls of EB buffer.   
Adapter ligation, size selection and amplification 
cDNA ends were subjected to an end repair protocol (Illumina Genomic DNA sequencing 
kit), followed by addition of an A base for ligation, and ligation of custom amplification 
adapters (Illumina).  After the final QiaQuick PCR cleanup, an additional cleanup was 
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performed over G50 Sephadex (USA Scientific), to prevent sample dispersal when loading 
into the agarose gel for size selection.  In order to size select the sample for a narrow 
distribution of cDNA around 200 bps, a 2% low melt agarose gel (NuSieve GTG Agarose, 
Cambrex) in TAE was prepared in a 10 cm mold.  The sample was loaded in the gel with a 
100 bp ladder (Invitrogen) located 3 lanes to the side to prevent contamination of the 
sample with ladder bands.  The gel was run at 80 volts constant voltage until the dye front 
was about 1.5 cm from the bottom of the gel.  The gel was post-stained in ethidium 
bromide for 20 minutes, destained for 20 minutes in ddH2O, and the bands were visualized 
and excised on a UV illumination stand.  Bands were excised in a narrow distribution of 
200 +/- 25 bps with a disposable scalpel.  The gel slices were extracted using the QiaExII 
kit (Qiagen) according to the manufacturer’s protocol, and 1/6 of the eluate volume was 
used in an amplification protocol with Phusion polymerase (Finnzymes) and custom 
amplification primers (Illumina).  The template was amplified for 15 cycles using the 
following protocol: 98°C for 30 seconds, 98°C for 10 seconds, 65°C for 30 seconds, 72°C 
for 30 seconds, and 72°C for 5 minutes.  The amplification product was cleaned up on a 
QiaQuick PCR column, reduced to 25 µLs volume in a speed vac, and then passed over a 
G50 Sephadex column.  The DNA concentration was determined on a Nanodrop 
spectrophotometer, and an aliquot of the sample was diluted to 10 nanomolar concentration 
with EB buffer to be used as input for the Illumina Cluster generation protocol.  We 
regularly use a 4 pmole mass to seed the flow cell to an approximate cluster density of 
30,000 clusters per tile.   
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Spike controls derivation and validation 
The MM9 version of the RefSeq database was used as a source of mRNA lengths for the 
known mouse transcriptome.  After plotting the length profile for the mouse transcriptome, 
we chose several lengths to cover the distribution of mouse mRNA lengths (~ 300 nts,       
~ 1500 nts, and ~ 10,000 nts).  Arabidopsis total RNA was reverse transcribed into double 
stranded DNA, and amplification primers were designed to 3 expressed sequences of about 
1400 nt length each and 3 sequences between 300 and 400 nts each.  After PCR 
amplification and gel electrophoresis, specific bands were excised, eluted, and cloned into a 
modified version of pBluescript KS II (-) (Stratagene).  Additionally, three fragments of the 
lambda genome were also recovered from electrophoresis after an Sph I digest of lambda 
genomic DNA, and cloned into the same expression vector.  The expression vectors were 
then digested to allow sense strand transcription for the expressed sequences, and in vitro 
transcription was performed using the AmpliScribe T3 or T7 kits (EpiCentre).  The 
reaction products were split in two, passed first over a G50 Sephadex column (USA 
Scientific), and then further cleaned up over RNEasy Minicolumns (Qiagen).  First pass 
quantitation was performed on the Nanodrop UV spectrophotometer.  To corroborate the 
Nanodrop estimates, further quantitation of RNA mass was performed using the RiboGreen 
reagent (Molecular Probes) in a BioRad Fluorometer.  The full length integrity of the RNA 
was inspected first on a 1.5% agarose gel stained with ethidium bromide, and also using the 
Agilent BioAnalyzer.  After determination of the concentration of the RNA samples, serial 
dilutions were made to the concentrations indicated.   
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Sequencing and read mapping on the genome and across splices 
Libraries were sequenced as 36-mers using the standard Solexa pipeline (version 0.2.6), but 
raw reads were truncated as 25-mers and remapped using version 0.3 of Eland (David Cox, 
under preparation) using the –multi option. Mouse ChIPSeq reads were mapped against the 
standard mm9 mouse build from UCSC (NCBI v37). Mouse RNAseq reads were similarly 
mapped against an expanded genome consisting of the standard mm9 genome and 42-mers 
representing the last 21 bp of the upstream exon and the first 21 bp of the corresponding 
downstream exon of each mRNA splice documented in the knownGene table for mm9.  
Normalized gene locus expression level analysis and multi-read probability assignment 
Unique reads in the expanded genome that landed within any exons of NCBI gene models 
(v37.1) were counted. Reads from all samples that did not fall within known exons where 
aggregated into candidate exons by requiring regions with at least 15 reads whose starts are 
not separated by more than 30 bp. These candidate exons were then rerun against the 
mappable, unmatched reads from each respective experiment to obtain their counts for that 
experiment. Reads that fell onto exons and candidate exons as well as splices were summed 
up for each locus and normalized by the locus length into the expanded exonic read 
density, i.e., reads per KB per million reads (RPKM), using the formula: 
! 
R =
10
9
C
NL  
where C is the number of mappable reads that fell onto the gene’s exons, N is the total 
number of mappable reads in the experiment, and L is the sum of the exons in base pairs. In 
particular, candidate exons are consolidated with neighboring NCBI gene models if they (a) 
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have an RPKM that is within the same order of magnitude or higher than that of the gene 
model and (b) meet either of 2 criteria: 
— candidate is within an intron of the gene model, 
— candidate is within 20 kb of the  3’ or 5’ end of the nearest, known exon. 
The requirement for (a) prevents counting of reads within introns of highly expressed genes 
that are likely from unspliced introns or downstream of the polyadenylation signal and that 
would be from partially unspliced hnRNA rather than processed mRNA. Candidate exons 
that fell within 20 kb of one another but further than 2 0kb from any other gene were 
aggregated into predicted “FAR” loci. 
The expanded RPKM were then used to calculate the probability that a multi-read came 
from a particular known or candidate exon, and the resulting fractional counts were added 
to the total count for the gene locus, which was renormalized into a multi RPKM. The 
expanded and multi RPKM for each locus were combined to produce a final RPKM. 
Conversion of RPKM into absolute transcript numbers 
Assuming uniform distribution of the mappable reads across the transcriptome, the 
probability of observing C reads on a transcript of length L in N tries corresponds to the 
fraction of the transcriptome composed of the transcript: 
! 
C
N
=
XL
T  
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where X is the copy number of the transcript  and T is the length of the transcriptome in 
base pairs. We can substitute final RPKMs to get: 
! 
X =
C
NL
T =
R
10
9
T
 
where we can either derive T from the starting amount of mRNA (assuming that we had 
100% efficiency in cDNA synthesis), or fit T from spike-in data, which should be more 
accurate. 
Chromatin Immunoprecipitations 
Chromatin immunoprecipitations and sequencing libraries were prepared as described in 
(Mortazavi et al., 2006) with the following modifications: 4 x 107 cells were used per IP 
using 100 uL of dynal anti-igG beads with 12.5 ug of antibodies. The following antibodies 
from Abcam were used: the monoclonal antibody 8WG16 (unphosphorylated CTD), rabbit 
polyclonal ab-5131 (Serine 5 CTD phosphorylated, ChIP-grade), and the rabbit polyclonal 
ab-5095 (Serine 2 CTD phosphorylated, ChIP-grade).  Libraries for each phosphorylation 
state and control libraries were prepared as previously described (Johnson, 2007) from a 
single IP. 
Polymerase Stalling Index Calculations 
Stalling index calculations were done as previously described (Zeitlinger, 2007; Schones, 
2008) with modifications to deal with ChIP-seq background and identification of 5’ and 3’ 
boundaries. Briefly, RNAFAR annotations were used to find gene boundaries, including 
the predicted TSS.  Normalized (i.e., per million) read counts in all regions for each ChIP 
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were corrected by subtracting the corresponding normalized reads from the control 
libraries. Stalling ratios were calculated by dividing the IP density on 600 bp region 
centered on the TSS by the read density over the gene model minus the first 600 bp. Genes 
with ratios over 15 were considered stalled. 
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C h a p t e r  5  
CONCLUSIONS 
I have spent the last four years of my life living and breathing NRSF, ChIP-seq, and RNA-
seq. It is difficult to think of the way things used to be without access to an ultra-high -
throughput sequencer, which is destined to be the biologist’s new best friend, alongside the 
old trusty QPCR thermocyclers. I don’t think this thesis would be complete without a 
couple of pages discussing my opinions on the outlook for the techniques introduced herein 
as well as where I see the field headed or, at least, where I would like it to go. 
ChIP-seq has been an unqualified success. Our publication of ChIP-seq for NRSF in 
Science, along with near simultaneous publication of two ChIP-seq publications primarily 
focused on ChIP-seq of histone modifications in Cell (Barski, 2007) , Nature  (Mikkelsen, 
2007) and of the transcription factor STAT1 (Robertson, 2007) marked a quantum leap in 
the field of  mammalian chromatin immunoprecipitation. The resolution and quality of the 
output were an order of magnitude above and beyond what anybody, including ourselves, 
thought was achievable at the time on the genomic scale. While not part of my thesis, the 
work that we have done in the Wold lab on ChIP-seq with the myogenic transcription 
factors MyoD and Myogenin makes it clear that the technique works spectacularly well 
even for the smallest binding site, and that there can be no turning back. For all practical 
purposes, ChIP-chip and other derivatives are now obsolete for mammalian genomes as 
long as one has access to Solexa-class sequencers, and the field is rapidly switching over as 
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the technology has caught on. This does not mean that ChIP-seq can save an otherwise 
lousy IP — if anything, we are more sensitive to the quality of the input than ever. 
However, the digital nature of the technology allows us to develop new metrics, such as our 
IP efficiency, to assess and compare different IPs and antibodies objectively. As the pool of 
ChIP-grade antibodies continues to expand, we can expect efforts such as ENCODE to 
produce ChIP-seq results for hundred of factors, thus giving us a real chance to look 
comprehensively at transcription factor-DNA binding in at least a few human cell types in 
the near future. I am also looking forward to seeing ChIP-seq applied to organisms other 
than mouse or human, as ChIP-seq, particularly with the Pol II CTD antibodies, can 
accommodate any of the sequenced eukaryotic genomes such as sea urchins or ascidians. 
RNA-seq is younger, yet seems also destined for a bright future. While finishing up my 
thesis, three papers have come out in April and May 2008 describing RNA-seq in 
Arabidopsis thaliana (Lister, 2008), S. cerevisiae (Nagalakshmi, 2008), and S. pombe 
(Wilhelm, 2008). The major benefits of RNA-seq are both transcript/exon discovery and 
the first comprehensive and quantitative assay of alternative splicing. While ChIP-seq 
effectively made mammalian tiling arrays obsolete, RNA-seq is threatening the primacy of 
the venerable microarray for expression analysis. While microarrays will continue to have a 
cost advantage in the foreseeable future, experiments that can benefit from exon and splice 
discovery and quantification will benefit greatly from RNA-seq. In particular, scaling down 
the amount of starting material so that we can sequence the transcriptome of a single cell, 
such as a nemtode or human neuron, is the next quantum step in the technology and is 
being worked on as we speak.  
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Stepping back to take in the state of (regulatory) biology in 2008, the sequencing of the 
reference human genome in 2001 represented a watershed in the history of biology, as it 
gave us access to the first mammalian scale genomes and forever transformed biology from 
a relatively data-poor field to a data-rich one, which has reshaped every aspect of being a 
biologist and doing biology. While the reference sequence for human and the other model 
organisms gave us much to work on in terms of annotating genes and regulatory elements, 
which continues to be the driving force behind projects such as the NHGRI ENCODE (the 
ENCyclopedia Of Dna Elements) initiative, the human genome project revolutionized 
high-throughput DNA sequencing technology, which had three major benefits, two of 
which were predictable and one of which has come as a surprise. All three are worth 
discussing, as together they will continue to influence the future of biology and of its allied 
fields. 
The first and most obvious benefit is that many mammalian and deuterostome genomes 
have been sequenced in the last decade, giving us the raw material necessary for the 
analysis of the evolution of vertebrates in general and of our own lineage in particular. As 
our analyses of the role of conservation and the evolution of gene regulation will extend 
beyond solo and possibly exceptional examples such as that of NRSF, we shall be able to 
understand and decode the gene regulatory networks underlying each species, and to 
identify those changes that have been selected for in the life history of each species. A 
logical extension of this is that we will be able to reconstruct our ancestral genomes, such 
as the ancestral primate and probably the ancestral mammal and vertebrate, as well as 
understand the evolution of these gene regulatory networks at the molecular and 
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informational level. While this will require much work and major advances in our 
understanding and prediction of protein-protein interaction, as well as protein-DNA 
binding, it is conceivable that we will have the requisite knowledge at hand in the coming 
decades. A predictive decoding and understanding of all gene regulatory relationships from 
primary sequence is the holy grail and would take its place alongside the Central Dogma of 
Biology and the Evolutionary Synthesis as one of the great foundational, intellectual 
achievements of the entire field. This is one of the grand, organizing projects of regulatory 
biology and may ultimately be our most significant achievement as a species. Whether it 
takes a decade or a century to achieve, it is worth pursuing regardless of any positive 
societal benefits or not. 
The second benefit is that the availability of the reference sequence has allowed us to ask 
how each individual member of our species differs from the reference and from one 
another as well as to quantify it. This has been a long time goal of human and population 
geneticists and offers the alluring prospects of identifying the underlying genetic 
determinants controlling phenotypic traits that are so evident when comparing a child to his 
parents. It also offers the hope to tailor personalized medical treatment to people based on 
their genotype. These twin promises have driven the recent progresses that has given us the 
current generation of ultra-high-throughput sequencing, where we can get 40–80 million 
reads of 25–32 bp per run, i.e., nearly 2.5 Gbp of sequence or nearly 1x coverage of the 
human genome. While still too expensive to do routinely at the 20x coverage necessary for 
these short reads to achieve a reliable resequencing of a human genome, we are within 
grasp of the “$1000 genome” that is considered the threshold for “routine” medical 
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resequencing. Of course, obtaining the genoptype simply to use it for the strictly 
correlational studies that are still the bread-and-butter of population genetics is not nearly 
as meaningful as one would hope. However, when individual genotypes are decoded down 
to the base-bp level changes to underlying, reference gene regulatory networks coming 
from the studies discussed as the first benefit, we may achieve the holy grail of 
understanding and acting upon our health predisposition and achieve even longer, more 
productive lives. 
The third, unexpected consequence of the rise of and rapid advances in ultra-high-
throughput sequencing is that any assay that can be converted into counting DNA fragment 
becomes immediately practical. There is today an effervescence of new techniques and 
protocols applying the sequence census assays to problems such as DNAse 
hypersensitivity, DNA methylation, small RNA discovery, etc., which will ultimately affect 
nearly all fields of biology. While counting assays such as SAGE or low-coverage mRNA 
sequencing (for transcript discovery) have been around for over a decade, they were 
expensive, technically challenging and not particularly comprehensive. The fortuitous 
availability of robust, cloning-free sequencing developed for resequencing repurposed for 
counting assays is one of these now-obvious ideas that nobody at the time (circa 2005), 
including I, thought was anything more than fanciful. It took the truly visionary and 
dedicated single-mindedness of my advisor to make it happen and her embrace of 
ENCODE made it all possible. I was fortunate that NRSF was the project that lead to the 
wonderful collaboration between Barbara’s and Rick Myers’ groups and which allowed me 
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to witness the birth of a transformational technology that will be a highlight of both of their 
distinguished careers. 
124 
 
 
BIBLIOGRAPHY 
 
Abderrahmani, A., M. Steinmann, V. Plaisance, G. Niederhauser, J.A. Haefliger, V. 
Mooser, C. Bonny, P. Nicod, and G. Waeber. 2001. The transcriptional repressor REST 
determines the cell-specific expression of the human MAPK8IP1 gene encoding IB1 
(JIP-1). Molecular and Cellular Biology 21: 7256–67. 
Abramovitz L., T. Shapira, I. Ben-Dror, V. Dror, L. Granot, T. Rousso, E. Landoy,  L. 
Blau, G. Thiel, and L .Vardimon. 2008. Dual role of NRSF/REST in activation and 
repression of the glucocorticoid response. Journal of Biological Chemistry 283(1):110–
9 
Andres, M.E., C. Burger, M.J. Peral-Rubio, E. Battaglioli, M.E. Anderson, J. Grimes, J. 
Dallman, N. Ballas, and G. Mandel. 1999. CoREST: a functional co-repressor required 
for regulation of neural-specific gene expression. Proceedings of the National Academy 
of Sciences of the United States of America 96: 9873–78. 
Atouf, F., P. Czernichow, and R. Scharfmann. 1997. Expression of neuronal traits in 
pancreatic beta cells — Implication of neuron-restrictive silencing factor/repressor 
element silencing transcription factor, a neuron-restrictive silencer. Journal of 
Biological Chemistry 272: 1929–34. 
125 
 
Ballas, N., C. Grunseich, D.D. Lu, J.C. Speh, and G. Mandel. 2005. REST and its co-
repressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 
121: 645–57. 
Bailey, T.L., and C. Elkan. 1995. Unsupervised Learning of Multiple Motifs In 
Biopolymers Using EM. Machine Learning 21: 51–80. 
Barski, A., S. Cuddapah, K. Cui, T.Y. Roh, D.E. Schones, Z. Wang, G. Wei, I. Chepelev, 
and K. Zhao. 2007. High-resolution profiling of histone methylations in the human 
genome. Cell 129(4):823–37. 
Bejerano, G., C.B. Lowe, N. Ahituv, B. King, A. Siepel, S.R. Salama, E.M. Rubin, W.J. 
Kent, and D. Haussler. 2006. A distal enhancer and an ultraconserved exon are derived 
from a novel retroposon. Nature 441:87–90. 
Berkes, C.A., and S.J. Tapscott. 2005. MyoD and the transcriptional control of myogenesis. 
Semin Cell Dev Biol. 16(4–5):585–95 
Boffelli, D., C.V. Weer, L. Weng, K.D. Lewis, M.I. Shoukry, L. Pachter, D.N. Keys, and 
E.M. Rubin. 2004. Intraspecies sequence comparisons for annotating genomes. 
Genome Research 14: 2406–11. 
Bruce, A.W., I.J. Donaldson, I.C. Wood, S.A. Yerbury, M.I. Sadowski, M. Chapman, B. 
Gottgens, and N.J. Buckley. 2004. Genome-wide analysis of repressor element 1 
silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target 
genes. Proceedings of the National Academy of Sciences of the United States of 
America 101: 10458–63. 
126 
 
Bruce, A.W., A. Krejcí, L. Ooi, J. Deuchars, I.C. Wood, V. Dolezal, and N.J. Buckley. 
2006. The transcriptional repressor REST is a critical regulator of the neurosecretory 
phenotype. Journal of Neurochemistry 98(6):1828–40. 
Buratowski, S. 2005. Connections between mRNA 3’ end processing and transcription 
termination. Curr Opin Cell Biol. (3):257–61. 
Cawley, S., S. Bekiranov, H.H. Ng, P. Kapranov, E.A. Sekinger, D. Kampa, A. Piccolboni, 
V. Sementchenko, J. Cheng, A.J. Williams, R. Wheeler, B. Wong, J. Drenkow, M. 
Yamanaka, S. Patel, S. Brubaker, H. Tammana, G. Helt, K. Struhl, and T.R. Gingeras. 
2004. Unbiased mapping of transcription factor binding sites along human 
chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116: 
499–509. 
Chapman, R.D., M. Heidemann, T.K. Albert, R. Mailhammer, A. Flatley, M. Meisterernst, 
E. Kremmer, and D. Eick. 2007. Transcribing RNA polymerase II is phosphorylated at 
CTD residue serine-7. Science 318(5857):1780-2 
Chen, Z.F., A.J. Paquette, and D.J. Anderson. 1998. NRSF/REST is required in vivo for 
repression of multiple neuronal target genes during embryogenesis. Nature Genetics 20: 
136-142. 
Chong, J.A., J. Tapia-Ramirez, S. Kim, J.J. Toledo-Aral, Y. Zheng, M.C. Boutros, Y.M. 
Altshuller, M.A. Frohman, S.D. Kraner, and G. Mandel. 1995. REST: a mammalian 
silencer protein that restricts sodium channel gene expression to neurons. Cell 80:949–
57. 
Corden JL. 2007. Transcription. Seven ups the code. Science 318(5857):1735–6. 
127 
 
Coulson, J.M., J.L. Edgson, P.J. Woll, and J.P. Quinn. 2000. A splice variant of the neuron-
restrictive silencer factor repressor is expressed in small cell lung cancer: a potential 
role in derepression of neuroendocrine genes and a useful clinical marker. Cancer 
Research 60(7):1840-4. 
Core, L.J., and J.T. Lis. 2008. Transcription Regulation Through Promoter-Proximal 
Pausing of RNA Polymerase II. Science 319 (5871):1791–2. 
D'Alessandro, R., A. Klajn, L. Stucchi, P. Podini, M.L. Malosio, and J. Meldolesi. 2008. 
Expression of the neurosecretory process in pc12 cells is governed by rest. Journal of 
Neurochemistry 105(4):1369–83. 
Dallman, J.E., J. Allopenna, A. Bassett, A. Travers, and G. Mandel. 2004. A conserved role 
but different partners for the transcriptional co-repressor CoREST in fly and 
mammalian nervous system formation. Journal of Neuroscience 24: 7186–93. 
Davidson, E.H. 2006. The regulatory genome: gene regulatory networks in development 
and evolution. Academic Press/Elsevier, San Diego, CA. 
Dehal, P., P. Predki, A.S. Olsen, A. Kobayashi, P. Folta, S. Lucas, M. Land, A. Terry, 
C.L.E. Zhou, S. Rash, Q. Zhang, L. Gordon, J. Kim, C. Elkin, M.J. Pollard, P. 
Richardson, D. Rokhsar, E. Uberbacher, T. Hawkins, E. Branscomb, and L. Stubbs. 
2001. Human chromosome 19 and related regions in mouse: Conservative and lineage-
specific evolution. Science 293: 104–11. 
Egloff S, D. O'Reilly, R.D. Chapman, A. Taylor, K. Tanzhaus, L. Pitts, D. Eick, and S. 
Murphy. 2007. Serine-7 of the RNA polymerase II CTD is specifically required for 
snRNA gene expression. Science 318(5857):1777–9. 
128 
 
Fickett, J.W. 1996. Quantitative discrimination of MEF2 sites. Molecular and Cellular 
Biology 16:437–41. 
Filippova, G.N. 2008. Genetics and epigenetics of the multifunctional protein CTCF. Curr 
Top Dev Biol. 80:337–60. 
Fuller, G.N., X. Su, R.E. Price, Z.R. Cohen, F.F. Lang, R. Sawaya, and S. Majumder. 2005. 
Many human medulloblastoma tumors overexpress repressor element-1 silencing 
transcription (REST)/neuron-restrictive silencer factor, which can be functionally 
countered by REST-VP16. Mol Cancer Ther. 4(3):343–9. 
Gaudet, J., and S.E. Mango. 2002. Regulation of organogenesis by the Caenorhabditis 
elegans FoxA protein PHA-4. Science 295(5556):821–5. 
Guardavaccaro, D., D. Frescas, N.V. Dorrello, A. Peschiaroli, A.S. Multani, T. Cardozo, A. 
Lasorella, A. Iavarone, S. Chang, E. Hernando, and M. Pagano. 2008. Control of 
chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 452(7185):365–9. 
Gradwohl, G., A. Dierich, M. LeMeur, and F. Guillemot. 2000. Neurogenin3 is required 
for the development of the four endocrine cell lineages of the pancreas. Proceedings of 
the National Academy of Sciences of the United States of America 97:1607–11. 
Griffiths-Jones, S. 2004. The microRNA Registry. Nucleic Acids Research 32:D109–111. 
Gromak, N., S. West, and N.J. Proudfoot. 2006. Pause sites promote transcriptional 
termination of mammalian RNA polymerase II. Molecular and Cellular Biology 
(10):3986–96. 
Guenther, M.G., S.S. Levine, L.A. Boyer, R. Jaenisch, and R.A. Young. 2007. A chromatin 
landmark and transcription initiation at most promoters in human cells. Cell 130(1):77–
88. 
129 
 
Hamilton, A.T., S. Huntley, J. Kim, E. Branscomb, and L. Stubbs. 2003. Lineage-specific 
expansion of KRAB zinc-finger transcription factor genes: Implications for the 
evolution of vertebrate regulatory networks. Cold Spring Harbor Symposia on 
Quantitative Biology 68:131–140. 
Harbers, M., and P. Carninci. 2005. Tag-based approaches for transcriptome research and 
genome annotation. Nature Methods. (7):495-502 
Harbison, C.T., D.B. Gordon, T.I. Lee, N.J. Rinaldi, K.D. Macisaac, T.W. Danford, N.M. 
Hannett, J.B. Tagne, D.B. Reynolds, J. Yoo, E.G. Jennings, J. Zeitlinger, D.K. 
Pokholok, M. Kellis, P.A. Rolfe, K.T. Takusagawa, E.S. Lander, D.K. Gifford, E. 
Fraenkel, and R.A. Young. 2004. Transcriptional regulatory code of a eukaryotic 
genome. Nature. 431(7004):99–104. 
Harris, T.D., P.R. Buzby, H. Babcock, E. Beer, J. Bowers, I. Braslavsky, M. Causey, J. 
Colonell, J. Dimeo, J.W. Efcavitch, E. Giladi, J. Gill, J. Healy, M. Jarosz, D. Lapen, K. 
Moulton, S.R. Quake, K. Steinmann, E. Thayer, A. Tyurina, R. Ward, H. Weiss, and Z. 
Xie. 2008. Single-molecule DNA sequencing of a viral genome. Science. 
320(5872):106–9 
Hart, C.E., L. Sharenbroich, B.J. Bornstein, D. Trout, B. King, E. Mjolsness, and B.J. 
Wold. 2005. A mathematical and computational framework for quantitative 
comparison and integration of large-scale gene expression data. Nucleic Acids 
Research 33: 2580–94. 
Hentsch, B., A. Mouzaki, I. Pfeuffer, D. Rungger, and E. Serfling. 1992. The Weak, Fine-
Tuned Binding of Ubiquitous Transcription Factors to the Il-2 Enhancer Contributes to 
Its T-Cell-Restricted Activity. Nucleic Acids Research 20: 2657–65. 
130 
 
Hersh, L.B. and M. Shimojo. 2003. Regulation of cholinergic gene expression by the 
neuron restrictive silencer factor/repressor element-1 silencing transcription factor. Life 
Sciences 72: 2021–28. 
Huang, H.P., Liu, M., El-Hodiri H.M., Chu K., Jamrich M., and Tsai M.J. 2000. Regulation 
of the pancreatic islet-specific gene BETA2 (neuroD) by neurogenin 3. Molecular and 
Cellular Biology 20: 3292–307. 
Huang, Y.F., S.J. Myers, and R. Dingledine. 1999. Transcriptional repression by REST: 
recruitment of Sin3A and histone deacetylase to neuronal genes. Nature Neuroscience 
2: 867–72. 
Impey, S., S.R. McCorkle, H. Cha-Molstad, J.M. Dwyer, G.S. Yochum, J.M. Boss, S. 
McWeeney, J.J. Dunn, G. Mandel, and R.H. Goodman. 2004. Defining the CREB 
regulon: a genome-wide analysis of transcription factor regulatory regions. Cell 
119(7):1041–54. 
John, B., A.J. Enright, A. Aravin, T. Tuschl, C. Sander, and D.S. Marks. 2004. Human 
MicroRNA targets. Public Library of Science Biology 2:1862–79. 
Johnson DS, A. Mortazavi, R.M. Myers, and B. Wold. 2007. Genome-wide mapping of in 
vivo protein-DNA interactions. Science 316(5830):1497–502. 
Johnson, R., C. Zuccato, N.D. Belyaev, D.J. Guest, E. Cattaneo, and N.J. Buckley. 2008. A 
microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis. 
3:438–45. 
Karolchik, D., R. Baertsch, M. Diekhans, T.S. Furey, A. Hinrichs, Y.T. Lu, K.M. Roskin, 
M. Schwartz, C.W. Sugnet, D.J. Thomas, R.J. Weber, D. Haussler, and W.J. Kent. 
2003. The UCSC Genome Browser Database. Nucleic Acids Research 31:51–54. 
131 
 
Kemp, D.M., J.C. Lin, and J.F. Habener. 2003. Regulation of Pax4 paired homeodomain 
gene by neuron-restrictive silencer factor. Journal of Biological Chemistry 
278(37):35057–62. 
Kent, W.J., C.W. Sugnet, T.S. Furey, K.M. Roskin, T.H. Pringle, A.M. Zahler, and D. 
Haussler. 2002. The human genome browser at UCSC. Genome Research 12: 996–
1006. 
Kim, J.B., G.J. Porreca, L. Song, S.C. Greenway, J.M. Gorham, G.M. Church, C.E. 
Seidman, and J.G. Seidman. 2007. Polony multiplex analysis of gene expression 
(PMAGE) in mouse hypertrophic cardiomyopathy. Science 316(5830):1481–4. 
Kim, T.H., and B. Ren. 2006. Genome-wide analysis of protein-DNA interactions. Annual 
Review of Genomics and Human Genetics 7:81–102. 
Kloosterman W.P., E. Wienholds, E. de Bruijn, S. Kauppinen, and R.H. Plasterk. 2006. In 
Situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide 
probes. Nature Methods 3:27–29. 
Kapranov, P., et al. 2007. RNA maps reveal new RNA classes and a possible function for 
pervasive transcription. Science. 316(5830):1484–8. 
Kraner, S.D., J.A. Chong, H.J. Tsay, and G. Mandel. 1992. Silencing the type II sodium 
channel gene: a model for neural-specific gene regulation. Neuron. 9(1):37–44. 
Krek, A., D. Grun, M.N. Poy, R. Wolf, L. Rosenberg, E.J. Epstein, P. MacMenamin, I. 
daPiedade, K.C. Gunsalus, M. Stoffel, and N. Rajewsky. 2002. Combinatorial 
microRNA target predictions. Nature Genetics 37: 495-500. 
Kosik, K.S., and A.M. Krichevsky. 2005. The elegance of the microRNAs: A neuronal 
perspective. Neuron 47: 779–782. 
132 
 
Krebs, C.J., L.K. Larskins, S.M. Khan, and D.M. Robins. 2005. Expansion and 
Diversification of KRAB zinc-finger genes within a cluster including regulation of sex-
limitation 1 and 2. Genomics 6: 752–61. 
Kuwabara, T., J. Hsieh, K. Nakashima, K. Taira, and F.H. Gage. 2003. A small modulatory 
dsRNA specifies the fate of adult neural stem cells. Cell 116: 779–793. 
Kuwahara, K., Y. Saito, M. Takano, Y. Arai, S. Yasuno, Y. Nakagawa, N. Takahashi, Y. 
Adachi, G. Takemura, M. Horie, Y. Miyamoto, T. Morisaki, S. Kuratomi, A. Noma, H. 
Fujiwara, Y. Yoshimasa, H. Kinoshita, R. Kawakami, I. Kishimoto, M. Nakanishi, S. 
Usami, M. Harada, and K. Nakao. 2003. NRSF regulates the fetal cardiac gene program 
and maintains normal cardiac structure and function. EMBO Journal 22:6310–21. 
Lakowski, B., S. Eimer, C. Gobel, A. Bottcher, B. Wagler, and R. Baumeister. 2003. Two 
suppressors of sel-12 encode C2H2 zinc-finger proteins that regulate presenilin 
transcription in Caenorhabditis elegans. Development 130:2117-2128. 
Lee C, Li X, Hechmer A, Eisen M, Biggin MD, Venters BJ, Jiang C, Li J, Pugh BF, 
Gilmour DS (2008) NELF and GAGA factor are linked to promoter proximal pausing 
at many genes in Drosophila. Molecular and Cellular Biology 28(10):3290–300.  
Lee, J.E.,  S.M. Hollenberg, L. Snider, D.L. Turner, N. Lipnick, and H. Weintraub. 1995. 
Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix 
protein. Science 268:836–44. 
Lee, J.H., M. Shimojo, Y.G. Chai, L.B. Hersh. 2000. Studies on the interaction of REST4 
with the cholinergic repressor element-1/neuron restrictive silencer element. Brain Res. 
Mol. Brain Res. 80:88–98 
133 
 
Lewis, B.P., C.B. Burge, and D.P. Bartel. 2005. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 
15–20. 
Lim, L.P., N.C. Lau, P. Garrett-Engele, A. Grimson, J.M. Schelter, J. Castle, D.P. Bartel, 
P.S. Linsley, and J.M. Johnson. 2005. Microarray analysis shows that some 
microRNAs downregulate large numbers of target mRNAs. Nature 433:769–773. 
Lister, R., R.C. O'Malley, J. Tonti-Filippini, B.D. Gregory, C.C. Berry, A.H. Millar, and 
J.R. Ecker. 2008. Highly integrated single-base resolution maps of the epigenome in 
Arabidopsis. Cell 133(3):523-36 
Lobanenkov, V.V., R.H. Nicolas, V.V. Adler, H. Paterson, E.M. Klenova, A.V. Polotskaja, 
and G.H. Goodwin. 1990. A novel sequence-specific DNA binding protein which 
interacts with three regularly spaced direct repeats of the CCCTC-motif in the 5'-
flanking sequence of the chicken c-myc gene. Oncogene 12:1743-53 
Lunyak, V.V., R. Burgess, G.G. Prefontaine, C. Nelson, S.H. Sze, J. Chenoweth, P. 
Schwartz, P.A. Pevzner, C. Glass, G. Mandel, and M.G. Rosenfeld. 2002. Co-
repressor-dependent silencing of chromosomal regions encoding neuronal genes. 
Science 298:1747–52. 
Magin, A., M. Lietz, G. Cibelli, and G. Thiel. 2002. RE-1 silencing transcription factor-4 
(REST4) is neither a transcriptional repressor nor a de-repressor. Neurochem 
International (3):195–202. 
Martin, D., F. Allagnat, G. Chaffard, D. Caille, M. Fukuda, R. Regazzi, A. Abderrahmani, 
G. Waeber, P. Meda, P. Maechler, and J.A. Haefliger. 2008. Functional significance of 
134 
 
repressor element 1 silencing transcription factor (REST) target genes in pancreatic 
beta cells. Diabetologia, Apr 3 (epub). 
Martone, R., G. Euskirchen, P. Bertone, S. Hartman, T.E. Royce, N.M. Luscombe, J.L. 
Rinn, F.K. Nelson, P. Miller, M. Gerstein, S. Weissman, and M. Snyder. 2003. 
Distribution of NF-kappa B-binding sites across human chromosome 22. Proceedings 
of the National Academy of Sciences of the United States of America 100:12247–52. 
Meinhart, A., T. Kamenski, S. Hoeppner, S. Baumli, and P. Cramer. 2005. A structural 
perspective of CTD function.Genes and Development 19(12):1401-15. 
Mikkelsen, T.S., M. Ku, D.B. Jaffe, B. Issac, E. Lieberman, G. Giannoukos, P. Alvarez, W. 
Brockman, T.K. Kim, R.P. Koche, W. Lee, E. Mendenhall, A. O'Donovan, A. Presser, 
C. Russ, X. Xie, A. Meissner, M. Wernig, R. Jaenisch, C. Nusbaum, E.S. Lander, and 
B.E. Bernstein. 2007. Genome-wide maps of chromatin state in pluripotent and lineage-
committed cells. Nature 448(7153):553–60. 
Monaco, C., S. Otto, J. Han, and G. Mandel. 2006. Reciprocal actions of REST and a 
microRNA promote neuronal identity. Proceedings of the National Academy of 
Sciences of the United States of America 103: 2422–27. 
Mori, N., C. Schoenherr, D.J. Vanderbergh, D.J. Anderson. 1992. A common silencer 
element in the SCG10 and type II Na+ channel gene binds a factor present in non-
neuronal cells but not in neuronal cells. Neuron 9: 45–54. 
Mortazavi, A., E.C. Leeper Thompson, S.T. Garcia, R.M. Myers, B. Wold. 2006. 
Comparative genomics modeling of the NRSF/REST repressor network: from single 
conserved sites to genome-wide repertoire. Genome Research (10):1208–21. 
135 
 
Mortazavi, A., B.A. Williams, K. McCue, L. Schaeffer, B. Wold. 2008. Mapping and 
quantifying mammalian transcriptomes by RNA-seq. Nature Methods, May 30 (epub). 
McCormick, M.B., R.M. Tamimi, L. Snider, A. Asakura, D. Bergstrom, and S.J. Tapscott. 
1996. neuroD2 and neuroD3: Distinct expression patterns and transcriptional activation 
potentials within the neuroD gene family. Molecular and Cellular Biology 16: 5792–
800. 
Nagalakshmi, U., Z. Wang, K. Waern, C. Shou, D. Raha, M. Gerstein, and M. Snyder. 
2008. The Transcriptional Landscape of the Yeast Genome Defined by RNA 
Sequencing. Science, May 1 (epub). 
Otto, S.J., S.R. McCorkle, J. Hover, C. Conaco, J.J. Han, S. Impey, G.S. Yochum, J.J. 
Dunn, R.H. Goodman, and G. Mandel. 2007. A new binding motif for the 
transcriptional repressor REST uncovers large gene networks devoted to neuronal 
functions. Journal of Neuroscience 27(25):6729–39. 
Pance, A., F.J. Livesey, and A.P. Jackson. 2006. A role for the transcriptional repressor 
REST in maintaining the phenotype of neurosecretory-deficient PC12 cells. Journal of 
Neurochemistry. 99(5):1435–44. 
Patel, P.D., D.A. Bochar, D.L. Turner, F. Meng, H.M. Mueller, and C.G. Pontrello. 2007. 
Regulation of tryptophan hydroxylase-2 gene expression by a bipartite RE-1 silencer of 
transcription/neuron restrictive silencing factor (REST/NRSF) binding motif. Journal of 
Biological Chemistry 282(37):26717–24. 
Peisach, E., and C.O. Pabo. 2003. Constraints for zinc finger linker design as inferred from 
X-ray crystal structure of tandem Zif268-DNA complexes. Journal of Molecular 
Biology 330(1):1–7. 
136 
 
Phatnani, H.P., and A.L. Greenleaf. 2006. Phosphorylation and functions of the RNA 
polymerase II CTD. Genes and Development 20(21):2922–36 
Poy, M.N., L. Eliasson, J. Krutzfeldt, S. Kuwajima, X.S. Ma, P.E. MacDonald, B. Pfeffer, 
T. Tuschl, N. Rajewsky, P. Rorsman, and M. Stoffel. 2004. A pancreatic islet-specific 
microRNA regulates insulin secretion. Nature 432:226–30. 
Robertson, G., M. Hirst, M. Bainbridge, M. Bilenky, Y. Zhao, T. Zeng, G. Euskirchen, B. 
Bernier, R. Varhol, A. Delaney, N. Thiessen, O.L. Griffith, A. He, M. Marra, M. 
Snyder, S. Jones. 2007. Genome-wide profiles of STAT1 DNA association using 
chromatin immunoprecipitation and massively parallel sequencing. Nature Methods. 
(8):651–7. 
Schoenherr, C.J., and D.J. Anderson. 1995. The Neuron-Restrictive Silencer Factor 
(NRSF) — a Coordinate Repressor of Multiple Neuron-Specific Genes. Science 
267:1360–63. 
Schoenherr, C.J., A.J. Paquette, and D.J. Anderson. 1996. Identification of potential target 
genes for the neuron-restrictive silencer factor. Proceedings of the National Academy 
of Sciences of the United States of America 93:9881–86. 
Scholl, T., M.B. Stevens, S. Mahanta, and J.L. Strominger. 1996. A zinc finger protein that 
represses transcription of the human MHC class II gene, DPA(1,2). Journal of 
Immunology 156:1448–57. 
Schones, D.E., K. Cui, S. Cuddapah, T.Y. Roh, A. Barski, Z. Wang, G. Wei, and K. Zhao. 
2008. Dynamic regulation of nucleosome positioning in the human genome. Cell 
132(5):887-98. 
137 
 
Sempere, L.F., S. Freemantle, I. Pitha-Rowe, E. Moss, E. Dmitrovsky, and V. Ambros. 
2004. Expression profiling of mammalian microRNAs uncovers a subset of brain-
expressed microRNAs with possible roles in murine and human neuronal 
differentiation. Genome Biology 5(3):R13. 
Shannon, M., A.T. Hamilton, L. Gordon, E. Branscomb, and L. Stubbs. 2003. Differential 
expansion of zinc-finger transcription factor loci in homologous human and mouse 
gene clusters. Genome Research 13:1097–110. 
Shimojo, M., J.H. Lee, and L.B. Hersh. 2001. Role of zinc finger domains of the 
transcription factor neuron-restrictive silencer factor/repressor element-1 silencing 
transcription factor in DNA binding and nuclear localization. Journal of Biological 
Chemistry 276(16):13121–6. 
Singh SK, Kagalwala MN, Parker-Thornburg J, Adams H, Majumder S. 2008. REST 
maintains self-renewal and pluripotency of embryonic stem cells. Nature 
453(7192):223–7. 
Sommer, L., Q. Ma, and D.J. Anderson. 1996. Neurogenins, a novel family of atonal-
related bHLH transcription factors, are putative mammalian neuronal determination 
genes that reveal progenitor heterogeneity in the developing CNS and PNS. Molecular 
and Cellular Neuroscience. 8: 221–41. 
Stark, A., M.F. Lin, P. Kheradpour, J.S. Pedersen, L. Parts, J.W. Carlson, M.A. Crosby, 
M.D. Rasmussen, S. Roy, A.N. Deoras, J.G. Ruby, J. Brennecke; Harvard FlyBase 
curators; Berkeley Drosophila Genome Project, E. Hodges, A.S. Hinrichs, A. Caspi, B. 
Paten, S.W. Park, M.V. Han, M.L. Maeder, B.J. Polansky, B.E. Robson, S. Aerts, J. 
van Helden, B. Hassan, D.G. Gilbert, D.A. Eastman, M. Rice, M. Weir, M.W. Hahn, Y. 
138 
 
Park, C.N. Dewey, L. Pachter, W.J. Kent, D. Haussler, E.C. Lai, D.P. Bartel, G.J. 
Hannon, T.C. Kaufman, M.B. Eisen, A.G. Clark, D. Smith, S.E. Celniker, W.M. 
Gelbart, and M. Kellis. 2007. Discovery of functional elements in 12 Drosophila 
genomes using evolutionary signatures. Nature 450(7167):219–32. 
Su, A.I., T. Wiltshire, S. Batalov, H. Lapp, K.A. Ching, D. Block, J. Zhang, R. Soden, M. 
Hayakawa, G. Kreiman, M.P. Cooke, J.R. Walker, and J.B. Hogenesch. 2004. A gene 
atlas of the mouse and human protein-encoding transcriptomes. Proceedings of the 
National Academy of Sciences of the United States of America 101: 6062–67. 
Tantravahi, J., M. Alvira, and E. Falck-Pedersen. 1993. Characterization of the mouse beta 
maj globin transcription termination region: a spacing sequence is required between the 
poly(A) signal sequence and multiple downstream termination elements. Molecular and 
Cellular Biology. (1):578-87. 
Thiel, G., M. Lietz, and M. Cramer. 1998. Biological Activity and Modular Structure of 
RE-1-silencing Transcription Factor (REST), a Repressor of Neuronal Genes. Journal 
of Biological Chemistry 273: 26891-26899. 
Ule, J., A. Ule, J. Spencer, A. Williams, J.S. Hu, M. Cline, H. Wang, T. Clark, C. Fraser, 
M. Ruggiu, B.R. Zeeberg, D. Kane, J.N. Weinstein, J. Blume, and R.B. Darnell. 2005. 
Nova regulates brain-specific splicing to shape the synapse. Nature Genetics 37:844–
52. 
Wagner, S., M.A. Hess, P. Ormonde-Hanson, J. Malandro, H.P. Hu, M. Chen, R. Kehrer, 
M. Frodsham, C. Schumacher, M. Beluch, C. Honer, M. Skolnick, D. Ballinger, and 
B.R. Bowen. 2000. A broad role for the zinc finger protein ZNF202 in human lipid 
metabolism. Journal of Biological Chemistry 275:15685–90. 
139 
 
Wasserman, W.W., and A. Sandelin. 2004. Applied bioinformatics for the identification of 
regulatory elements. Nature Reviews Genetics 5: 276–87. 
Watanabe, Y., S. Kameoka, V. Gopalakrishnan, K.D. Aldape, Z.Z. Pan, F.F. Lang, and S. 
Majumder. 2004. Conversion of myoblasts to physiologically active neuronal 
phenotype. Genes and Development 8(8):889–900. 
Weber, M.J. 2005. New human and mouse microRNA genes found by homology search. 
FEBS Journal 272:59–73. 
Wei, C.L.,Q. Wu, V.B. Vega, K.P. Chiu, P. Ng, T. Zhang, A. Shahab, H.C. Yong, Y. Fu, Z. 
Weng, J. Liu, X.D. Zhao, J.L. Chew, Y.L. Lee, V.A. Kuznetsov, W.K. Sung, L.D. 
Miller, B. Lim, E.T. Liu, Q. Yu, H.H. Ng, and Y. Ruan. 2006. A global map of p53 
transcription-factor binding sites in the human genome. Cell 124(1):207–19. 
Westbrook, T.F., E.S. Martin, M.R. Schlabach, Y.M. Leng, A.C. Liang, B. Feng, J.J. Zhao, 
T.M. Roberts, G. Mandel, G.J. Hannon, R.A. DePinho, L. Chin, and S.J. Elledge. 2005. 
A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837–848. 
Westbrook ,T.F., G. Hu, X.L. Ang, P. Mulligan, N.N. Pavlova, A. Liang, Y. Leng, R. 
Maehr, Y. Shi, J.W. Harper, and S.J. Elledge. 2008. SCFbeta-TRCP controls oncogenic 
transformation and neural differentiation through REST degradation. Nature. 
452(7185):370–4. 
Wilhelm B.T., S. Marguerat, S. Watt, F. Schubert, V. Wood, I. Goodhead, C.J. Penkett, J. 
Rogers, and J. Bähler. 2008. Dynamic repertoire of a eukaryotic transcriptome 
surveyed at single-nucleotide resolution. Nature, (epub). 
Wold, B., and R.M. Myers. 2008. Sequence census methods for functional genomics. 
Nature Methods. (1):19–21. 
140 
 
Xie, X., J. Lu, E.J. Kulbokas, T.R. Golub, V. Mootha, K. Lindblad-Toh, E.S. Lander, and 
M. Kellis. 2005. Systematic discovery of regulatory motifs in human promoters and 3' 
UTRs by comparison of several mammals. Nature 434(7031):338–45. 
Yeo, M., S.K. Lee, B. Lee, E.C. Ruiz, S.L. Pfaff, and G.N. Gill. 2005. Small CTD 
phosphatases function in silencing neuronal gene expression. Science 307:596–600. 
Ying, S.Y., and S.L. Lin. 2004. Intron-derived microRNAs - fine tuning of gene functions. 
Gene 342:25–28. 
Zhao, Y.U., H.Z. Sheng, R. Amini, A. Grinberg, E. Lee, S.P. Huang, M. Taira, and H. 
Westphal. 1999. Control of hippocampal morphogenesis and neuronal differentiation 
by the LIM homeobox gene Lhx5. Science 284:1155–58. 
Zhang, C., Z. Xuan , S. Otto, J.R. Hover, S.R. McCorkle, G. Mandel, and M.Q. Zhang. 
2006. A clustering property of highly-degenerate transcription factor binding sites in 
the mammalian genome. Nucleic Acids Research 34: 2238–46. 
Zeitlinger, J., A. Stark, M. Kellis, J.W. Hong, S. Nechaev, K. Adelman, M. Levine, and 
R.A. Young. 2007. RNA polymerase stalling at developmental control genes in the 
Drosophila melanogaster embryo. Nature Genetics 39(12):1512-6. 
 
